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A B S T R A C T
Background
Acute respiratory infections (ARIs) comprise of a large and heterogeneous group of infections including bacterial, viral, and other
aetiologies. In recent years, procalcitonin (PCT), a blood marker for bacterial infections, has emerged as a promising tool to improve
decisions about antibiotic therapy (PCT-guided antibiotic therapy). Several randomised controlled trials (RCTs) have demonstrated the
feasibility of using procalcitonin for starting and stopping antibiotics in different patient populations with ARIs and different settings
ranging from primary care settings to emergency departments, hospital wards, and intensive care units. However, the effect of using
procalcitonin on clinical outcomes is unclear. This is an update of a Cochrane review and individual participant data meta-analysis first
published in 2012 designed to look at the safety of PCT-guided antibiotic stewardship.
Objectives
The aim of this systematic review based on individual participant data was to assess the safety and efficacy of using procalcitonin for
starting or stopping antibiotics over a large range of patients with varying severity of ARIs and from different clinical settings.
Search methods
We searched theCochraneCentral Register ofControlledTrials (CENTRAL),which contains theCochraneAcuteRespiratory Infections
Group’s Specialised Register, MEDLINE, and Embase, in February 2017, to identify suitable trials. We also searched ClinicalTrials.gov
to identify ongoing trials in April 2017.
Selection criteria
We included RCTs of adult participants with ARIs who received an antibiotic treatment either based on a procalcitonin algorithm (PCT-
guided antibiotic stewardship algorithm) or usual care. We excluded trials if they focused exclusively on children or used procalcitonin
for a purpose other than to guide initiation and duration of antibiotic treatment.
Data collection and analysis
Two teams of review authors independently evaluated themethodology and extracted data from primary studies. The primary endpoints
were all-cause mortality and treatment failure at 30 days, for which definitions were harmonised among trials. Secondary endpoints
were antibiotic use, antibiotic-related side effects, and length of hospital stay. We calculated odds ratios (ORs) and 95% confidence
intervals (CIs) using multivariable hierarchical logistic regression adjusted for age, gender, and clinical diagnosis using a fixed-effect
model. The different trials were added as random-effects into the model. We conducted sensitivity analyses stratified by clinical setting
and type of ARI. We also performed an aggregate data meta-analysis.
Main results
From 32 eligible RCTs including 18 new trials for this 2017 update, we obtained individual participant data from 26 trials including
6708 participants, which we included in the main individual participant data meta-analysis. We did not obtain individual participant
data for four trials, and two trials did not include people with confirmed ARIs. According to GRADE, the quality of the evidence was
high for the outcomes mortality and antibiotic exposure, and quality was moderate for the outcomes treatment failure and antibiotic-
related side effects.
Primary endpoints: there were 286 deaths in 3336 procalcitonin-guided participants (8.6%) compared to 336 in 3372 controls (10.0%),
resulting in a significantly lower mortality associated with procalcitonin-guided therapy (adjusted OR 0.83, 95% CI 0.70 to 0.99, P
= 0.037). We could not estimate mortality in primary care trials because only one death was reported in a control group participant.
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Treatment failure was not significantly lower in procalcitonin-guided participants (23.0% versus 24.9% in the control group, adjusted
OR 0.90, 95% CI 0.80 to 1.01, P = 0.068). Results were similar among subgroups by clinical setting and type of respiratory infection,
with no evidence for effect modification (P for interaction > 0.05). Secondary endpoints: procalcitonin guidance was associated with a
2.4-day reduction in antibiotic exposure (5.7 versus 8.1 days, 95% CI -2.71 to -2.15, P < 0.001) and lower risk of antibiotic-related
side effects (16.3% versus 22.1%, adjusted OR 0.68, 95% CI 0.57 to 0.82, P < 0.001). Length of hospital stay and intensive care unit
stay were similar in both groups. A sensitivity aggregate-data analysis based on all 32 eligible trials showed similar results.
Authors’ conclusions
This updated meta-analysis of individual participant data from 12 countries shows that the use of procalcitonin to guide initiation and
duration of antibiotic treatment results in lower risks of mortality, lower antibiotic consumption, and lower risk for antibiotic-related
side effects. Results were similar for different clinical settings and types of ARIs, thus supporting the use of procalcitonin in the context
of antibiotic stewardship in people with ARIs. Future high-quality research is needed to confirm the results in immunosuppressed
patients and patients with non-respiratory infections.
P L A I N L A N G U A G E S U M M A R Y
Testing blood procalcitonin levels to decide when to start and stop antibiotics in adults with acute respiratory tract infections
Review question
What are the effects of using procalcitonin to start or discontinue antibiotics in people with acute respiratory infections compared to
routine care on mortality and treatment failure?
Background
In people with acute respiratory infections, unnecessary antibiotic use significantly contributes to increasing bacterial resistance, medical
costs, and the risk of drug-related adverse events. The blood marker procalcitonin increases in bacterial infections and decreases when
patients recover from the infection. Procalcitonin can be measured in the blood of patients by different commercially available assays
with a turnaround time of around one to two hours and support clinical decision making about initiation and discontinuation of
antibiotic therapy.
Search date
We conducted electronic searches on 10 February 2017. We conducted searches for ongoing trials on 12 April 2017.
Study characteristics
All included trials randomised participants with acute respiratory infections to receive antibiotics based on procalcitonin levels (’procal-
citonin-guided’ group) or a control group. The trials were performed in primary care, the emergency department and medical wards,
and the intensive care unit. Included participants had acute upper or lower respiratory infections, including pneumonia, bronchitis,
exacerbation of chronic obstructive pulmonary disease, and others.
Study funding sources
All studies were investigator-initiated trials. Half of the trials were funded by national agencies or did not report funding, and half of
the trials received funding from the biomarker industry (e.g. Thermo Fisher Scientific).
Key results
We studied 6708 participants from 26 trials in 12 countries. Mortality at 30 days was significantly lower in procalcitonin-guided
participants compared to control participants (286 deaths in 3336 procalcitonin-guided participants (8.6%) versus 336 deaths in 3372
controls (10.0%)). There was no significant difference with regard to treatment failures. Results were similar for different clinical
settings (primary care, emergency department, intensive care unit) and types of respiratory infection. Regarding antibiotic exposure,
participants in the procalcitonin-guided group had a 2.4-day reduction in antibiotic exposure and a reduction in antibiotic-related side
effects (16.3% versus 22.1%).
Quality of the evidence
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The quality of the evidence was high for mortality and antibiotic exposure. Most of the trials did not use blinding, however we did not
expect that mortality would be biased by this limitation. The quality of the evidence was moderate for treatment failure and antibiotic-
related side effects because the definitions for these endpoints among trials were not identical.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Procalcitonin algorithm compared to standard care for guiding antibiotic therapy in acute respiratory tract infections
Patient or population: people with acute respiratory tract infect ions
Settings: primary care, emergency department, intensive care unit
Intervention: PCT-guided care
Comparison: standard care
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; OR: odds rat io: PCT: procalcitonin
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1No downgrading for serious concerns. St ill, there is some concern about unconcealed allocat ion in several trials in the
emergency department and intensive care sett ings. There is also some concern about low adherence with the PCT algorithm
in the intervent ion group. We consider unblinded outcome assessment as not relevant for the outcome of death.
2Downgraded one level for serious inconsistency: trials used dif fering def init ion of treatment failure and some rare events
were not systematically assessed among trials.
3For the primary care sett ing, treatment failure was def ined as death, hospitalisat ion, acute respiratory infect ion (ARI)-specif ic
complicat ions (e.g. empyema for lower ARI, meningit is for upper ARI), recurrent or worsening infect ion, and part icipants
report ing any symptoms of an ongoing respiratory infect ion (e.g. fever, cough, dyspnoea) at follow-up. For the emergency
department sett ing, treatment failure was def ined as death, intensive care unit (ICU) admission, rehospitalisat ion af ter index
hospital discharge, ARI-associated complicat ions (e.g. empyema or acute respiratory distress syndrome for lower ARI), and
recurrent or worsening infect ion within 30 days of follow-up. For the ICU sett ing, treatment failure was def ined as death within
30 days of follow-up.
4Downgraded one level for incomplete report ing: only 6 trials reported side ef fects f rom antibiot ics, and none of these trials











































































































B A C K G R O U N D
Acute respiratory infections (ARIs) account for over 10% of global
disease burden and are the most common reason for antibi-
otic therapy in primary care and hospital settings (Evans 2002;
Gonzales 1997; Zaas 2014).
Description of the condition
Acute respiratory infections comprise a heterogeneous group of
infections including bacterial, viral, and other aetiologies. Asmany
as 75% of all antibiotic doses are prescribed for ARIs, despite their
mainly viral cause (Doan 2014; Evans 2002). Early initiation of
adequate antibiotic therapy is the cornerstone in the treatment
of bacterial ARIs and is associated with improved clinical out-
comes (Hoare 2006; Kumar 2006; Kumar 2009; Liberati 2009b;
Spurling 2010). However, overuse of antibiotics by overprescrip-
tion in outpatients with bronchitis (Arnold 2005), for instance,
and prolonged duration of antibiotic therapy in people with bac-
terial ARIs in the hospital and intensive care unit (ICU) settings
is associated with increased resistance to common bacteria, high
costs, and adverse drug reactions (Gonzales 1997; Goossens 2005;
Lawrence 2009; Zaas 2014).
Description of the intervention
The presence of a diagnostic ’gold standard’ or reference standard
represents the best available method for establishing the presence
or absence of a disease. Optimally, a morphological verification
such as histopathology or, in the case of ARIs, growth of typical
pathogens in blood cultures or sputum cultures can be obtained to
establish the ’correct’ diagnosis. Regrettably, the use of blood cul-
tures as the assumed gold standard in ARIs lacks sensitivity, speci-
ficity, or both, with only around 10% of people with pneumonia
having positive cultures and some of them being false positives
(Muller 2010). In this diagnostic uncertainty, surrogate biomarker
to estimate the likelihood for the presence of a bacterial infection
and to grade disease severity are of great interest (Schuetz 2015).
In such a circumstance, two fundamentally different concepts are
employed. One concept tends to ignore potential dilemmas in the
accuracy of the alleged gold standard but assumes a well-defined
illness, which is represented by the assumption drawn following a
diagnostic test or a clinical diagnosis. The second concept discards
alleged gold standards and focuses on patient outcomes. In the
case of ARIs, the clinical benefit of a diagnostic biomarker, such
as procalcitonin (PCT), can be measured by clinical outcomes of
randomised intervention studies, assuming that if the person re-
covered without antibiotics then there was no relevant bacterial
illness.
In recent years, PCT has emerged as a promising marker for the di-
agnosis of bacterial infections because higher levels are found in se-
vere bacterial infections but remain fairly low in viral infections and
non-specific inflammatory diseases (Muller 2000; Muller 2001;
Muller 2010). Procalcitonin is released in multiple tissues in re-
sponse to bacterial infections via a direct stimulation of cytokines,
such as interleukin (IL)-1β, tumour necrosis factor (TNF)- ,
and IL-6. Conversely, PCT production is blocked by interferon
gamma, a cytokine released in response to viral infections (Muller
2000). Hence, PCTmay be used to support clinical decision mak-
ing for the initiation and discontinuation of antibiotic therapy in
different types of infections and indications (Sager 2017; Schuetz
2016). Randomised controlled trials (RCTs) have demonstrated
the feasibility of such a strategy in different ARI patient popula-
tions and different settings ranging from primary care to emer-
gency departments and hospital wards to medical and surgical
ICUs (Bloos 2016; Branche 2015; Corti 2016; De Jong 2016;
Deliberato 2013; Layios 2012; Long 2014; Maravi -Stojkovi
2011; Oliveira 2013; Shehabi 2014; Verduri 2015; Wang 2016).
How the intervention might work
Procalcitonin levels correlate with the risk of relevant bacterial
infections and decrease upon recovery. Procalcitonin testing may
therefore help physicians decide in which patients antibiotics are
needed and when it is safe to stop treatment (Kutz 2015). The
use of PCT in clinical protocols may thus decrease antibiotic con-
sumption in two ways: by preventing unnecessary antibiotic pre-
scriptions and by limiting durations of antibiotic treatment (Sager
2017; Schuetz 2011a).
Why it is important to do this review
While several RCTs have evaluated PCT-guided antibiotic treat-
ment, most individual trials included participants with different
types of respiratory and non-respiratory infections and lacked the
statistical power to assess the risk for mortality and severe infec-
tious disease complications associated with PCT-guided decision
making. Previous meta-analyses of RCTs investigating the effect
of PCT algorithms on antibiotic use focused on the critical care
setting, people with suspicion of bacterial infections, and people
with sepsis and respiratory infections (Heyland 2011; Hoeboer
2015; Tang 2009; Wacker 2013). However, these meta-analyses
used aggregated data and were not able to investigate the effects
of PCT on different ARI diagnoses and on outcomes other than
mortality. A previous meta-analysis based on individual partici-
pant data published in the Cochrane Library did not find a sig-
nificant difference in clinical outcomes, but confidence intervals
remained relatively wide (Schuetz 2012). Safety of using PCT for
antibiotic decision making remained thus unproven.
O B J E C T I V E S
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The aim of this systematic review based on individual participant
data was to assess the safety and efficacy of using procalcitonin for
starting or stopping antibiotics over a large range of patients with
varying severity of ARIs and from different clinical settings.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Prospective RCTs comparing a strategy to initiate or discontinue
antibiotic therapy based on PCT levels with a control arm with-
out PCT measurements were eligible for inclusion. Participants
were randomised to receive antibiotics either based on PCT levels
(’PCT-guided’ group) or a control group without knowledge of
PCT levels, including antibiotic management based on usual care
or guidelines. We did not include non-randomised studies.
Types of participants
We included adult participants with clinical diagnoses of ARIs:
either a lower ARI including community-acquired pneumo-
nia (CAP), hospital-acquired pneumonia (HAP), ventilator-as-
sociated pneumonia (VAP), acute bronchitis, exacerbation of
asthma, or exacerbation of chronic obstructive pulmonary disease
(COPD); or an upper ARI including common cold, rhino-sinusi-
tis, pharyngitis, tonsillitis, or otitis media.We also included people
with sepsis and suspected ARIs in the analyses. We excluded trials
if they focused exclusively on children or used PCT to escalate
antibiotic therapy. We made no exclusions based on language of
reports or clinical setting. We included trials from primary care,
emergency departments, and medical and surgical ICUs.
Types of interventions
Strategies to initiate or discontinue antibiotic therapy based on
PCT levels compared with usual care were eligible.
Types of outcome measures
We defined primary and secondary outcomes to a follow-up time
of 30 days. For trials with shorter follow-up periods, we used the
available information (i.e. until hospital discharge). We excluded
all trials with different follow-up times for mortality in a sensitivity
analysis.
Primary outcomes
1. All-cause mortality following randomisation up to a follow-
up time of 30 days.
2. Setting-specific treatment failure within 30 days of
inclusion.
For the primary care setting, we defined treatment failure as
death, hospitalisation, ARI-specific complications (e.g. empyema
for lower ARIs,meningitis for upper ARIs), recurrent or worsening
infection, and still having ARI-associated discomfort at 30 days.
For the emergency department setting, we defined treatment fail-
ure as death, ICU admission, rehospitalisation after index hospital
discharge, ARI-associated complications (e.g. empyema or acute
respiratory distress syndrome for lower ARIs), and recurrent or
worsening infection within 30 days of follow-up. For the medical
and surgical ICU setting, we defined treatment failure as death
within 30 days of follow-up and recurrent or worsening infection.
Secondary outcomes
1. Antibiotic use (initiation of antibiotics, duration of
antibiotics, and total exposure to antibiotics (total amount of
antibiotic days divided by total number of participants)).
2. Length of hospital stay for hospitalised participants.
3. Length of ICU stay for critically ill participants.
4. Number of days with restricted activities within 14 days
after randomisation for primary care participants.
5. Antibiotic-related side effects.
Search methods for identification of studies
We updated the search strategy for this review in February 2017
in collaboration with the Cochrane Acute Respiratory Infections
Group’s Information Specialist. We performed data collection
based on the protocol of a previousmeta-analysis of individual par-
ticipant data published in the Cochrane Library (Schuetz 2008).
Electronic searches
Weupdated the searches for this review in February 2017, running
the search across all databases from the date of inception to 10
February 2017. We screened all new references identified by the
search. We searched the following databases for published studies:
• The Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 1), part of the Cochrane Library,
which includes the Cochrane Acute Respiratory Infections
Group’s Specialised Register, www.cochranelibrary.com/
(accessed 10 February 2017) (Appendix 1);
• MEDLINE Ovid (1966 to 10 February 2017) (Appendix
2);
• Embase.com (1980 to 10 February 2017) (Appendix 3).
We used the search strategy in Appendix 4 to conduct searches for
the 2012 version of this review (Schuetz 2012).
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We also searched for ongoing and completed trials in the following
trial register:
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov/; searched 12 April
2017).
We did not apply any language or publication restrictions.
Searching other resources
We contacted experts for further eligible trials.
Data collection and analysis
We requested individual participant data from the investigators of
all included trials. We checked all provided data against published
reports, and if needed, corrected any discrepancies.
We prepared this review update according to PRISMA guidelines
and the PRISMA-IPD guideline (Liberati 2009a; Stewart 2015).
Selection of studies
At least two review authors (RS, YW, PS) independently assessed
trial eligibility based on titles, abstracts, full-text reports, and fur-
ther information from investigators as needed.
Data extraction and management
We checked data from each trial against reported results and re-
solved any queries with the principal investigator, trial data man-
ager, or statistician. The mortality and adverse outcome rates from
trials included in this review may differ slightly from previous re-
ports because we treated data in a consistent manner across all
trials.
Assessment of risk of bias in included studies
Two review authors (RS, YW) assessed the methodological qual-
ity of each included study using the Cochrane ’Risk of bias’ tool
and resolved any disagreements by discussion (Higgins 2011).
Methodological criteria included: adequate sequence generation
and concealment of treatment allocation; blinding of participants,
physicians and clinical outcome assessment; whether the studywas
free of selective reporting; and the proportion of participants lost
to follow-up. We documented the proportion of participants in
the PCT group that adhered to the PCT algorithm used in each
study, defining adherence to the PCT algorithm of lower than
70% as high risk of bias, and, if not reported, as unclear risk.
Due to the study design of the included studies, physicians were
aware of the participants’ study group because in the intervention
group physicians used the PCT result for decision making about
antibiotic treatment, while in the control group no PCT result
was communicated to the physicians. Blinding of physicians was
therefore not feasible, resulting in an unclear risk for performance
bias in all studies.
We assessed the quality of evidence at the outcome level using the
GRADE approach (GRADEpro GDT 2014).
Measures of treatment effect
We calculated odds ratios (ORs) and 95% confidence intervals
(CIs) using multivariable hierarchical logistic regression for the
co-primary endpoints of mortality from any cause and treatment
failure (Thompson 2001; Turner 2000). We fitted corresponding
linear and logistic regression models for continuous and binary
secondary endpoints, respectively. We calculated Kaplan-Meier
curves for time to death for graphical display.
We used Stata version 12.1 (College Station, TX) for statistical
analyses (Stata 12.1).
Unit of analysis issues
The unit of our primary analysis was the individual study partic-
ipant. We analysed all participants in the study group to which
they were randomised. We calculated summary estimates using
aggregated data from individual trials as a sensitivity analysis.
Dealing with missing data
We received the full data sets from all trials included in the indi-
vidual participant data analysis (n = 26) with all available follow-
up information (if recorded in the trials).
We assumed in our main analysis that participants lost to follow-
up did not experience an event. We explored if a complete-case
analysis (excluding participants lost to follow-up) or an analysis
assuming that participants lost to follow-up experienced an event
would change the results for the primary outcomes of mortality
and treatment failure in sensitivity analyses. We checked all indi-
vidual participant data against the published results but did not
find significant differences that warranted further exploration.
Assessment of heterogeneity
We performed prespecified analyses stratified by clinical setting
(i.e. primary care, emergency department, ICU) and ARI diagno-
sis (CAP, COPD, bronchitis, VAP) to investigate the consistency
of results across our heterogeneous patient populations in terms
of disease severity. We formally tested for potential subgroup ef-
fects by adding the clinical setting and ARI diagnosis in turn to
the regression model together with the corresponding interaction
term with the PCT group as a fixed-effect model. We assessed
heterogeneity by estimating the I2 statistic (the percentage of to-
tal variance across trials that is due to heterogeneity rather than
chance) in meta-analyses using aggregated data and by testing for
heterogeneity using the Cochran Q test (Higgins 2003).
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Assessment of reporting biases
We assessed reporting bias by attempting to identify if the study
was included in a trial registry, a protocol was available, and if
the methods section provided a list of outcomes. We compared
listed outcomes from those sources to outcomes reported in the
published papers.
Data synthesis
We used multivariable hierarchical logistic regression to combine
participant data from the trials (Thompson 2001; Turner 2000).
Apart from the group variable indicating the use of a PCT algo-
rithm, we included important prognostic factors such as partici-
pant age and ARI diagnosis as an additional fixed effect; to account
for within- and between-trial variability, we added a categorical
trial variable to the model as a random effect. In meta-analyses
with aggregated trial data we calculated summary ORs using a
random-effects model and the Mantel-Haenszel facility of Review
Manager 5 (RevMan 2014).
GRADE and ’Summary of findings’ table
We created a ’Summary of findings’ table using the following out-
comes: all-cause mortality at 30 days, setting-specific treatment
failure at 30 days, total exposure to antibiotics, and antibiotic-re-
lated side effects (Summary of findings for the main comparison).
The results reported in this table correspond to the main IPD
analysis and are slightly different from the aggregate data analysis.
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness, and publication bias)
to assess the quality of a body of evidence as it relates to the stud-
ies that contribute data to the meta-analyses for the prespecified
outcomes (Atkins 2004). We used the methods and recommen-
dations in Section 8.5 and Chapter 12 of the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011), employing
GRADEpro GDT software (GRADEpro GDT 2014). We justi-
fied all decisions to down- or upgrade the quality of studies using
footnotes, and we made comments to aid the reader’s understand-
ing of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We performed prespecified analyses stratified by clinical setting
and ARI diagnosis and formally tested for potential subgroup ef-
fects by adding an interaction term into the statistical model.
Sensitivity analysis
We performed prespecified sensitivity analyses based on the main
quality indicators: allocation concealment, blinded outcome as-
sessment, adherence to the PCT algorithm (we defined low adher-
ence to PCT algorithms as < 70%), and follow-up time for mor-
tality other than one month. We also performed an aggregate data
meta-analysis using all trials with potentially eligible participants.
R E S U L T S
Description of studies
See:Characteristics of included studies, Characteristics of excluded
studies, and Characteristics of ongoing studies tables.
Results of the search
After removal of duplicates, we identified 998 records that we fur-
ther assessed based on title and abstracts, excluding 919 records.
We obtained 79 full-text study reports, and following assessment
excluded 39 that did not meet our inclusion criteria. Eight studies
were ongoing trials. From 32 eligible RCTs (9909 participants)
including 18 new trials for this 2017 update, we obtained indi-
vidual participant data from 26 trials including 6708 participants,
which were included in themain individual participant data meta-
analysis (see Figure 1). We did not obtain individual participant
data for four trials, and two trials did not include participants with
confirmed ARIs. The sensitivity aggregate analysis includes all 32
trials.
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Figure 1. Study flow diagram.Abbreviations: ARI: acute respiratory infection; IPD: individual participant
data; RCT: randomised controlled trial
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Included studies
We included a total of 26 studies involving 6708 participants in
the main individual participant data meta-analysis. Study charac-
teristics are presented in Table 1.
Participants
Baseline characteristics of included participants were similar in
the PCT and control groups with respect to important prognostic
features (Table 2). Most participants were recruited either in the
emergency department or ICU setting, and CAPwas the most fre-
quent ARI diagnosis, reported in more than 40% of participants.
Settings
Trials were conducted in 12 countries: Switzerland, Germany,
France, Italy, USA, China, Denmark, Netherlands, Brazil, Bel-
gium, Australia, and Serbia. Trials were conducted in different
clinical settings including primary care, emergency departments
and medical wards, and ICU. There were two primary care trials
with upper and lower respiratory infection patients; 11 emergency
department and medical ward trials with lower ARI patients; and
13 ICU trials with mostly septic patients due to infections of the
lower respiratory tract.
Interventions
Procalcitonin algorithms used in the different trials were similar
in concept and recommended initiation and/or continuation of
antibiotic therapy based on similar PCT cut-off levels (reviewed
in Schuetz 2011a). However, there were differences: some trials
in primary care and the emergency department used only a sin-
gle PCT measurement on admission to guide initiation of antibi-
otics, while the other trials (predominantly in hospitalised patients
with severe infections) used repeated measurements for guiding
the duration of treatment. One trial used a point-of-care device
(Corti 2016). Adherence to algorithms varied, ranging from 44%
to 100% (Table 3).
Comparators
In control group participants, PCT was not used to guide treat-
ment decisions, but this decision was up to the treating physi-
cian team. In some trials, physicians were asked to follow antibi-
otic guidelines for control group participants (Briel 2008; Schuetz
2009). In one trial, the control group was guided with C-reactive
protein levels (Oliveira 2013).
Funding sources
All studies were investigator-initiated trials. Half of the trials were
funded by national agencies or did not report funding; the other
half of the trials received funding from the biomarker industry
(e.g. Thermo Fisher Scientific).
Excluded studies
We excluded a total of 39 studies due to wrong intervention (n
= 1), wrong population (n = 2), and wrong design (not RCT) (n
= 36). A total of nine studies reported as ongoing in the 2012
reviewwere now available for assessment; we included four of these
studies in this current update (Annane 2013; Bloos 2016; De Jong
2016; Lima 2016), and did not include five studies due to wrong
population (paediatrics).
Ongoing studies
Our searches of the trial register identified seven ongoing stud-
ies that we will assess for inclusion for the next review update
(Ongoing studies). These studies focus on the utility of PCT in
people with pneumonitis (NCT02862314), pulmonary embolism
(NCT02261610), lower respiratory infection (NCT02130986),
heart failure (NCT02787603), and intraoperative positive-end ex-
piratory pressure optimisation (NCT02931409). Two trials are
antibiotic efficacy trials (NCT02332577; NCT02440828).
Risk of bias in included studies
The overall risk of bias is presented graphically in Figure 2 and
Figure 3. The risk of bias wasmostly low for random sequence gen-
eration, allocation concealment, incomplete outcome data, and
selective reporting; unclear for blinding of personnel in all studies;
and mostly high for blinding of outcome assessment.
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Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All studies randomised participants to intervention (PCT testing)
or control groups. A total of 25 trials with mainly computer-gen-
erated lists and centralised randomisation were at low risk of selec-
tion bias. Seven trials were at high or unclear risk of selection bias.
Risk for selection bias with regard to random sequence generation
was due to weekly allocation (Christ-Crain 2004), unnumbered
envelopes (Christ-Crain 2006; Stolz 2007), use of odd and even
patient identification numbers (Long 2009; Long 2011), and un-
concealed drawing of lots (Hochreiter 2009; Schroeder 2009).
Blinding
None of the included trials blinded physicians to group allocation
because PCT was used for decision making in the intervention
group, thus all trials had unclear risk for blinding of participants
and personnel.
All trials used blinded outcome assessment (Briel 2008; Bouadma
2010; Branche 2015; Layios 2012; Schuetz 2009; Shehabi 2014;
Stolz 2007; Tang 2013), employing blinded telephone interviews
to assess vital status and other outcomes.
Incomplete outcome data
The included trials had a high follow-up for mortality with few
participants lost to follow-up (Table 3). In seven trials, outcome
assessment was done after hospital or ICU discharge (Deliberato
2013; Hochreiter 2009; Kristoffersen 2009; Layios 2012; Long
2009; Schroeder 2009; Shehabi 2014). One trial had a high num-
ber of post randomisation exclusions (six in the intervention arm
versus four in the control group) and thus had an unclear risk of
bias (Ding 2013).
Selective reporting
No reporting bias was foundwhen study protocols and final results
were compared. However, we did not find registration numbers
for four trials (Ding 2013; Layios 2012;Maravi -Stojkovi 2011;
Najafi 2015), which we considered to be at unclear risk of bias.
We found no evidence of reporting bias by visual inspection of
funnel plots (Figure 4).
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Figure 4. Funnel plot of comparison: 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified
by clinical setting, outcome: 1.1 Mortality at 30 days.
Other potential sources of bias
Another potential source of bias relates to low adherence to the
PCT algorithms, particularly for safety endpoints. Overall, adher-
ence varied, ranging from 44% to 100% (Table 3).
With regard to funding, 16 trials reported no industry funding
(six did not report any funding, 10 reported public funding), and
in 16 trials Thermo Fisher, the producer of the PCT assay, funded
or co funded the studies by providing free-of-charge PCT kits or
additional research funds, or both.
Effects of interventions
See: Summary of findings for the main comparison
Procalcitonin algorithm compared to standard care for guiding
antibiotic therapy in acute respiratory tract infections
Primary outcomes
1. All-cause mortality following randomisation up to a
follow-up time of 30 days
There were 286 deaths in 3336 PCT-guided participants (8.6%)
compared to 336 in 3372 controls (10.0%) resulting in a signif-
icantly lower mortality associated with PCT-guided therapy (ad-
justed odds ratio (OR) 0.83, 95% confidence interval (CI) 0.70 to
0.99, P = 0.037) (Table 4). This effect was consistent across clin-
ical settings (P for interaction > 0.05), although mortality could
not be estimated in primary care trials because only one death was
reported in a control group participant. The effect on mortality
was also consistent among different ARI diagnoses (CAP, COPD,
bronchitis, VAP) (P for interaction > 0.05). As a further sensitiv-
ity analysis and to investigate heterogeneity among trials, we also
calculated an aggregate data meta-analysis based on the aggregate
results of all 32 potentially eligible trials (thus not limited to ARI
participants only). In this analysis, the results proved robust, al-
though the mortality estimate did not reach statistical significance
(OR 0.89, 95% CI 0.78 to 1.01; Analysis 1.1; Figure 5). There
was no evidence of heterogeneity (I2 = 0%).
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Figure 5. Forest plot of comparison: 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified
by clinical setting, outcome: 1.1 Mortality at 30 days.
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2. Setting-specific treatment failure within 30 days of
inclusion
Treatment failure was not significantly lower in PCT-guided par-
ticipants (23.0% versus 24.9%, adjusted OR 0.90, 95% CI 0.80
to 1.01, P = 0.068). These results were similar among subgroups
by clinical setting and type of respiratory infection (P for interac-
tion > 0.05). With an OR of 0.90 (95% CI 0.81 to 0.99), treat-
ment failure was significantly lower in PCT group participants in
an aggregate data meta-analysis based on all 32 potentially eligible
trials (thus relying on the original definition of treatment failure
as used in the trials). There was no evidence of heterogeneity (I2 =
0%) (Figure 6). We also performed several predefined sensitivity
analyses, which showed no evidence for interactions (see summary
in Table 5).
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Figure 6. Forest plot of comparison: 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified
by clinical setting, outcome: 1.2 Treatment failure at 30 days.
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Secondary outcomes
1. Antibiotic use (initiation of antibiotics, duration of
antibiotics, and total exposure to antibiotics (total amount
of antibiotic days divided by total number of participants))
Procalcitonin guidance was associated with a reduction in total
antibiotic exposure (mean 8.1 days compared to 5.7 days, regres-
sion coefficient -2.43 days (95% CI -2.71 to -2.15), P < 0.001).
Also, duration of antibiotic treatment in treated participants was
shorter (mean 9.4 days compared to 8.0 days, adjusted coefficient
-1.83 days (95% CI -2.15 to -1.5), P < 0.001) (Table 6).
2. Length of hospital stay for hospitalised participants
However, the effect on antibiotic consumption differed according
to clinical setting. In the primary care setting, lower antibiotic ex-
posure wasmainly due to lower initial prescription rates (P < 0.001
for interaction between primary care setting and PCT group on
antibiotic prescriptions). Similarly, lower antibiotic exposure due
to lower prescription rates was found in selected infections such as
acute bronchitis (adjusted OR 0.18, 95% CI 0.12 to 0.26; P for
interaction < 0.001). Lower antibiotic prescription rates (adjusted
OR 0.49, 95% CI 0.41 to 0.58) and shorter duration of antibi-
otic therapy in participants with initiation of antibiotic (adjusted
coefficient -2.45 days, 95% CI -2.86 to -2.05) contributed to the
lower overall exposure in the emergency department setting.
Length of hospital stay and ICU stay were similar in both groups
with no evidence for different effects in subgroups (P for interac-
tion > 0.05).
3. Length of ICU stay for critically ill participants
For the ICU setting, the lower exposure was mainly explained
by shorter treatment durations (adjusted difference in days -1.23,
95% CI -1.82 to -0.65). Similarly, for CAP, the lower exposure
was mainly explained by shorter durations (adjusted difference in
days -2.45, 95% CI -2.87 to -2.02).
4. Number of days with restricted activities within 14 days
after randomisation for primary care participants
For studies conducted in the primary care setting, there was no
difference in days with restricted activities of daily living between
PCT and control group participants (days, 8.9 ± 4.2 versus 8.9
± 4.1, regression coefficient 0.07 (95% CI -0.44 to 0.59), P =
0.777).
5. Antibiotic-related side effects
There was also a significant reduction in antibiotic-related side
effects (16.3% versus 22.1%, adjusted OR 0.68, 95% CI 0.57 to
0.82, P < 0.001). This outcome was only assessed in some of the
primary care and emergency department trials (n = 6), and not
in ICU trials. There was no evidence for subgroup effects (P for
interaction > 0.05).
D I S C U S S I O N
Summary of main results
This updated systematic review and meta-analysis included 32 tri-
als, of which 26 trials were used for themain individual participant
data analysis. Trials were conducted in 12 countries and included
different clinical settings and types of respiratory infections. There
was mostly low risk for random sequence generation, allocation
concealment, incomplete outcome data, and selective reporting.
There was unclear risk in all studies for blinding of personnel,
and mostly high risk for blinding of outcome assessment. The
results indicate a significant reduction in mortality (high-quality
evidence according to GRADE, Summary of findings for themain
comparison) and non-significant result for treatment failure (mod-
erate-quality evidence according toGRADE, Summary of findings
for the main comparison) when PCT was used to guide initiation
and duration of antibiotic treatment inARI participants compared
to control participants. Additionally, antibiotic consumption and
side effects from antibiotics were significantly reduced across dif-
ferent clinical settings and types of ARIs. There was no effect on
length of hospital stay and ICU length of stay. Results were similar
in subgroup and sensitivity analyses including an aggregate data
analysis with all 32 potentially eligible trials. Limitations include
incomplete individual participant data, with four research groups
not agreeing to the sharing of individual participant data; incom-
plete follow-up information in some of the trials where no out-
come assessment was done after 30 days of enrolment; differences
in definitions of treatment failure among trials; and exclusion of
some patient populations such as immunosuppressed people. Still,
results from this updated individual participant data meta-analysis
support the use of PCT in the context of antibiotic stewardship
in people with ARIs.
Overall completeness and applicability of
evidence
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The strengths of our review include an explicit study protocol, a
comprehensive search to retrieve all relevant trials, access to in-
dividual participant-level data from all but four of the included
trials, and standardised outcome definitions across trials, thereby
overcoming limitations of meta-analyses using aggregated data. To
minimise the risk of data-driven associations, we prespecified a
limited number of prognostic factors and subgroup variables for
our statistical model. We allowed for potential clustering effects
by using random-effects models for included trials. Our results
proved robust in sensitivity analyses focusing on high-quality trials
and on participants with complete follow-up data.
The accuracy of PCT for diagnosing bacterial infections has
been called into question by previous meta-analyses of observa-
tional studies, which demonstrated mixed results (Jones 2007;
Simmonds 2005; Tang 2007; Uzzan 2006). However, a more re-
cent meta-analysis using positive culture as the reference method
found moderate to high discrimination of systematic inflamma-
tory response syndrome and sepsis (Wacker 2013). Since there are
no available gold standards for the diagnosis of the clinical condi-
tions included in our analysis, most studies used clinical consen-
sus criteria, which may differ among studies. Rather than relying
on these imperfect diagnostic criteria, we were able to assess the
value of PCT algorithms by means of RCTs measuring clinically
relevant, participant-level outcomes.
Despite these merits, this review has several limitations. We lim-
ited our analysis to adults with ARIs who were mostly immuno-
competent, and excluded some pathogens (i.e. Legionella or Pseu-
domonas infections). The results of these trials may therefore not
be generalised to people who are immunocompromised, with spe-
cific pathogens or infections other than ARIs, or children. Previ-
ous RCTs have shown that PCT guidance also reduces antibiotic
exposure in a neonatal sepsis population but not in children with
fever without a source (Manzano 2010). We found several ongo-
ing RCTs in children evaluating PCT algorithms that should shed
further light on the benefits and harms of PCT use for children.
The included trials compared the PCT strategy to a control group
where antibiotic therapy was guided based on ’usual practice’ or
based on current guideline recommendations. The magnitude of
antibiotic reduction obviously correlates strongly with antibiotic
prescription patterns, and in regions of low antibiotic prescription
the PCT strategy may have smaller effects.
Quality of the evidence
Characteristics of the individual trials are presented in Table 1.
Most trials had a follow-up of one month, with two trials assessing
outcome after 14 to 21days and several trials followingparticipants
until hospital discharge (or ICU discharge) only. Procalcitonin al-
gorithms used in the different trials were similar in concept and
recommended initiation and/or continuation of antibiotic ther-
apy based on similar PCT cut-off levels (Table 1). However, there
were differences: some trials in primary care and the emergency
department used only a single PCT measurement on admission
to guide initiation of antibiotics (Burkhardt 2010; Christ-Crain
2004), while the other trials (predominantly in hospitalised par-
ticipants with severe infections) used repeated measurements for
guiding the duration of treatment. Adherence to algorithms was
variable. In terms of methodological quality, trials had concealed
allocation, but in several trials blinded outcome assessment was
not done. All trials achieved complete or near-complete follow-up
for mortality. None of the trials blinded participants or physicians
to group allocation. The overall quality of the evidence according
to GRADE was moderate to high (Summary of findings for the
main comparison).
Potential biases in the review process
Due to the differences in patient populations included in this
analysis, which ranged from primary care to the ICU, we adapted
the definition of treatment failure to clinical settings by including
setting-specific components in this composite outcome. This may
challenge the clinical interpretation in the overall analysis.
Agreements and disagreements with other
studies or reviews
While mortality did not differ significantly in our initial meta-
analysis (adjustedOR0.94, 95%CI 0.71 to 1.23) (Schuetz 2012),
we found a significantly lower mortality rate in PCT-guided par-
ticipants in this update. This result was robust in subgroup anal-
yses and in our sensitivity analysis. Also, when considering all tri-
als in the aggregate data analysis, mortality tended to be reduced,
although not significantly (OR 0.89, 95% CI 0.78 to 1.01). Im-
portantly, the largest-yet ICU trial from the Netherlands has re-
ported a significantly lower mortality in PCT-guided participants
(De Jong 2016).
Two of the included individual trials reported reduced length of
stay, particularly within the ICU. Yet, despite a marked reduc-
tion in the duration of antibiotic therapy across trials and settings,
there was no difference in length of ICU and hospital stay between
the two groups in our comprehensive analysis. One might expect
that clinically stable patients with discontinued intravenous an-
tibiotics could be safely discharged unless there are extenuating
circumstances. Perceived needs by physicians to further monitor
these patients in the unit or inability to transfer patients to other
inpatient or aftercare locations may partly explain this finding.
There is ongoing controversy about the diagnostic performance of
PCT and other blood markers to correctly identify patients with a
bacterial infection. In fact, several observational studies have ques-
tioned the added value of PCT in addition to clinical signs, such
as a primary care study authored by van Vugt and colleagues re-
porting no additional benefit of PCT to a clinical assessment (van
Vugt 2013). Importantly, in the context of respiratory infections,
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diagnostic studies are limited by the lack of a reference standard,
with blood cultures only detecting a minority of cases (e.g. only
10% to 20% of patients with clinically and radiologically con-
firmed CAP have positive blood cultures) (Muller 2010; Wacker
2013). Interventional research, such as the trials included in the
current analysis, do not rely on a reference standard but compare
resource use (e.g. antibiotics) and clinical outcomes in people with
and without use of the diagnostic marker. For the primary care
setting, PCT had a very strong effect on antibiotic consumption
(reduction of antibiotic exposure by 70%, from 4.6 to 1.6 days)
without compromising disease resolution and patient safety. Of
note, we were not able to assess the effect of PCT onmortality due
to the very low risk situation with only one non-survivor (control
group) among the 1008 included participants.
The available evidence from RCTs, as summarised in this report,
supports the use of PCT for de-escalation of antibiotic therapy
for people with ARIs. The same may not be true for escalation
of antibiotic therapy when PCT levels increase as demonstrated
in a recent large sepsis trial (Jensen 2011), where PCT-guided
escalation of diagnostic procedures and antimicrobial therapy in
the ICU did not improve survival and led to organ-related harm
and prolonged ICU stays.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Emerging bacterial resistance tomultiple antibiotic agents calls for
more stringent efforts to reduce the empiric use of antimicrobial
agents in self limited and non-bacterial diseases and to shorten the
duration of antibiotic treatment in bacterial infection with clini-
cal resolution. The results of our study suggest that procalcitonin
(PCT) is a safe and effective tool to guide clinical decisions for
antibiotic initiation and duration of treatment. In all trials, PCT
was used to inform physicians about the need for initiation or dis-
continuation of antibiotic therapy, or both. However, there were
differences in PCT protocols among trials depending on the clin-
ical setting (see Table 1 for details about PCT recommendations
used in the individual trials) (Schuetz 2011a; Schuetz 2015). In
brief, PCT was mainly used to inform about initiation of antibi-
otic treatment in primary care trials, and re-measurement of PCT
was recommended in participants not being treated with antibi-
otics and not showing a resolution of illness at follow-up. In the
emergency room and hospital ward setting, PCT was used to in-
form about initiation of antibiotic treatment (mainly in low-risk
patients with bronchitis or chronic obstructive pulmonary dis-
ease exacerbation), and also about discontinuation of treatment in
community-acquired pneumonia patients. In intensive care unit
patients, PCT was mainly used to monitor treatment and discon-
tinue antibiotics in participants with clinical improvement and a
drop in PCT levels. Thus for clinical practice, PCT should also
be adapted to clinical settings and the risk of patients - similar to
patients with suspicion of pulmonary embolism where D-dimer
levels are used differently depending on the pre-test probability
(Konstantinides 2008).
The use of PCT to guide initiation and duration of antibiotic
treatment in people with acute respiratory infections (ARIs) was
associated with lower mortality rates and significantly reduced an-
tibiotic consumption and associated side effects across different
clinical settings and ARI diagnoses. Of note, mortality was very
low in primary care patients, and we were thus not able to assess
the effect of PCT onmortality. The use of PCT embedded in clin-
ical algorithms has the potential to improve the antibiotic man-
agement of ARI patients and has substantial clinical and public
health implications to reduce antibiotic exposure and the associ-
ated risk of antibiotic resistance. Several assays for the measure-
ment of PCT are currently available (Schuetz 2017), and the US
Food and Drug Administration recently cleared the Vidas assay,
among others, for antibiotic stewardship and prognostication of
patients using a PCT kinetics algorithm (Schuetz 2016). Impor-
tantly, all trials have used highly sensitive assays to measure PCT
in order to have optimal sensitivity and thus test performance.
Factors such as accessibility and time taken to get reports of the
tests are equally important in whether PCT will be used in the
clinical decision-making process for antibiotic therapy in ARIs. In
this regard, a point-of-care test would be important, especially for
the primary care setting (Kutz 2016).
Importantly, all trials included PCT into clinical algorithms, and
physicians could deviate from the PCT algorithm if needed. Post-
study surveys have beenpublished in order to better understand the
effects and challenges of PCT testing in clinical practice (Albrich
2012; Balk 2017).
Implications for research
Future studies should establish cost-effectiveness by considering
country-specific costs of PCT measurement (around USD 20 to
USD 30 per sample) and potential savings in consumption of
antibiotics and other healthcare resources (Stojanovic 2017).
In addition, it would be interesting to conduct a head-to-head
trial comparing a PCT strategy to a strategy based on another
biomarker, such as C-reactive protein (CRP) or interleukin-6
(Meili 2015; Meili 2016). A similar randomised controlled trial
was recently conducted in primary care in the Netherlands with a
treatment algorithm based on either CRP levels, communication
training, or both, compared to a control group (Cals 2009). The
trial authors reported a 42% relative reduction in antibiotic use
with CRP guidance, which was similar to the effect of commu-
nication training in this setting. However, the usefulness of CRP
for antibiotic guidance outside the primary care setting is not yet
supported by controlled intervention trials.
While there is strong evidence for the use of PCT in respiratory in-
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fections, its role in other infections remains unclear. Several studies
have investigated PCT as a diagnostic and antibiotic stewardship
marker in different types of infections (Albrich 2012; Drozdov
2015; Sager 2017). However, larger trials powered for safety are
needed to understand the effect of PCT outside respiratory infec-
tions.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Annane 2013
Methods Randomised, multicentre, single-blind clinical trial in 8 French ICUs
Participants Inclusion criteria: Adults admitted to a participating ICU were eligible if they, < 48 h,
had SIRS, acute dysfunction of at least 1 organ, absence of indisputable clinical infection,
and negative microbial cultures
Exclusion criteria: Pregnancy, burns over ≥ 15% of body surface area, trauma, outpa-
tient or inpatient cardiac arrest, post-orthopaedic surgery status, drug-related neutrope-
nia, withdrawal of life-supportive therapies or a decision to withhold them, indisputable
clinical infection or antibiotic exposure ≥ 48 h during the time shortly before ICU
admission
Included in this study: 62/1250 screened patients were eligible for the study, of whom
31 were randomised to each arm. 4 post randomisation exclusion (4 withdrew their
consent)
Interventions Guiding antibiotic decisions in ICU patients with non-microbiologically proven appar-
ent severe sepsis
Algorithm used in this study: In the experimental arm, both initiation and discon-
tinuation of antibiotics were guided by a PCT-based algorithm, applied at 6 h and on
day 3 and day 5 post randomisation. Briefly, antibiotic therapy was not to be started or
was to be halted when PCT was < 0.25 µg/L, was strongly discouraged when PCT was
≥ 0.25 to < 0.5 µg/L, was recommended when PCT was ≥ 0.5 to < 5 µg/L, and was
strongly recommended when PCT was ≥ 5 µg/L. Owing to the fact that surgery can
increase PCT levels, for 12 participants enrolled in the 48-hour postoperative period,
the respective PCT cut-offs were < 4 µg/L,≥ 4 to < 9 µg/L, and≥ 9µg/L. Investigators
were strongly advised not to overrule the algorithm every day up to the study day 5. In
the control arm, the decision to start or stop antibiotic therapy was at the discretion of
the participant’s physician, without knowledge of the participant’s PCT concentrations
Outcomes • proportion of participants receiving antibiotics at day 5 post randomisation
• death at day 5, at ICU discharge, and at hospital discharge
• proportion of participants started on antibiotics post randomisation
• duration of antibiotic exposure
• SOFA score at day 3 and day 5
• proportion of participants with infection acquired between randomisation and
day 3, day 5, and ICU discharge
• ICU and hospital length-of-stay
Notes Funding: Research grant partly by Thermo Fisher B·R·A·H·M·S France. The sponsor
had no input in study design, conduct, or reporting.
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Annane 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised in a 1:1 ra-
tio according to a computer-generated list.
Randomisation was centralised through a
secured web site and performed by an in-
dependent statistician
Allocation concealment (selection bias) Low risk Centralised randomisation using permuta-
tion blocks
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The control arm remained blinded to PCT
levels. Masking of antibiotic therapy was
not feasible in this study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Investigators remained blinded to PCT lev-
els in the control arm, but no blinding of
overall outcome assessment was mentioned
in the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up for participants on antibiotic on
day 5 was: 58/62. 4 participants withdrew
their consent
Selective reporting (reporting bias) Low risk Outcomes correspond to study protocol.
Trial registered (NCT01025180)
Other bias Unclear risk Moderate adherence in the PCT arm:
physicians were non-compliant with the
PCT-based algorithm in 19% of partici-
pants at 6 h, 17% on day 3, and 37% on
day 5.
The study was stopped prematurely owing
to the low incidence of eligible patients.
As a consequence, the study population is
small with low statistical power
Bloos 2016
Methods Randomised, investigator-initiated, multicentre, partially blinded clinical trial, in 33
multidisciplinary ICUs across Germany
Participants Inclusion criteria: Adults with severe sepsis or septic shock (severe sepsis was defined
as SIRS caused by infection combined with acute organ dysfunction. Septic shock was
defined as sepsis in combinationwith arterial hypotension or need for vasopressor therapy
despite adequate fluid resuscitation)
Exclusion criteria: Pregnant or lactating women, patients with selenium intoxication,
individuals with infections for which guidelines recommend a longer duration of an-
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timicrobial therapy, immunocompromised patients, and those without commitment to
full therapy or where death was imminent owing to coexisting diseases were excluded
from the trial.
Included in this study: 1180 participants were randomised; 91 participants were ex-
cluded from the final analysis because informed consent was not obtainable in the de-
ferred consent process, resulting in 1089 participants with valid data
Interventions Guiding antibiotic decisions and effect of sodium selenite administration in people with
severe sepsis or septic shock
Algorithm used in this study:Using a 2 × 2 factorial design, participants were randomly
assigned to receive intravenous sodium selenite or placebo as well as antimicrobial therapy
guided by a PCT algorithm or conventional antimicrobial therapy.
In participants randomised to the PCT guidance arm, PCT was measured locally on
days 0, 1, 4, 7, 10, and 14 after randomisation if the participant was still in the ICU.
Procalcitonin concentration on day 0 or day 1 served as the baseline value. Depending
on the PCT results, an algorithm provided recommendations to change or discontinue
antimicrobial therapy or trigger diagnostic procedures to optimise source control. On
day 4, no change in antimicrobial therapy was recommended if the PCT level dropped
by at least 50% compared with the baseline value. Otherwise, change or optimisation
of antimicrobial therapy or interventions regarding source control were recommended.
On the other days, stopping antimicrobial therapy was recommended if the PCT level
was 1 ng/mL or lower or if the PCT level dropped by at least 50% compared with the
previous value. Otherwise, change or optimisation of antimicrobial therapy or interven-
tions regarding source control were recommended. The treating physician was allowed
to overrule the algorithm recommendation.
In the group without PCT guidance, no PCTmeasurements were obtained until day 14;
changes in antimicrobial therapy were made at the discretion of the treating physician.
Investigators agreed to treat all participants according to the Guidelines of the Germany
Sepsis Society, which included recommendations to re-evaluate antimicrobial therapy
after 48 to 72 hours and to restrict duration of antimicrobial therapy to no more than
10 days
Outcomes • death from any cause by 28 days after inclusion
• 90-day all-cause mortality
• mean total SOFA score and its sub scores
• duration of ICU and hospital stay
• ventilator-, vasopressor-, and dialysis-free days until day 90
• duration and costs of antimicrobial therapy
• duration until change of antimicrobial therapy
• antimicrobial exposure days
• days free of antimicrobial therapy
• frequency of surgical source control
• frequency of diagnostic procedures for localisation of the infection focus
• clinical and microbiologic treatment response
• secondary infections
• emergence of antibiotic-resistant bacteria
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Notes Funding: The study infrastructure was partially funded by grant 01 KI 0106 from the
German Federal Ministry of Education and Research. Biosyn (Germany) and Thermo





Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Web-based, centralised randomisation
Allocation concealment (selection bias) Low risk quote “Using a 2 × 2 factorial design, we
randomly assigned patients to receive in-
travenous sodium selenite or placebo as
well as antimicrobial therapy guided by a
PCT algorithm or conventional antimicro-
bial therapywithout PCTguidance with an
allocation ratio of 1:1:1:1 by use of a cen-
tral randomisation web server. Randomisa-
tion was stratified by study centre, sex, and
sepsis severity”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Due to the study design, blinding of physi-
cians was not feasible. Procalcitonin val-
ues were only available in participants with
study intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment was
mentioned in study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Postrandomisation exclusions were about
even among intervention arms with a very
low dropout rate for mortality
Selective reporting (reporting bias) Low risk Outcomes correspond to trial registration
(NCT00832039)
Other bias Unclear risk Overruling of the PCT algorithm was very
high (adherence was lower than 50%)
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Bouadma 2010
Methods Randomised, multicentre clinical trial in 9 French ICUs
Participants Inclusion criteria: Patients with suspected bacterial infections during ICU stay without
prior AB (> 24 h)
Exclusion criteria: Aged under 18 years; known pregnancy; expected stay in the ICU
of less than 3 days; bone marrow transplant or chemotherapy-induced neutropenia (<
500 neutrophils per mL); infections for which long-term antibiotic treatment is strongly
recommended (i.e. infective endocarditis, osteoarticular infections, anteriormediastinitis
after cardiac surgery, hepatic or cerebral abscesses, chronic prostatitis, or infection with
Mycobacterium tuberculosis, Pneumocystis jirovecii, or Toxoplasma gondii); poor chance of
survival, defined as a simplified acute physiology score (SAPS II) of more than 65 points
at screening; and do-not-resuscitate orders
Included in this analysis: 394 participants with CAP and VAP out of 630 randomised
participants; 9 post randomisation exclusions (8 withdrew consent, 1 randomised twice)
, and 227 not considered for this analysis due to diagnosis other than ARI
Interventions Guiding antibiotic decisions in ICU patients with repeated PCT measurements
Algorithm used in this study: Investigators were encouraged to discontinue ABs when
PCT concentration was less than 80% of the peak concentration or an absolute concen-
tration of less than 0.5 µg/L was reached
Outcomes • all-cause mortality at day 28
• all-cause mortality at day 60
• antibiotic use
• relapse or superinfection (days 1 to 28)
• number of days without mechanical ventilation (days 1 to 28)
• SOFA score (days 1, 7, 14, and 28)
• length of stay in the ICU and hospital
Notes Funding: Research grant from the Départment à la Recherche Clinique et au
Développement, Assistance Publique-Hopitaux de Paris (PHRC AOR06019), France.
B·R·A·H·M·S, Germany (manufacturer of PCT assay) provided all assay-related mate-
rials free of charge for the study (Kryptor machines if not already available on-site and
kits and maintenance required for study-related measurements)
Follow-up: Fixed period of 60 days for mortality
Registration: NCT00472667
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Independent, centralised, computer-gener-
ated randomisation sequence (CleanWEB,
Telemedicine Technologies, Boulogne,
France)
Allocation concealment (selection bias) Low risk Centralised randomisation
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label trial where physicians knew to
which groupparticipants hadbeen assigned
and where PCT levels were only commu-
nicated in the intervention arm
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “Although treatment assignments
were not masked, all investigators were un-
aware of aggregate outcomes during the
study and primary endpoints were strictly
defined and not patient-reported.”
Quote: “An adjudication committee com-
prised of 4 specialists in infectious diseases
and critical caremedicinewhoweremasked
to the randomisation assignment reviewed
and validated all infectious episode classifi-
cations by consensus.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up for mortality: 393/394 (100%)
Selective reporting (reporting bias) Low risk Outcomes correspond to study protocol.
Trial registered (NCT00472667)
Other bias Unclear risk Low adherence to PCT algorithm in PCT
group (47%)
Branche 2015
Methods Single-centre, randomised, open-label clinical trial in Rochester, NY, USA
Participants Inclusion criteria: Adults≥ 21 years of age with symptoms compatible with LRTI (i.e.
admission diagnosis of pneumonia, acute exacerbations of COPD, bronchitis, asthma,
influenza, viral syndrome, respiratory failure, and congestive heart failure CHF) were
identified by reviewing the daily admission census.
Exclusion criteria: Patients with characteristics indicative of a high risk for bacterial
infection (i.e. ICU requirement, active chemotherapy or radiation, immunosuppression,
definitive infiltrate on chest radiograph, enrolment systolic bloodpressure of < 90mmHg,
and ≥ 15% band forms in peripheral blood). Patients who had conditions known to
increase PCT levels (i.e. trauma, renal failure, and pancreatitis) or who had received
antibiotics prior to admission were also excluded.
Included in this study: 300/685 screened patients were eligible for the study, of whom
151 were randomised to the intervention group and 149 to the non-intervention group
Interventions Guiding antibiotic decisions in hospitalised patients with respiratory infections
Algorithm used in this study: In the intervention group serum PCT and viral/atypical
pathogen PCR testing were performed on admission (in addition to all standard-of-
care diagnostic tests). Antibiotic decisions were made based on a PCT algorithm (for
PCT values of ≤ 0.1 ng/mL, initiation of antibiotic treatment is strongly discouraged;
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for values of 0.11 to 0.24 ng/mL, initiation is discouraged; for values of 0.25 to 0.49
ng/mL, initiation is encouraged; and for values of ≥ 0.5 ng/ mL, initiation is strongly
encouraged). In the standard care group standard-of-care testing (bacterial and viral
cultures of respiratory samples, hospital influenza/RSV duplex PCR, and urine Legionella
antigen analysis) were obtained on admission and antibiotic decisions were made by the
attending physician. Participants in the standard care group had PCT and viral testing
samples frozen and tested at study termination
Outcomes • duration of antibiotic therapy





Notes Funding: This work was supported by Rochester General Hospital (KIDD Fund); the
National Institutes of Health, National Institute of Allergy and Infectious Diseases (con-
tract HHSN27220120005C); and BioFire (FilmArray respiratory panel instrument).
Follow up time: Study personnel reviewed the EMR daily until hospital discharge.
Participants were contacted by phone at 30 days and 3 months by personnel blinded
to randomisation, who collected information about healthcare utilisation, antibiotic use
and complications, and return to baseline health.
Registration: NCT01907659
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were stratified by the presence
of COPD and were randomly assigned at
a ratio of 1:1, using blocks of 4, to receive
standard care or the intervention
Allocation concealment (selection bias) Low risk Small block size (4) for randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding was not feasible due to the study
design.
Although the control arm remained
blinded, there was a risk for spillover care
resulting from providers caring for partici-
pants in both arms
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants in the standard care group had
blood samples frozen and tested at study
termination,making the data only available
at the end of the study. Phone follow-up by
personnel blinded to randomisation
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Over 3months of follow-up36participants
were lost to follow-up, 13 died, and 4 with-
drew their consent (237/300 completed 3-
month follow-up)
Selective reporting (reporting bias) Low risk Outcomes correspond to study protocol.
Trial registered (NCT01907659)




Methods Randomised clinical trial, multicentre in 53 primary care practices in northwest Switzer-
land
Participants Inclusion criteria: People with upper or lower ARIs in primary care and the physician’s
intention to prescribe antibiotics on the basis of evidence-based guidelines
Exclusion criteria: Antibiotic use within the previous 28 days, psychiatric disorders or
inability to give written informed consent, not being available for follow-up, not fluent
in German, severe immunosuppression, cystic fibrosis, active tuberculosis, and the need
for immediate hospitalisation
Included in this analysis: 458 out of 458 randomised participants
Interventions Guiding antibiotic decisions in primary care with repeated measurements
Algorithm used in this study: In participants with PCT levels lower than 0.1 µg/L, a
bacterial infection was considered highly unlikely and the use of ABs was discouraged. In
participants with a PCT level higher than 0.25µg/L, a bacterial infection was considered
likely and the use of ABs was recommended. For PCT concentrations of 0.1 to 0.25 µg/
L, a bacterial infectionwas considered unlikely and the use of ABswas not recommended.
When ABs were withheld from participants, a second measurement of the PCT level was
mandatory within 6 to 24 hours for safety reasons. The use of ABs was recommended if
this second measurement was higher than 0.25 µg/L or if the PCT level had increased
from the first measurement by more than 50% and the participant showed no clinical
improvement. All participants given ABs based on PCT level were reassessed after 3 days.
Discontinuation of AB treatment was then recommended in participants with a PCT
level of 0.25 µg/L or lower
Outcomes • number of days, within the first 14 days after baseline, during which a participant’s
daily activities (work or recreation) were restricted by a respiratory tract infection
• degree of discomfort from infection (scored on a scale from 0 (no discomfort) to
10 (a great deal of discomfort)) at 14 days
• days of work missed within 14 days
• days with adverse effects from medication (abdominal pain, diarrhoea, vomiting,
skin rash) within 14 days
• antibiotic use
• participants with any symptoms of ongoing or relapsing infection at 28 days
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Notes Funding: Swiss National Science Foundation (Grant 3300C0-107772) and Association
for the Promotion of Science and Postgraduate Training of the University Hospital Basel,
Switzerland. B·R·A·H·M·S,Germany provided assay and kitmaterial related to the study
Follow-up: Fixed period of 28 days
Registration: ISRCTN73182671
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Independent statistician generated the ran-
domisation sequence
Allocation concealment (selection bias) Low risk Centralised randomisation communicated
by phone to physician
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label trial where physicians knew to
which groupparticipants hadbeen assigned
and where PCT levels were only commu-
nicated in the intervention arm
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded medical students performed inter-
views with participants at 14 and 28 days
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up for mortality: 454/458 (99%)
Selective reporting (reporting bias) Low risk Outcomes correspond to study protocol.
Other bias Low risk 85% adherence to PCT algorithm in PCT
group
Burkhardt 2010
Methods Randomised clinical trial, multicentre in 15 primary care practices in the Hanover,
Germany area
Participants Inclusion criteria: Adults with upper or lower ARIs in primary care
Exclusion criteria: Treatment with antibiotics during the previous 2 weeks, chronic
liver disease, major surgery that had required hospitalisation during the last 4 weeks,
autoimmune or systemic disorders, dialysis, medullary C-cell carcinoma and other in-
flammatory diseases
Included in this analysis: 550 out of 571 randomised participants; 21 post randomi-
sation exclusions (2 withdrew consent, 1 due to loss of sample, 15 with autoimmune,
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inflammatory, or systemic disease, 2 with advanced liver disease, 1 with prior use of
antibiotics)
Interventions Guiding antibiotic decisions in primary care with initial measurement only
Algorithm used in this study: PCT value < 0.25 µg/L indicated that a relevant bacterial
infection of the respiratory tract is unlikely
Outcomes • days with impairment during everyday life or leisure activities, or both, due to the
infection of the respiratory tract within the first 14 days according to self assessment
• revisit to the physician’s office with a respiratory tract infection within 28 days
• number of days with antibiotic-induced side effects
• antibiotic use
• change of antibiotics within 28 days
• participants with any symptoms of ongoing or relapsing infection at 28 days
• all-cause mortality
• hospitalisation
Notes Funding: B·R·A·H·M·S AG, Germany
Follow-up: Fixed period of 28 days
Registration: NCT00827060 and NCT00688610
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Quote: “Baseline adaptive randomisation
was realised through a web-based ran-
domisation data bank (IOMTech GmbH,
Berlin, Germany), which had been pro-
grammed specifically for that purpose.”
Allocation concealment (selection bias) Low risk Central randomisation
Quote: “In the central laboratory, the web-
based randomisation of the patient into the
PCTgroupor the control group tookplace.
”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label trial where physicians knew to
which groupparticipants hadbeen assigned
and where PCT levels were only commu-
nicated in the intervention arm
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Structured interviews by blinded personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up for mortality: 546/550 (99%)
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Selective reporting (reporting bias) Low risk Outcomes correspond to study protocol.
Other bias Low risk 87% adherence to PCT algorithm in PCT
group
Christ-Crain 2004
Methods Randomised clinical trial, single-centre, emergency department at the University Hos-
pital Basel, Switzerland
Participants Inclusion criteria: People with lower ARIs presenting at a medical emergency depart-
ment
Exclusion criteria: Severely immunocompromised people, i.e. with HIV infection and
a CD4 count less than 200 cells per mL, neutropenic patients, and stem cell transplant
recipients; those with cystic fibrosis or active tuberculosis; and individuals with nosoco-
mial pneumonia
Included in this analysis: 243 participants out of 243 randomised participants
Interventions Guiding antibiotic decisions in emergency department patients with different ARIs with
initial PCT values only
Algorithm used in this study: A PCT value of 0.1 to 0.25 µg/L was regarded as an
indication that bacterial infection was unlikely and use of ABs was discouraged. A serum
PCT between 0.25 and 0.5 g/L was deemed indicative of a possible bacterial infection,
and the treating doctor was advised to initiate antimicrobial treatment. A PCT value of
0.5 µg/L or greater was judged suggestive of the presence of bacterial infection and AB
treatment was strongly recommended. For participants on antimicrobial therapy at the
time of admission, discontinuation of ABs was recommended if PCT concentrations
were less than 0.25 µg/L
Outcomes • antibiotic use
• all-cause mortality
• ICU admission
• frequency and length of hospital admission
• quality of life
• rate of re-exacerbation in COPD patients
Notes Funding: Freiwillige Akademische Gesellschaft Basel, Switzerland; Department of In-
ternal Medicine and the Divisions of Endocrinology and Pneumology, University Hos-
pital Basel; B·R·A·H·M·S AG, Germany and Orgenium Laboratories, Finland, provided
assay material and partial support of the investigator-initiated study
Follow-up: Fixed period of 10 to 14 days; in participants with acute exacerbations of
COPD the follow-up period comprised 4 to 6 months
Registration: None
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “We randomly assigned eligible pa-
tients either standard antimicrobial ther-
apy (standard group) or PCT-guided an-
timicrobial treatment (PCTgroup) accord-
ing to a computer-generated week wise-
randomisation scheme.”
Allocation concealment (selection bias) High risk Recruiting physicians were aware of group
allocation based on week-wise randomisa-
tion
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label trial where physicians knew to
which groupparticipants hadbeen assigned
and where PCT levels were only commu-
nicated in the intervention arm
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded investigators
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up for mortality: 230/243 (95%)
Selective reporting (reporting bias) Low risk Outcomes correspond to study protocol.
Other bias Low risk 83% adherence to PCT algorithm in PCT
group
Christ-Crain 2006
Methods Randomised clinical trial, single-centre, emergency department at the University Hos-
pital Basel, Switzerland
Participants Inclusion criteria: CAP with X-ray confirmation in the emergency department
Exclusion criteria: People with cystic fibrosis or active pulmonary tuberculosis, people
with hospital-acquired pneumonia, and severely immunocompromised individuals
Included in this analysis: 302 out of 302 randomised participants
Interventions Guiding antibiotic decisions in emergency department patients with CAP with repeated
PCT measurements
Algorithm used in this study: a PCT level of less than 0.1 µg/L suggested the absence of
bacterial infection, and the initiation or continuation of ABs was strongly discouraged.
A PCT level between 0.1 and 0.25 µg/L indicated that bacterial infection was unlikely,
and the initiation or continuation of ABs was discouraged. A PCT level from 0.25 to 0.
5 µg/L was considered indicative of a possible bacterial infection, and the initiation or
continuation of AB therapy was encouraged. A PCT level greater than 0.5 µg/L strongly
suggested the presence of bacterial infection, and AB treatment and continuation was
strongly encouraged. Re-evaluation of the clinical status and measurement of serum
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PCT levels were recommended after 6 to 24 h in all participants from whom ABs were
withheld. PCT levels were reassessed after 4, 6, and 8 d. Antibiotics were discontinued
on the basis of the PCT cut-offs defined above. In participants with very high PCT
values on admission (e.g. greater than 10 µg/L), discontinuation of ABs was encouraged
if levels decreased to less than 10% of the initial value (e.g. 1 µg/L, instead of less than
0.25 µg/L)




• complications due to CAP
• cure defined as resolution of clinical, laboratory, and radiographic signs of CAP
• improvement was defined as reduction of clinical signs and symptoms,
improvement of laboratory findings, and reduction of the number or intensity of
radiographic signs of CAP
• treatment success represented the sum of the rates for cure and improvement.
Treatment failure included death, recurrence, relapse, or persistence of clinical,
laboratory, and radiologic signs of CAP and participants lost to follow-up
Notes Funding: Funding obtained from B·R·A·H·M·S (Hennigsdorf, Germany), Pfizer
(Schweiz AG), and Mepha (Schweiz AG) was used for assay material and salaries of
technical personnel involved in laboratory work and for shipping and handling of data
and specimens and presentation of data at scientific meetings. Additional support, which
provided more than two-thirds of the total study costs, was granted by funds from the
Departments of Internal Medicine and Emergency Medicine, the Stiftung Forschung
Infektionskrankheiten (SFI), and mainly from the Departments of Endocrinology and
Pulmonary Medicine, University Hospital Basel, Switzerland
Follow-up: Fixed period of 6 weeks
Registration: ISRCTN04176397
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Independent statistician created randomi-
sation list.
Allocation concealment (selection bias) Unclear risk Quote: “On admission, patients were ran-
domly assigned to one of the two groups by
sealed, opaque envelopes.” Envelopes were
not numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label trial where physicians knew to
which groupparticipants hadbeen assigned
and where PCT levels were only commu-
nicated in the intervention arm
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Non-blinded study members
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up for mortality: 300/302 (99%)
Selective reporting (reporting bias) Low risk Outcomes correspond to study protocol.
Other bias Low risk 87% adherence to PCT algorithm in PCT
group
Corti 2016
Methods Randomised, single-centre clinical trial in an ED of a university hospital in Denmark
Participants Inclusion criteria: 1) 18 years old and 2) admitted with an AECOPD (clinician’s diag-
nosis at admission), defined according to the Global Initiative for Chronic Obstructive
Lung Disease (GOLD)
Exclusion criteria: 1) person unable to understand or respond to oral or written infor-
mation; 2) previously been enrolled in the study; and 3) do-not-resuscitate order in place
Included in this analysis: 120/630 screened people with AECOPD were randomised
and used for the ITT analysis (62 in the PCT group, 58 in the control group)
Interventions The aim was to assess whether PCT-guided antibiotic treatment could reduce the overall
use of antibiotics among people hospitalised for AECOPD.
Algorithm used in this study: In the control group, antibiotic therapy followed treat-
ment strategies for AECOPD according to GOLD guidelines. In the PCT group, initi-
ation or continuation of antibiotics was strongly discouraged if PCT was 0.15 ng/mL or
lower and discouraged if levels were between 0.15 ng/mL and 0.25 ng/mL. Initiation or
continuation of antibiotics was encouraged if PCT was > 0.25 ng/mL. In participants
with PCT over 5 ng/mL on admission, the algorithm recommended stopping antibiotics
when PCT levels decreased by 80% of the peak value
Outcomes • fraction of participants using antibiotics for at least 5 days within 28 days after
inclusion
• cumulative number of days with any antibiotic therapy within 28 days
• fraction of participants using antibiotics for a) at least 1 day, b) at least 3 days, c)
at least 7 days
• length of hospital stay
• adverse events (composite endpoint of mortality, readmission, ICU admission all
within 28 days
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were allocated according to the
random part of the civil registration num-
ber in Denmark
Allocation concealment (selection bias) Low risk The randomisation algorithm was con-
cealed to treating clinicians and partici-
pants
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding was not feasible, but PCT was
only measured in the intervention arm
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No mentioning of blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up for mortality: 120/120 (100%)
Selective reporting (reporting bias) Low risk Outcomes correspond to study protocol.
Trial registered (NCT01950936)
Other bias High risk Moderate adherence to the PCT algorithm
in PCT group (61.1%)
De Jong 2016
Methods Randomised, multicentre, controlled, open-label intervention trial in 15 hospitals in the
Netherlands
Participants Inclusion criteria: Eligible patients had to be at least 18 years of age, be admitted to
the ICU, and have received their first dose of antibiotics no longer than 24 h before
inclusion to the trial for an assumed or proven infection.
Exclusion criteria: Patients were excluded in cases of systemic antibiotics as prophylaxis
only, antibiotics solely as part of selective decontamination of the digestive tract, pro-
longed therapy (e.g. endocarditis), expected ICU stay of less than 24 h, severe immuno-
suppression, severe infections (due to viruses, parasites, or Mycobacterium tuberculosis),
and moribund patients. Patients who received corticosteroids were not excluded.
Included in this study: 1575/4507 screened patients were enrolled in the study (776
in the PCT group, 799 in the control group) for an intention-to-treat analysis
Interventions Guiding antibiotic decisions in critically ill ICU patients
Algorithm used in this study: Antibiotics in the standard-of care group were stopped
according to local or national guidelines and according to the discretion of attending
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physicians. Procalcitonin concentration was not measured in the standard-of-care group.
For participants randomly assigned to the PCT-guided group, once-a-day measurements
of PCT concentrations were taken and made available to the attending physicians, in-
cluding a baseline measurement as close to initiation of antibiotics as possible, at least
within 24 h. The study protocol advised stopping the prescribed antibiotics if PCT con-
centration had decreased by 80% or more of its peak value (relative stopping threshold)
or when it reached a value of 0.5 µg/L or lower (absolute stopping threshold). The
attending physician was free to decide whether to continue antibiotic treatment in par-
ticipants who had reached these thresholds
Outcomes • consumption of antibiotics (expressed as defined daily doses)
• duration of antibiotic treatment (defined as the number of 24-hour periods
between start and end of antibiotic treatment)
• percentage of participants who had a recurrent infection
• length of stay in hospital and ICU
• costs of antibiotics
• costs of PCT tests




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was done centrally by use
of a computer-generated list produced
by an independent research organisation
(the Julius Centre for Human Research,
Utrecht, Netherlands)
Allocation concealment (selection bias) Low risk Centralised randomisation by an indepen-
dent organisation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants and investigators were aware of
treatment assignment
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment men-
tioned in the study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1546 of 1575 participants included in the
intention-to-treat population analysis
Selective reporting (reporting bias) Low risk The outcomes correspond to the trial reg-
istration (NCT01139489)
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Other bias High risk Physicians did not adhere to the stopping
advice inmore than half of the participants.
About 30% of participants randomly as-
signed to the PCT group were discharged
from ICU before the algorithm recom-
mended stopping antibiotic treatment
Deliberato 2013
Methods Randomised, single-centre, controlled clinical trial at an ICU of a tertiary care, private
hospital in São Paulo, Brazil
Participants Inclusion criteria: People with microbiologically confirmed infections (blood, urine,
tracheal aspirate, or bronchoalveolar lavage fluid cultures) with sepsis, severe sepsis, and
septic shock
Exclusion criteria were: Onset of antibiotic therapy more than 48 hours before the
date when the cultures were performed; people under 18 years old; known pregnancy;
infections requiring prolonged antibiotic therapy, such as bacterial endocarditis, hepatic
or brain abscess, deep abscess, mediastinitis, and osteomyelitis; severe infection caused
by viruses, parasites, fungi, or mycobacteria; chronic localised infections, such as chronic
osteomyelitis or chronic prostatitis; people without indication for ICU admission, as
determined by the attending physician; and negative cultures (blood, urine, tracheal
aspirate, or bronchoalveolar lavage fluid) in people with suspected sepsis, severe sepsis,
or septic shock
Included in this study: 81/265 eligible patients randomised for a intention-to-treat
analysis; after further exclusions, 51/265 patients remained for per-protocol analysis
Interventions Guiding antibiotic decisions in ICU patients with proven bacterial infection
Algorithm used in this study: All participants received antibiotic therapy. For the con-
trol group, stopping antibiotic therapy was at the discretion of the attending physician.
For the intervention group, physicians were guided by the PCT protocol to stop antibi-
otic treatment. The protocol stated 2 conditions: 1) PCT dropped more than 90% from
the peak level, or 2) an absolute value < 0.5 ng/mL was reached
Outcomes • duration of antibiotic therapy
• in-hospital mortality
• ICU mortality
• ICU length of stay
• recurrence of the initial infection
• analysis of the CRP levels along with the PCT protocol
• therapy costs
Notes Funding: No funding declared in the main article.
Follow-up time: Data were recorded from 2 days before the bacteraemia (when appli-
cable), with day 0 defined as the day sepsis was diagnosed, until 14 days after or at ICU
discharge, whichever came first.
Registration: NCT01494675
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A blind randomisation scheme was used
where a black box contained 100 folders,
and 2 authors randomly drew 1 folder as
soon as an informed consent was present
Allocation concealment (selection bias) Low risk Folders were randomly and blindly as-
signed as “PCT group” or “standard
group”. 2 of the authors would randomly
draw 1 folder from a black box containing
100 folders (50 “PCT group” and 50 “con-
trol group”)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding of the treating physicians was not
feasible in this study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of the outcome assessment
mentioned in the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk In the intention-to-treat analysis the fol-
low-up for mortality was 81/81 (100%)
Selective reporting (reporting bias) Low risk Outcomes correspond to study protocol.
Trial registered (NCT01494675)
Other bias High risk Low adherence to the PCT algorithm (47.
6%)
Single-centre study where not all attending
physicians agreed to participate (also a rea-
son for exclusions in the PCT arm in the
per-protocol analysis and low adherence)
Ding 2013
Methods Randomised, single-centre, open-label, controlled clinical trial in HeNan Hospital,
China
Participants Inclusion criteria: All patients with suspected AE-IPF admitted to the respiratory de-
partment were assessed for eligibility from January 2009 to December 2011. Acute ex-
acerbation of idiopathic pulmonary fibrosis was defined according to the criteria estab-
lished by the Idiopathic Pulmonary Fibrosis Clinical Research Network: (1) previous
or concurrent diagnosis of idiopathic pulmonary fibrosis; (2) unexplained worsening or
development of dyspnoea within 30 days; (3) high-resolution computed tomography
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with new bilateral ground-glass; (4) abnormality and/or consolidation superimposed on
a background reticular or honeycomb pattern consistent with usual interstitial pneumo-
nia pattern; (5) no evidence of pulmonary infection by endotracheal aspirate or bron-
choalveolar
lavage; (6) exclusion of left heart failure, pulmonary embolism, and identifiable cause of
acute lung injury.
Exclusion criteria: Patients treated with antibiotics during the previous 2 weeks were
excluded.
Included in this study: 68 of 78 randomised participants finished at follow-up.
Interventions Guiding antibiotic decisions in people with acute exacerbation of idiopathic pulmonary
fibrosis
Algorithm used in this study: Serum PCT level was measured every 3 days. The first
PCT measurement was available before the clinical decision to start antibiotics treat-
ment. Participants whose serum PCT value exceeded the threshold of 0.25 ng/mL were
administered antibiotics and were treated until PCT value fell to ≤ 0.25 ng/mL. In the
routine treatment group, the decision to administer antibiotics was guided by the clinical
experience of the clinician, typically by conventional laboratory tests such as sputum
bacteriology and white blood cell count
Outcomes • length of hospitalisation
• the numbers of participants exposed to antibiotics treatment
• duration of antibiotic treatment
• cases of mechanical ventilation
Notes Funding: No funding declared in the main paper.
Follow-up: 30 days
Trial registration: No trial registration found for this clinical trial.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Low risk Participants were randomly assigned to ei-
ther PCT-guided antibiotic treatment or a
control group receiving routine antibiotic
therapy by the statistician using computer-
generated random numbers
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No blinding was performed. “In the rou-
tine treatment group, patients were treated
by antibiotics according to the clinical ex-
perience of clinicians typically guided by
conventional laboratory tests, such as spu-
tum bacteriology and white blood cell
count.”
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment was
mentioned in this study
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Postrandomisation exclusion rate was rela-
tively high but similar in both study arms
(6 in the intervention arm versus 4 in the
control group)
Selective reporting (reporting bias) Unclear risk No trial registrationwas found for this trial.
Other bias Low risk 100% adherence to PCT protocol in the
per-protocol analysed participants (all pro-
tocol violations were defined as “with-
drawn”)
Hochreiter 2009
Methods Randomised clinical trial, single-centre, ICU in Germany
Participants Inclusion criteria: Patients in the surgical ICU with suspected bacterial infections and
> 1 SIRS criteria
Exclusion criteria: Patients who refused study consent, whose antibiotic treatment had
been initiated before intensive care admission, or who had therapy limitations
Included in this analysis: 43 (110); 67 not considered for this analysis due to diagnosis
other than ARI
Interventions Guiding antibiotic decisions in postoperative patients in a surgical ICU
Algorithm used in this study: Antibiotic therapy in the PCT-guided group was dis-
continued if clinical signs and symptoms of infection improved and PCT decreased to
less than 1 µg/L, or if the PCT value was more than 1 µg/L, but had dropped to 25% to
35% of the initial value over 3 days
Outcomes • antibiotic use
• mortality (ICU-free days alive)




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Unconcealed drawing of lots
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Allocation concealment (selection bias) High risk Unconcealed drawing of lots
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label trial where physicians knew to
which groupparticipants hadbeen assigned
and where PCT levels were only commu-
nicated in the intervention arm
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Non-blinded study members
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up for mortality: 393/394 (100%)
Selective reporting (reporting bias) Low risk No selective reporting (oral verification
with first author)
Other bias Unclear risk Adherence to PCT protocol not reported/
assessed
Kristoffersen 2009
Methods Randomised clinical trial, multicentre, 3 hospitals in Denmark
Participants Inclusion criteria: Hospitalised patients with suspected pneumonia (no X-ray confir-
mation); quote: “The assessment of eligibility (i.e. the clinical diagnosis) was made by
the admitting physician and was based on medical history and physical examination.”
Exclusion criteria: Not meeting the diagnostic criteria
Included in this analysis: 210 out of 223 randomised participants; 13 post randomisa-
tion exclusions (3 no PCT testing, 6 not meeting inclusion criteria, 4 withdrew informed
consent)
Interventions Guiding antibiotic decisions in CAP patients with initial values only
Algorithm used in this study: Physicians were not asked to wait for PCT results before
initiating antimicrobial therapy, therefore PCT values were, in most cases, used to mo-
tivate either cessation or continuation of already initiated treatments. Discontinuation
of AB treatment was recommended if PCT at admission was below 0.25 µg/L, despite
delays in test results
Outcomes • antibiotic use
• mortality
• ICU admission
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
scheme
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label trial where physicians knew to
which groupparticipants hadbeen assigned
and where PCT levels were only commu-
nicated in the intervention arm
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Non-blinded study members
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up for mortality: 210/210 (100%
until discharge)
Selective reporting (reporting bias) Low risk No selective reporting (oral verification
with first author)
Other bias High risk 59% adherence to PCT algorithm in PCT
group
Layios 2012
Methods Randomised, single-centre, prospective, controlled clinical study in 5 ICUs in Belgium
Participants Inclusion criteria: Patients older than 18 yrs of age and hospitalised for > 2 days in 1
of the 5 ICUs
Included in this study:Of 509 randomised participants, 441 developed infection, and
PCT was obtained and analysed in 389 of these participants
Interventions Guiding antibiotic decisions in ICU patients
Algorithm used in this study: According to the proposal by Mueller and colleagues, for
participants in the PCTgroup, the use of antibioticswasmore or less strongly discouraged
if PCT level was < 0.25 µg/L or 0.50 µg/L, respectively, and more or less recommended
if PCT level was above 1 µg/L or 0.50 µg/L, respectively. This strategy was applied to
all infectious episodes encountered during participants’ ICU stay
Outcomes • difference of antibiotic consumption between the PCT group and the control
group
• usefulness of PCT levels in the ICU diagnostic algorithm in deciding whether or
not to initiate antibiotics whenever infection was suspected and determination of
concordance of the infection’s diagnostic ratings by the ICU physician and the
50Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Layios 2012 (Continued)
infectious disease specialist, bearing in mind that the latter was blinded to PCT results
in all of the cases
Notes Funding: No information provided.
Follow-up:During ICU stay
Trial registration: No trial registration found.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information on method of randomisa-
tion provided.
Allocation concealment (selection bias) Unclear risk No information on allocation concealment
provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Procalcitonin levels in the control armwere
blinded for treating physicians, but the
study arm to which participants had been
assigned was not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk At the end of ICU stay, participants’ charts
were reviewed by infectious disease special-
ists blinded to PCT results, who classified
them as confirmed, probable, possible, or
no infection using all the clinical data and
biological results including microbiologi-
cal cultures and results from investigational
procedures
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up for mortality 509/509 (100%)
Selective reporting (reporting bias) Unclear risk No trial registration found for this research
article.
Other bias High risk Low adherence to PCT algorithm (46.3%)
Lima 2016
Methods Randomised, single-centre, prospective, controlled clinical trial in Minas Gerais, Brazil
Participants Inclusion criteria: Presence of febrile neutropenia (axillary temperature ~37.8°C, neu-
trophils count < 500 cells/mm3) in people with diagnosis of haematological disease (ex-
cept people undergoing allogeneic stem cell transplantation); with expected duration of
neutropenia of more than 3 days; ongoing broad-spectrum antibiotic therapy according
to institutional guideline, based on Infectious Diseases Society of America; and no cur-
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rent use of therapeutic antibiotics or antifungals with the last day of use was > 14 days
before inclusion in the study
Exclusion criteria: Severe organ dysfunction (e.g. hypotension, ICU admission, trans-
retinoic acid syndrome, respiratory insufficiency, and disseminated intravascular coagu-
lation); previous proven or probable invasive fungal infection according to the Springer
Ann Hematol (2016) European Organisation for Research and Treatment of Cancer-
Mycosis StudyGroup (EORTC-MSG) criteria; infections due to Pseudomonas spp,Acine-
tobacter spp, Staphylococcus aureus, Mycobacterium tuberculosis, Pneumocystis jirovecii,Tox-
oplasma gondii, or HIV; infections requiring antibodies for a long time (e.g. infectious
endocarditis, osteomyelitis); grade 3 or 4 oral mucositis, since this condition increases
the risk of S aureus bacteraemia; and pregnancy
Included in this study: 62 randomised participants, 1 post randomisation exclusion
due to withdrawal of informed consent
Interventions Guiding antibiotic decisions in people with febrile neutropenia
Algorithm used in this study: Attending physicians were encouraged to discontinue
antibiotics in participants when both of the following criteria were met: (i) no febrile
episodes for 2 consecutive days (if no Ionger neutropenia) or 3 consecutive days (if still
neutropenia), and (ii) PCT concentration at least 90% lower than highest baseline Ievels
or lower than 0.5 ng/mL for 2 consecutive days, regardless of the initial Ievels. The final
decision to discontinue antibiotics was left at the attending physician’s discretion. Pro-
calcitonin Ievels were measured for 2 additional days following antibiotics interruption
to monitor a possible relapse of infection. For safety reasons, at least 5 days of antibiotic
therapy were ensured for all included participants. Participants with bacteraemia were
treated for at least 7 days. In the control group, duration of antibiotic therapy was based
on institutional protocol, according to Infectious Diseases Society of America recom-
mendations
Outcomes • antibiotic exposure, measured by the duration of the first course of antibiotic
therapy (in days) and days without antibiotics during follow-up (28 days)
• clinical cure rate
• infection relapse rate (infection diagnosed 48 h or more after antibiotic
discontinuation)
• superinfection rate (defined as occurrence of infection due to 1 or more different
pathogens, in the same or in another site, during the first antibiotic therapy)
• length of hospital stay from inclusion (in days)
• all-cause 28- and 90-day mortality
Notes Funding: This work was supported by Funda of the de Amparo a Pesquisa do Eatado




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised on the third
day of follow-up, in a 1:1 ratio for the PCT
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group and the control group
Allocation concealment (selection bias) Low risk Randomisation was performed using a ta-
ble of random, computer-generated num-
bers, and sealed, opaque envelopes were
used
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk For participants randomised into the con-
trol group, results of PCT serum Ievels were
kept concealed during the study and were
only revealed for the final analysis. How-
ever, physicians were aware of the study
group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment was
mentioned in the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Most randomised participants finished fol-
low-up. Only 1 post randomisation exclu-
sion
Selective reporting (reporting bias) Low risk Outcomes correspond to trial registration.
Other bias Low risk High adherence to the PCT protocol (73.
3%)
Long 2009
Methods Randomised clinical trial, single-centre, emergency department outpatients in China
Participants Inclusion criteria: CAP with X-ray confirmation
Exclusion criteria: Use of antibiotic therapy in 2 weeks before enrolment, systemic
immune deficiency, organ dysfunction, tumour, mental illness, CAP onset ≥ 5 days,
coexisting extrapulmonary infection requiring antibiotic therapy
Included in this analysis: 127 out of 127 randomised participants
Interventions Guiding antibiotic decisions in CAP patients with repeated levels
Algorithm used in this study: A PCT level of less than 0.1 µg/L suggested the absence
of bacterial infection, and the initiation or continuation of ABs was strongly discouraged.
A PCT level between 0.1 and 0.25 µg/L indicated that bacterial infection was unlikely,
and the initiation or continuation of ABs was discouraged. A PCT level of 0.25 µg/L
or greater was considered indicative of a possible bacterial infection, and the initiation
or continuation of AB therapy was encouraged. Re-evaluation of the clinical status and
measurement of PCT levels was recommended after 6 to 12 h in all participants from
whom ABs were withheld
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Outcomes • antibiotic use
• mortality
• ICU admission
• treatment success represented the sum of the rates for cure and improvement.
Cure was defined as resolution of clinical, laboratory, and radiographic signs of CAP.
Improvement was defined as reduction of clinical signs and symptoms, improvement of
laboratory findings, and reduction of the number or intensity of radiographic signs of
CAP.
• treatment failure included death, recurrence, relapse, or persistence of clinical,
laboratory, and radiologic signs of CAP and participants lost to follow-up




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Odd and even patient ID numbers
Allocation concealment (selection bias) High risk Odd and even patient ID numbers
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label trial where physicians knew to
which groupparticipants hadbeen assigned
and where PCT levels were only commu-
nicated in the intervention arm
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Non-blinded study members
Incomplete outcome data (attrition bias)
All outcomes
Low risk 210/210 (100% until discharge)
Selective reporting (reporting bias) Low risk No selective reporting (oral verification
with first author)
Other bias Unclear risk Adherence to PCT protocol not reported/
assessed.
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Methods Randomised clinical trial, single-centre, emergency department outpatients in China
Participants Inclusion criteria: CAP with X-ray confirmation in an outpatient setting
Exclusion criteria: Pregnancy, commencement of antibiotic therapy ≥ 48 h before en-
rolment, systemic immune deficiency, withholding of life-support, and active tubercu-
losis
Included in this analysis: 156 out of 172 randomised participants; 16 post randomi-
sation exclusions (6 lost to follow-up, 7 withdrew consent, 3 with final diagnosis other
than CAP)
Interventions Guiding antibiotic decisions in CAP patients with repeated levels
Algorithm used in this study: A PCT level of less than 0.1 µg/L suggested the absence
of bacterial infection, and the initiation or continuation of ABs was strongly discouraged.
A PCT level between 0.1 and 0.25 µg/L indicated that bacterial infection was unlikely,
and the initiation or continuation of ABs was discouraged. A PCT level of 0.25 µg/L
or greater was considered indicative of a possible bacterial infection, and the initiation
or continuation of AB therapy was encouraged. Re-evaluation of the clinical status and
measurement of PCT levels was recommended after 6 to 12 h in all participants from
whom ABs were withheld
Outcomes • antibiotic use
• mortality
• ICU admission
Notes Funding: The study was sponsored by a grant from the Shanghai Fifth People’s Hospital
Science Foundation (09YRCPY11)
Follow-up: Fixed period of 4 weeks
Registration: NA
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Odd and even patient ID numbers
Allocation concealment (selection bias) High risk Odd and even patient ID numbers
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label trial where physicians knew to
which groupparticipants hadbeen assigned
and where PCT levels were only commu-
nicated in the intervention arm
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Non-blinded study members
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up formortality: 156 (156) (100%)
55Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Long 2011 (Continued)
Selective reporting (reporting bias) Low risk No selective reporting (oral verification
with first author)
Other bias Unclear risk Adherence to PCT protocol not reported/
assessed.
Long 2014
Methods Randomised, single-centre, open-label, controlled clinical trial in Shanghai, China
Participants Inclusion criteria: People aged 18 to 65 years with severe acute exacerbations of asthma.
A severe asthma exacerbation was defined as at least 1 of the following: need for systemic
corticosteroids, or an increase from a stable maintenance dose, for at least 3 days and/or
hospitalisation or ED visit because of asthma requiring systemic corticosteroids.
Exclusion criteria: People with antibiotic use within the previous 14 days, psychiatric
disorders or other inability to give written informed consent, not being available for
follow-up, severe immunosuppression, heart failure, cystic fibrosis, active tuberculosis,
pregnancy, and chest radiography-confirmed pneumonia
Included in this study: 180/216 screened individuals were eligible for the study (90
intervention group, 90 non-intervention group); 169 finished the follow-up
Interventions Guiding antibiotic decisions in people with acute severe exacerbation of asthma
Algorithm used in this study: Antibiotic treatment was strongly discouraged when
serum PCT level was less than 0.1 µg/L; antibiotic treatment was discouraged when
serum PCT level was less than 0.25 µg/L; and antibiotic treatment was encouraged
when serum PCT level was higher than 0.25µg/L.When antibiotics were withheld from
participants, a secondmeasurement of the PCT level wasmandatory within 6 to 24 hours
for safety reasons. The use of antibiotics was recommended if this second measurement
was higher than 0.25 µg/L. Physicians were permitted to overrule the algorithm, but
they had to indicate the reasons for overruling. The control group received antibiotic
according to the discretion of the treating physician, whowas unaware of the participant’s
PCT levels
Outcomes • antibiotic use, expressed as rate of antibiotic prescriptions in percentage and
relative risk of antibiotic exposure
• measures of treatment success
• length of hospital stay
• clinical, laboratory, and spirometry outcomes at discharge
• results of spirometry at the 12-month follow-up examination, as well as the results
of the Asthma Control Test, the results of the Asthma Quality of Life Questionnaire at
the 12-month follow-up visit
• clinical events during the 12-month follow-up period, including numbers of
asthma exacerbations, ED visits, hospitalisations, and need for systemic corticosteroid
use for treatment of asthma
Notes Funding: The study was sponsored by a grant from the Shanghai Fifth People’s Hospital
Science Foundation andMinhang District Natural Science Foundation of Shanghai. The
funding bodies had no involvement in the design, collection, analysis, or interpretation
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of data; in the writing of the manuscript; or in the decision to submit the manuscript
for publication.
Follow-up time: 12 months
Registration: ChiCTR-TRC-12002534
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation to either intervention was con-
ducted according to computer-generated
random numbers produced by an indepen-
dent statistician
Allocation concealment (selection bias) Low risk After randomisation, an opaque, sealed, se-
quentially numbered envelope containing
the PCT or control protocol was prepared
for each participant according to group as-
signment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label study with blinding of PCT
level in the control group
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment men-
tioned in the study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 169/180 participants completed 1-year fol-
low-up visit (11 participants lost to follow-
up)
Selective reporting (reporting bias) Low risk Outcomes correspond to study pro-
tocol. Trial registered (ChiCTR-TRC-
12002534)
Other bias Low risk High adherence toPCTalgorithm (93.3%)
Maravi -Stojkovi 2011
Methods Randomised, single-centre, open-label, controlled clinical trial at a 200-bed academic
tertiary care hospital in Belgrade, Serbia
Participants Inclusion criteria: People scheduled to undergo open heart surgery on cardio-pulmonal
bypass. We assessed people who were selected for elective cardiac surgery at the 200-bed
academic tertiary care hospital. The criterion for inclusion in the study was the type of
operation: coronary artery bypass grafting (CABG) surgery, valve reconstruction, com-
bined CABG and valve procedures. Entry criteria included stable and unstable angina
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pectoris, valve insufficiency, left ventricle ejection fraction (LVEF) above 30%, and epi-
demiological status with saprophyte bacteria.
Exclusion criteria: People selected for redo cardiac operations, thoracic aortic surgery,
as well as people having active endocarditis and people with LVEF < 30%. People with
preoperative signs of infection (leukocyte count > 12,000/L; body temperature > 38°C)
were also excluded.
Included in this study: 205/205 included participants finished for follow-up (102 PCT
group/103 standard group)
Interventions Guiding antibiotic decisions in patients after cardiac surgery
Algorithm used in this study: Antibiotic prophylaxis was performed in all participants.
The participants were divided at the time of surgery into the standard group and the
PCT group.
In the standard group, the antibiotic use was applied according to the criteria based on
the laboratory and clinical signs; no antibiotic therapy was administrated routinely in
the absence of clinical signs of infection or a bacteriologic positive sample.
In the PCT group, the use of antibiotics was encouraged or discouraged on the basis of
serum PCT concentrations. A serum PCT concentration of 0.5 ng/mL or less indicated
the absence of bacterial infection, at which point the use of antibiotics was discouraged
Outcomes • proportion of participants treated with antibiotics
• overall cost of antibiotics per 1 patient
• total cost of antibiotics per 1 hospital day after operation
• ICU stays and hospital stay
• rehospitalisation
• incidence of infections
• severe non-infection complications
• mortality rate
Notes Funding: No funding is mentioned in the main article.
Follow-up: 1 year
Trial registration: No trial registration found.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
scheme
Allocation concealment (selection bias) Low risk The participants were divided at the time
of surgery into the standard group and the
PCT group by centralised randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No blinding of physicians due to the study
design
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment men-
tioned in the study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up for mortality: 205/205 (100%)
Selective reporting (reporting bias) Unclear risk No trial registration found.
Other bias Unclear risk No information about adherence
Najafi 2015
Methods Randomised, single-centre, single-blinded clinical trial in a 30-bed ICU in Tehran, Iran
Participants Inclusion criteria: Patients with at least 2 of 4 criteria including body temperature above
38°C or below 36°C; tachycardia > 90/min; tachypnoea > 20/min; and leukocytosis >
12 × 109/L or a leftward shift with more than 10% band cells or leukopenia < 4 × 109/
L were defined as patient with SIRS.
Exclusion criteria: Documented infection, pus from wound or abscess, empyema,
thrombophlebitis, infection due to viral or parasites, hypoxaemia (PO2 < 60 mmHg),
oliguria (urine output < 30 mL/h), Glasgow Coma Scale 3 without sedation, parenteral
antibiotic usage 24 hours before admission to ICU, hospitalisation 48 hours before en-
rolment, conditions requiring prolonged antibiotic therapy such as endocarditis, chronic
localised infection such as osteomyelitis, and severely immunocompromised patients
Included in this study: 60 participants were randomised (30 in the intervention group
and 30 in the control group)
Interventions Guiding antibiotic decisions in critically ill ICU patients
Algorithm used in this study: In case group, according to serum level of PCT, par-
ticipants were divided into 3 groups as: PCT level 0.5 ng/mL or less (group A), PCT
value of 0.5 to 2 ng/mL (group B), and PCT level 2 ng/mL or more (group C). Group
A indicated a low probability of bacterial infection; use of antibiotics was discouraged,
and PCT level was rechecked after 12 hours. In group B, with a medium probability of
infection, antibiotic therapy was not administered, and PCT level was rechecked after 8
hours. In group C, with a high probability of bacterial infection, participants underwent
antibiotic treatment. If the PCT level was higher than 2 ng/mL after recheck in group A
and B, antibiotics therapy was administered; if the PCT level was lower than 2 ng/mL,
participants underwent close observation, and PCT was rechecked until culture results
were obtained
Outcomes • use of antibiotic treatment
• change in clinical status
• early mortality
Notes Funding: No funding declared in the original research article.
Follow-up:No precise follow-up found in the original research article.
Trial registration: No trial registration found in the original research article
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk All participantswere randomly divided into
2 groups by computer-based random num-
ber generation
Allocation concealment (selection bias) Low risk All participantswere randomly divided into
2 groups by computer-based random num-
ber generation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Procalcitonin was only measured in the in-
tervention arm, but blinding was not feasi-
ble due to the study design
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment was
mentioned in the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants finished the
study andwere assessed for the primary out-
come
Selective reporting (reporting bias) Unclear risk No trial registration was found for this
study.
Other bias Unclear risk Adherence to the PCT algorithm was not
known.
Nobre 2008
Methods Randomised clinical trial, single-centre, medical ICU in Switzerland
Participants Inclusion criteria: Suspected severe sepsis or septic shock in the ICU
Exclusion criteria:
• microbiologically documented infections caused by Pseudomonas aeruginosa,
Acinetobacter baumannii,Listeria spp,Legionella pneumophila,Pneumocystis jirovecii,
orMycobacterium tuberculosis, for which a prolonged duration of antibiotic therapy is
standard of care
• severe infections due to viruses or parasites (e.g. haemorrhagic fever, malaria)
• infectious conditions requiring prolonged antibiotic therapy (e.g. bacterial
endocarditis, brain abscess, deep abscesses)
• antibiotic therapy started 48 hours or more before enrolment
• chronic, localised infections (e.g. chronic osteomyelitis)
• severely immunocompromised patients, such as patients infected with HIV and
with a CD4 count < 200 cells/mm3, neutropenic patients (0.500 neutrophils/mm3), or
patients on immunosuppressive therapy after solid organ transplantation
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• withholding of life-support
• absence of antimicrobial treatment despite clinical suspicion of sepsis
Included in this analysis: 52 out of 79 randomised participants; 27 not considered for
this analysis due to a diagnosis other than RTI
Interventions Guiding antibiotic decisions in ICU patients with repeated measurements
Algorithm used in this study: Procalcitonin levels measured at baseline and daily. For
participants presenting a favourable clinical course, investigators used predefined “stop-
ping rules” based on circulating PCT levels to encourage physicians to discontinue ABs.
Participants with baseline PCT level ≥ 1 µg/L were re-evaluated at day 5. Investigators
encouraged treating physicians to discontinue ABs when:
1. PCT dropped more than 90% from the baseline peak level; or
2. an absolute value below 0.25 µg/L was reached.
Participants with PCT level below 1 µg/L at baseline were re-evaluated at day 3; treating
physicians were encouraged to discontinue ABs when PCT level was below 0.1 µg/L and
careful clinical evaluation ruled out severe infection
Outcomes • all-cause mortality at day 28
• clinical cure defined as clinical signs and symptoms present at baseline that had
resolved by the final clinical assessment
• reoccurrence of the initial infection
• length of ICU stay
Notes Funding: B·R·A·H·M·S AG
Follow-up: Fixed follow-up period of 28 days
Registration: NCT00250666
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-based random number genera-
tion
Allocation concealment (selection bias) Low risk Sequentially numbered, opaque, sealed en-
velopes
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label trial where physicians knew to
which groupparticipants hadbeen assigned
and where PCT levels were only commu-
nicated in the intervention arm
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Non-blinded study members
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up for mortality: 52/52 (100%)
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Selective reporting (reporting bias) Low risk Outcomes correspond to study protocol.
Other bias Low risk 81% adherence to PCT algorithm in PCT
group
Ogasawara 2014
Methods Randomised, single-centre, prospective, open-label, non-inferiority clinical trial in
Shizuoka, Japan
Participants Inclusion criteria: Patients at risk for aspiration, who had been hospitalised after devel-
oping pneumonia, were enrolled. Aspiration pneumonia was clinically diagnosed on the
basis of the findings on computed tomography (e.g. bronchopneumonia in the dorsal
lower lobes), combined with a history of aspiration pneumonia, stroke or dementia, poor
systemic condition, or any combination of these (e.g. bedridden patients or patients
fed by a nasogastric tube or percutaneous endoscopic gastrostomy). Selection criteria
included the following: at least 1 month had elapsed since the last treatment for relapsed
pneumonia, and ventilator use was not scheduled for the pneumonia treatment
Exclusion criteria: Patients with a known severe allergy to any drugs; patients with sepsis
or a severe infectious disease; patients with severe underlying diseases (e.g. malignancy,
COPD, heart failure) that affected the prognosis; and patients who could not safely have
cessation of oral intake or hydration as a treatment for aspiration pneumonia because of
dementia
Included in this study: The study enrolled 105 participants; 2 participants withdrew
their informed consent, 5 were excluded because of other final diagnoses, and 1 was
excluded because of a defect in the PCT data. The ITT population thus comprised 96
participants: 48 in the PCT group and 48 in the control group
Interventions Guiding antibiotic decisions in patients with aspiration pneumonia and assessment of
the continuation of oral intake
Algorithm used in this study: Procalcitonin levels were measured via outsourcing to
SRL (Tokyo, Japan); the results were obtained 2 or 3 days after admission. In the PCT
group, if the PCT levels upon admission were < 0.5 ng/mL, 0.5 to 1.0 ng/mL, or >
1.0 ng/mL, the duration of antibiotic therapy was determined to be 3, 5, or 7 days,
respectively. If the PCT level upon admission was 45.0 ng/mL, antibiotic treatment was
continued until it was less than 10% of the peak PCT level reached.
In the control group, antibiotic therapy followed the recommendations of the Japanese
Respiratory Society guideline for management of community-acquired pneumonia in
adults. Antibiotic therapy was discontinued if 3 of the following 4 criteria were met:
fever declined (body temperature < 37.0°C), normalisation of leukocyte count, decrease
in the CRP level to 30% of the maximum, and an obvious improvement as observed
by chest radiography. In both groups, the choice of antibiotic regimen was left to the
discretion of the treating physician
Outcomes • primary non-inferiority endpoint was a composite of a relapse of aspiration
pneumonia and death from any cause occurring within 30 days of admission
• antibiotic exposure
• adverse events from antibiotic therapy
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly allocated in 1:1 ratio
Allocation concealment (selection bias) Unclear risk No clear mention of allocation conceal-
ment is made in the main article. Citation
“Following enrolment, the patients were
randomly allocated in a 1:1 ratio to groups
assigned different durations of antibiotic
therapy…”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Procalcitonin was only measured in the in-
tervention arm, but study design was open-
label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment men-
tioned in the study.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Most participants were followed for 30
days. Reasons for post randomisation ex-
clusions are clearly reported in the article
Selective reporting (reporting bias) Low risk Outcomes correspond to trial registration.
Other bias Unclear risk As cited by authors under limitations, time
until analysis of PCT concentrations was
available was relatively long (3 days)
Adherence to PCT algorithm not known
Oliveira 2013
Methods Randomised, multicentre, open-label, controlled clinical trial in the ICUs of 2 university
hospitals in Brazil
Participants Inclusion criteria: All adult patients 18 years of age or older with suspected severe sepsis
or septic shock were assessed for potential inclusion.
Exclusion criteria: Confirmed microbiological infection by Pseudomonas aeruginosa,
Acinetobacter baumannii, Listeria spp,Mycobacterium tuberculosis, or fungi; Staphylococcus
aureus bacteraemia; suspected or confirmed severe infections caused by viruses or par-
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asites; infections that required long-term treatment, regardless of the aetiologic agent
(e.g. bacterial endocarditis); localised chronic infections (e.g. chronic osteomyelitis); >
48 hours of antibiotic treatment; immunosuppressed patients (such as those diagnosed
with HIV), patients with neutropenia (< 500 neutrophils/mm3), patients post-solid or-
gan transplant, patients under immunosuppressive therapy, and patients who received
more than 1 mg/kg of prednisone or equivalent; patients under palliative care; patients
who suffered multiple trauma, burns, or major surgery in the previous 5 days; patients
diagnosed with pulmonary neoplasias, carcinoid tumours, or medullary tumours of the
thyroid; and patients who remained in the ICU for 24 hours or less
Included in this study: 94/355 patients assessed for eligibility were included in the final
analysis (49 in the PCT group and 45 in the CRP group)
Interventions Guiding antibiotic decisions with CRP versus PCT in septic patients
Algorithm used in this study:Antibiotic therapy was discontinued following a protocol
based on serum levels of these markers, according to the allocation group. For both
groups, at least 7 full days of antibiotic therapy were ensured in participants with SOFA
score greater than 10 and/or bacteraemia at inclusion, and participants with evident
resolutionof the infectious process had antibiotics stopped after 7 days, despite biomarker
levels
Outcomes • duration of antibiotic therapy for the first episode of infection
• total number of days on antibiotic therapy
• days off antibiotic therapy
• death from any cause during the 28 days of follow-up in the hospital
• length of stay (LOS) in the ICU and LOS in the hospital
• clinical cure, recurrent infection, and nosocomial infection
Notes Funding: Supported in part by the Minas Gerais Research Foundation (Fundação de
Amparo à Pesquisa do Estado de Minas Gerais, FAPEMIG)
Follow-up: 28 days or until death or hospital discharge
Trial registration: NCT00934011
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was performed using a
computer-generated random number table
Allocation concealment (selection bias) Low risk Sealed, opaque envelopes were used for the
randomisation.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No blinding due to the study design
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment men-
tioned in the study.
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Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants were included in the ITT
analysis.
Selective reporting (reporting bias) Low risk Outcomes correspond to study protocol.
Trial registered (NCT00934011)
Other bias Low risk High adherence to the PCT protocol (87.
8%)
Schroeder 2009
Methods Randomised clinical trial, single-centre, surgical ICU in Germany
Participants Inclusion criteria: Patients after abdominal surgery with antibiotic treatment because
of severe sepsis in the surgical ICU
Exclusion criteria: Patients were excluded if they did not meet the respective inclusion
criteria, refused informed consent, or had already received antibiotic treatment prior to
admission to the ICU
Included in this analysis: 8 out of 27 randomised participants; 19 not considered for
this analysis due to diagnosis other than RTI
Interventions Guiding antibiotic decisions in postoperative patients in a surgical ICU
Algorithm used in this study: In the PCT-guided group, antibiotic therapy was dis-
continued if clinical signs and symptoms of sepsis improved and PCT values had either
decreased to 1 µg/L or less or had dropped to 25% to 35% of the initial PCT concen-
tration over 3 consecutive days
Outcomes • antibiotic use





Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unconcealed drawing of lots
Allocation concealment (selection bias) High risk Unconcealed drawing of lots
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label trial where physicians knew to
which groupparticipants hadbeen assigned
and where PCT levels were only commu-
nicated in the intervention arm
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Non-blinded study members
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up for mortality: 8/8 (100% until
discharge)
Selective reporting (reporting bias) Low risk No selective reporting (oral verification
with first author)
Other bias Unclear risk Adherence to PCT protocol not reported/
assessed.
Schuetz 2009
Methods Randomised clinical trial, multicentre, 6 sites in Switzerland
Participants Inclusion criteria: Clinical diagnosis of CAP, ECOPD, bronchitis with X-ray confir-
mation
Exclusion criteria: People with active intravenous drug use, severe immunosuppression
other than corticosteroid use, life-threatening medical comorbidity leading to possible
imminent death, hospital-acquired pneumonia (development of pneumonia 48 hours
after hospital admission or if they were hospitalised within 14 days before presentation)
, and chronic infection necessitating antibiotic treatment
Included in this analysis: 1359 out of 1381 randomised participants; 22 post randomi-
sation exclusions due to withdrawal of consent
Interventions Guiding antibiotic decisions in emergency department patients with different ARIs with
repeated measurements
Algorithm used in this study: Initiation or continuation of ABs was strongly discour-
aged if PCT was less than 0.1 µg/L and discouraged if levels were 0.25 µg/L or lower.
Initiation or continuation of ABs was strongly encouraged if PCT was higher than 0.5
µg/L and encouraged if levels were higher than 0.25 µg/L. If ABs were withheld, hospi-
talised patients were clinically re-evaluated and PCT measurement was repeated after 6
to 24 hours
Outcomes • composite of overall adverse outcomes including death from any cause, ICU
admission for any reason, disease-specific complications, and recurrence of LRTI in
need of ABs
• any of above outcomes
• length of stay
• side effects from antibiotics
Notes Funding: This work was supported in part by grant SNF 3200BO-116177/1 from the
Swiss National Science Foundation and contributions from santésuisse and the Got-
tfried and Julia Bangerter-Rhyner-Foundation, the University Hospital Basel, the Med-
ical University Clinic Liestal, the Medical Clinic Buergerspital Solothurn, the Cantonal
HospitalsMuensterlingen, Aarau and Lucerne, respectively, the Swiss Society for Internal
Medicine, and the Department of Endocrinology, Diabetology and Clinical Nutrition,
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University Hospital Basel. B·R·A·H·M·S Inc, the major manufacturer of the PCT assay,
provided all assay-related material, Kryptor machines if not already available onsite, and
kits and maintenance required for 10,000 measurements related to the study
Follow-up: Fixed follow-up period after 30 days and 180 days
Registration: ISRCTN95122877
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Independent statistician created randomi-
sation scheme.
Allocation concealment (selection bias) Low risk Central randomisation using a study web
site
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label trial where physicians knew to
which groupparticipants hadbeen assigned
and where PCT levels were only commu-
nicated in the intervention arm
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Interviews by blinded medical students,
data safety monitoring board
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up for mortality: 1358/1359
(100%)
Selective reporting (reporting bias) Low risk Outcomesmatch previously publishedpro-
tocol.
Other bias Low risk 91% adherence to PCT algorithm in PCT
group
Shehabi 2014
Methods Randomised, multicentre, single-blind, controlled clinical trial in 11 ICUs in Australia
Participants Inclusion criteria: Patients older than 18 years of age, admitted to ICU within the
previous 72 hours, receiving parenteral and/or enteral antibiotics for a suspected bacterial
infection (with 2 or more SIRS criteria) and expected to remain in the ICU for longer
than 24 hours were eligible.
Exclusion criteria: Patients receiving antibiotics for surgical prophylaxis or with proven
bacterial infection requiring more than 3 weeks’ antibiotic therapy, isolated systemic
fungal or systemic viral infection in the absence of bacterial infection, neutropenia with a
neutrophil count less than 1000 cells/mL, receiving immunosuppressive agents, cardiac
surgery or trauma or heat stroke within 48 hours, medullary thyroid or small cell lung
cancer, patient not expected to survive to hospital discharge, or known pregnancy
Included in this study: Of 400 randomised participants, 394 finished 90 days’ follow-
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up for survival. 6 withdrew their consent
Interventions Guiding antibiotic decisions in critically ill patients in the ICU with undifferentiated
infection or suspected sepsis
Algorithm used in this study: Cessation of antibiotics was recommended if initial or
any subsequent PCT was negative (<0.10 ng/mL) or if initial or any subsequent PCTwas
between 0.10 to 0.25 ng/mL, and infection was highly unlikely; Subsequent PCT level
declined more than 90% from baseline, and 2. Assess antibiotic appropriateness and/
or adequacy of source control if PCT level at 48 hours is 70% of baseline value. Daily
PCT results were made available to the treating clinician for participants randomised
to the PCT group. Antibiotic prescription in both the standard care and PCT groups
was according to the Australian Antibiotics Therapeutic Guidelines and the antimicro-
bial stewardship (implemented by infectious diseases twice-weekly rounds and on-need
consultations). The algorithm was implemented only in the ICU
Outcomes • time to antibiotic cessation at 28 days, hospital discharge, or death, whichever
came first after randomisation
• antibiotic-free days at day 28 after randomisation
• number of antibiotic daily defined doses at day 28
• ICU and hospital length of stay
• mortality and 90-day all-cause mortality
• additional a priori outcomes included the relationship between baseline (taken at
randomisation) PCT and sepsis severity, microbiologically confirmed infections within
72 hours, and the predictive value of baseline and serial PCT of mortality
• readmission
• emergence of resistant micro-organisms
• number of algorithm violations
Notes Funding:Fundedby a competitive grant from the IntensiveCare Foundation ofAustralia
and New Zealand. Material support was provided by Roche Diagnostics, Thermo Fisher
Scientific, and bioMérieux. Roche Diagnostics and Thermo Fisher Scientific provided
additional unrestricted grant funding.
Follow-up: 90 days’ post randomisation for survival
Trial registration: ACTRN12610000809033
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were variable block randomised 1:
1 via a secured central study web site into
either a PCT-guided or clinician-guided
group
Allocation concealment (selection bias) Low risk Central randomisationwith variable blocks
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk For the standard care group, clinicians were
blinded to the PCT levels, but the physi-
cians were aware of the participants’ study
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group due to the study design
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Data were collected by professional re-
search personnel at each site and entered
into a central secured database at the Clin-
ical Informatics and Data Management
Unit, Department of Epidemiology and
Preventive Medicine, Monash University
and analysed by a blinded biostatistician at
Monash University, Melbourne, Australia.
The study was monitored by an indepen-
dent data safety and monitoring commit-
tee, with no interim analysis performed
Incomplete outcome data (attrition bias)
All outcomes
Low risk The follow-up for mortality was 394/394
(100%).
Selective reporting (reporting bias) Low risk Outcomes cor-
respond to study protocol. Trial registered
(ACTRN12610000809033)
Other bias Low risk High adherence to the PCT algorithm
(97%). “The proportion of study days
where the PCT algorithmwas not followed
was less than 3%, themajority of whichwas
due to missed PCT sampling.”
Stolz 2007
Methods Randomised clinical trial, single-centre, University Hospital Basel, Switzerland
Participants Inclusion criteria: Clinical diagnosis of COPD exacerbation
Exclusion criteria: People who were considered to be vulnerable study participants (i.
e. those with psychiatric comorbidity) were excluded from the study. Other exclusion
criteria were immunosuppression, asthma, cystic fibrosis, and the presence of infiltrates
on chest radiographs on hospital admission
Included in this analysis: 208 out of 226 randomised participants; 18 post randomi-
sation exclusions due to absence of COPD according to GOLD criteria
Interventions Guiding antibiotic decisions in COPD patients with repeated measurements
Algorithm used in this study: Procalcitonin level of 0.1 µg/L was considered indicative
of the absence of bacterial infection, and the use of ABs was discouraged. A level of 0.1 to
0.25 µg/L indicated possible bacterial infection, and the use of ABs was discouraged or
encouraged, respectively, based on the stability of the participant’s clinical condition. A
PCT level of 0.25 µg/L was considered suggestive of the presence of bacterial infection,
and AB treatment was encouraged
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Outcomes • antibiotic use
• “clinical success” defined as improvement of symptoms compared to exacerbation
status
• “clinical failure” defined as the absence of the attenuation of symptoms, the
worsening of symptoms, or death
• mortality
• ICU admission
• hospital readmission after 30 days and 6 months
Notes Funding: This study was funded by the Clinic of Pulmonary Medicine; the Clinic of
Endocrinology, Diabetes and Clinical Nutrition; and the Emergency Department of
the University Hospital Basel. B·R·A·H·M·S provided PCT assays for this investigator-
driven study




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Independent statistician created randomi-
sation list.
Allocation concealment (selection bias) High risk Sealed envelopes, not numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label trial where physicians knew to
which groupparticipants hadbeen assigned
and where PCT levels were only commu-
nicated in the intervention arm
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinded personnel
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up for mortality: 208/208 (100%)
Selective reporting (reporting bias) Low risk Outcomes correspond to study protocol.
Other bias Unclear risk Adherence to PCT protocol not reported/
assessed.
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Stolz 2009
Methods Randomised clinical trial, multicentre with 7 European and US intensive care units
Participants Inclusion criteria: VAP when intubated for > 48 h
Exclusion criteria: Patients were excluded it they 1) were pregnant; 2) were enrolled in
another trial; 3) had received immunosuppressants or long-term corticosteroid therapy
(> 0.5 mg/kg per day for > 1 month); 4) were severely immunosuppressed, including
AIDS; or 5) had a coexisting extrapulmonary infection diagnosed between day 1 and 3
requiring antibiotic therapy for > 3 days
Included in this analysis: 101 (101) (100%)
Interventions Guiding antibiotic decisions in VAP patients with repeated measurements
Algorithm used in this study: A PCT level of < 0.25 µg/L suggested the absence of
VAP, and discontinuation of ABs was strongly encouraged. A PCT level between 0.25
µg/L and 0.5 µg/L or a decrease by≥ 80% as compared to day 0 indicated that bacterial
infection was unlikely, and reduction or discontinuation of ABs was encouraged. A PCT
level≥ 0.5 µg/L or decrease by < 80% as compared to day 0 was considered indicative of
unresolved bacterial infection, and reduction or discontinuation of AB was discouraged.
A PCT level of > 1 µg/L strongly suggested unresolved bacterial infection, and AB
discontinuation was strongly discouraged
Outcomes • antibiotic-free days alive
• any antibiotic exposure after inclusion, i.e. total antibiotic exposure days and total
antibiotic agent days, regardless of indication
• the number of mechanical ventilation-free days
• the number of ICU-free days alive
• the evolution of the signs and symptoms potentially linked to pulmonary infection
• SaO2, PaO2/FiO2
• the evolution of the SOFA, ODIN, and CPIS scores
• length of hospital stay
• the VAP-related clinical deterioration rate and overall mortality at 28 days
Notes Funding: Funding was granted by the Clinic of Pulmonary Medicine, University Hos-
pital Basel. Funding obtained from B·R·A·H·M·S AG (Hennigsdorf, Germany)
Follow-up: Fixed follow-up period of 28 days
Registration: ISRCTN61015974
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Independent statistician created randomi-
sation list.
Allocation concealment (selection bias) Low risk Quote: “Randomisation was through arbi-
trary allocation to one of the two treatment
assignments based on sealed, opaque en-
velopes. Block size was 20 envelopes. Treat-
ing physicians were not aware of envelope
contents before randomisation”
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Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Open-label trial where physicians knew to
which groupparticipants hadbeen assigned
and where PCT levels were only commu-
nicated in the intervention arm
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded study member
Incomplete outcome data (attrition bias)
All outcomes
Low risk Follow-up for mortality: 101/101 (100%)
Selective reporting (reporting bias) Low risk Outcomes correspond to study protocol.
Other bias Unclear risk Adherence to PCT protocol not reported/
assessed.
Tang 2013
Methods Randomised, single-centre, single-blinded, controlled clinical trial in the emergency
department of the Fifth People’s Hospital of Shanghai, China
Participants Inclusion criteria: 1) ≥ 18 years old; 2) has any, or all, of the following clinical features
as defined by the Global Initiative for National Asthma (GINA) Guidelines: dyspnoea,
wheeze, acute cough, increased work of breathing, increased requirement for beta2-ago-
nist from baseline use, O2 saturation < 95%, a peak expiratory flow (PEF) at randomi-
sation ≤ 80% of their known best (within the last 12 months) or, in the absence of this
information, of their predicted PEF
Exclusion criteria: 1) treatment with antibiotics within 2 weeks prior to recruitment;
2) bacterial infection in other parts of body than the respiratory system; 3) chest X-ray-
confirmed pneumonia; 4) suffering from other chronic respiratory diseases; 5) suffering
from severe organ dysfunction
Included in this study: 265 people were eligible, and 255 participants completed the
study
Interventions Guiding antibiotic decisions in patients with acute exacerbation of asthma
Algorithm used in this study: Participants in the PCT group were treated with antibi-
otics based on their PCT serum level according to the following guidelines: antibiotics
treatment was strongly discouraged when serum PCT level was < 0.1 µg/L; antibiotics
treatment was discouraged when serumPCT level was < 0.25µg/L; antibiotics treatment
was encouraged when serum PCT level was > 0.25 µg/L
Outcomes • antibiotic prescription rate and the relative risk of antibiotic exposure
• clinical, laboratory, and lung function outcomes at the follow-up visit (6 weeks)
• secondary ED visits, hospital readmissions, repeated need for steroids or dosage
increase, need for antibiotics, white blood cell count, PCT levels, and FEV1% were
assessed during the 6-week follow-up period
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Tang 2013 (Continued)
Notes Funding: The study was sponsored by a grant from the Shanghai Fifth People’s Hospital
Science Foundation and Minhang District Natural Science Foundation of Shanghai.
Follow-up: 6 weeks
Trial registration: ICTRP ChiCTR-TRC-12002534
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation to either intervention was con-
ducted according to computer-generated
random numbers produced by an indepen-
dent statistician
Allocation concealment (selection bias) Low risk After randomisation, an opaque, sealed,
and sequentially numbered envelope con-
taining the PCT or control protocol was
prepared for each participant according to
the group
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Attending physicians responsible for par-
ticipants in the control group remained un-
aware of the participants’ PCT concentra-
tions throughout the study, but blinding
was not feasible due to the study design
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All participants, laboratory technicians, in-
vestigators, and research designers were
blinded to participant assignments until
the data analysis was completed. There
were no protocol violations during the
study
Incomplete outcome data (attrition bias)
All outcomes
Low risk 265/265 participants completed follow-up
for mortality.
Selective reporting (reporting bias) Low risk Outcomes correspond to study protocol:
ICTRP ChiCTR-TRC-12002534
Other bias Low risk 100% adherence to the PCT algorithm.
“There were no protocol violations during
the study.”
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Verduri 2015
Methods Randomised, multicentre, open, controlled, parallel-group, non-inferiority trial involv-
ing 18 university/city hospital pulmonary departments in Italy
Participants Inclusion criteria: Study participants were male or female, 18 years of age, current or
former smokers, and diagnosed with COPD stages I-IV as defined by GOLD guidelines
available at the time the study was designed, with protocol deviation. Participants were
hospitalised for severe ECOPD requiring antibiotic treatment, i.e. type 1 exacerbation
(increased dyspnoea, sputum volume, and sputum purulence verified by the attending
clinician) according to Anthonisen, and/or characterised by respiratory failure. Exacer-
bation of chronic obstructive pulmonary disease was defined as “an acute event charac-
terised by a worsening of the patient’s respiratory symptoms that is beyond normal day-
to-day variations and leads to a change in medication”.
Exclusion criteria: Bronchial asthma, unstable concomitant disease (cardiovascular, re-
nal, hepatic, gastrointestinal, neurological, metabolic, musculoskeletal, neoplastic, res-
piratory, or other disease), pregnancy and breastfeeding, clinically significant laboratory
abnormalities suggestive of unstable concomitant disease, survival for 1 year unlikely,
and inability to give written consent. Antibiotic pretreatment before hospital admission
and radiographic signs of pneumonia did not preclude eligibility for the study.
Included in this study: 183 participants were randomised, of which 178 participants,
88 in the PCT group and 90 in the standard care group, were analysed
Interventions Guiding antibiotic decisions in people with severe exacerbations of COPD
Algorithm used in this study: On admission, all patients received a 3-day course of
antibiotics (either amoxicillin plus clavulanate or quinolones) according to 2005 inter-
national guidelines. Procalcitonin levels were measured on hospital admission, on day
1, and on day 2. On day 2 each eligible patient was randomly assigned to 1 of the 2
treatment plans.
quote “Participants randomised to the standard group continued antibiotic therapy for
10 days, whereas participants randomised to the PCT group either continued treatment
for 10 days or stopped on day 3, depending on their PCT levels, according to previously
recommended cut-off values. Specifically, participants continued antibiotic treatment
for 10 days if 1 or more of the PCT values on the first 3 days of hospitalisation were 0.25
µg/L. When PCT values were < 0.25 µg/L but > 0.1 µg/L on any occasion, antibiotic
treatment was continued for 10 days if participants were clinically unstable or had acute
respiratory failure; otherwise, treatment was stopped on day 3. If all PCT values were
consistently < 0.1 µg/L, treatment was stopped on day 3.”
All participants were also treated with systemic corticosteroids for 14 days, plus regular
inhaled short-acting or long-acting bronchodilators
Outcomes • percentage of participants with at least 1 exacerbation within 6 months after the
index exacerbation
• hospital readmission
• admission to the ICU
• change in lung function (1FEV1)
• length of hospital stay
• death from any cause
Notes Funding:The trial was approved and funded by the Agenzia Italiana del Farmaco (AIFA)
, the Italian agency for drugs, which is an official body of the Italian Ministry of Health.
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Follow-up: Follow-up visits were scheduled on day 1, day 3, and 6 months after dis-
charge; telephone interviews were conducted at 2, 4, and 5 months after discharge.
Trial registration: NCT01125098
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation was web based, and
only statisticians and the web site adminis-
trator knew the randomisation sequence
Allocation concealment (selection bias) Low risk Eligible patients were randomly assigned to
receive standard antibiotic therapy (stan-
dard group) or PCT-guided antibiotic
treatment (PCT group) according to a
1:1 permuted block computer-generated
scheme, stratified according to hospital
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Blinding was not feasible due to the study
design
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessment men-
tioned in the study. The authors state that:
“... because we anticipated that the primary
outcome (exacerbations of COPD) would
be strong and easy to identify, and thus un-
likely to be biased by investigator influence,
we did not adopt any procedure to reduce
bias during the follow-up part of the trial.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 187 of 192 randomised participants were
included in final analysis
Selective reporting (reporting bias) Low risk Results correspond to the trial registration.
Other bias Low risk High adherence to the PCT protocol (95.
5%)
The study planned to enrol 400 partici-
pants to have enough statistical power for
the primary endpoint, but randomised only
183
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Methods Randomised, single-centre, single-blinded, controlled clinical trial in the Beijing Luhe
Hospital, China
Participants Inclusion criteria: Patients with AECOPD who were 40 years of age, had sound under-
standing and language abilities, and who had a PCT level < 0.1 ng/mL were included.
Exclusion criteria: Fever (38°C), tracheal intubation within 24 h after hospital admis-
sion, a PCT level of 0.1 ng/mL on admission, pneumonia, chronic renal failure, history
of malignant disease, immunosuppressive therapy, and refusal to participate
Included in this study: 194 randomised participants. 191 finished the 30-day follow-
up
Interventions Guiding antibiotic decisions in patients with acute exacerbation of chronic obstructive
pulmonary disease
Algorithm used in this study: Patients with a PCT concentration < 0.1 ng/mL were
randomised. Antibiotics were withheld from participants in the control group. However,
antibiotics could be administered later for participants whose clinical condition was
unstable or who had a worsening of symptoms and signs, and for those with positive
evidence of bacteria as assessed by the attending physicians. In the antibiotic group,
antibiotics were administered routinely
Outcomes • treatment success rate on day 10 after admission
• symptoms assessed by visual analogue scale (at hospital admission, 3 days after
hospitalisation, and on the day of hospital discharge)
• length of hospital stay
• intubation rate
• mortality during hospitalisation and the 30-day follow-up period
• rate of antibiotic use
• readmission due to AECOPD in the 30-day follow-up period
Notes Funding: The study was sponsored by the National Science Fund for Distinguished
Young Scholars (81425001/H0104) for Dr Bin Cao.
Follow-up: 30 days after hospital discharge
Trial registration: ChiCTR-TRC-14004726
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk A computer digital table method was used
to generate randomisation numbers
Allocation concealment (selection bias) Low risk Researchers in this study had 24-hour ac-
cess to randomisation numbers, allowing
immediate and concealed allocation to the
trial
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No blinding feasible due to the study pro-
tocol.
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Individuals responsible for allocation con-
cealment were not allowed to take part in
the measurement of results, but no over-
all blinding of the outcome assessment was
mentioned in this study
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 3 participants were excluded during
the 30-day follow-up, due to a diagnosis of
pneumonia according to chest X-ray
Selective reporting (reporting bias) Low risk Outcomes correspond to the trial registra-
tion (ChiCTR-TRC-14004726)
Other bias Low risk High adherence to the PCT protocol (82.
3%)
AB: antibiotic
AECOPD: acute exacerbation of chronic obstructive pulmonary disease
AE-IPF: acute exacerbation of idiopathic pulmonary fibrosis
ARIs: acute respiratory infections
CAP: community-acquired pneumonia
COPD: chronic obstructive pulmonary disease




ECOPD: exacerbation of chronic obstructive pulmonary disease
EMR: electronic medical record
FEV1%: forced expiratory volume for 1 second expressed as a percentage of the forced vital capacity
GOLD: Global Initiative for Chronic Obstructive Lung Disease
h: hour
ICU: intensive care unit
ID: identification
ITT: intention-to-treat
LRTI: lower respiratory tract infection
NA: not available
ODIN: Organ Dysfunction and/or Infection
PaO2/FiO2: relationship between arterial oxygen tension (PaO2) and inspiratory oxygen fraction (FiO2)
Pa: arterial
PCR: polymerase chain reaction
PCT: procalcitonin
RSV: respiratory Syncytial virus
RTI: respiratory tract infection
SaO2: oxygen saturation
SIRS: systemic inflammatory response syndrome
SOFA: Sequential Organ Failure Assessment
VAP: ventilator-associated pneumonia
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Dharaniyadewi 2013 Poster presentation only
Esposito 2012 Not adult participants (paediatrics)
Heyland 2011 Meta-analysis of previous RCTs
Jensen 2011 Not using procalcitonin to de-escalate antibiotic therapy but for improving mortality by escalation of therapy
Jones 2007 Meta-analysis of observational studies
Kook 2012 Not an RCT; before-after study design
Liew 2011 Not an RCT
Liu 2013 Not an RCT
Qu 2012 Not a respiratory infection (pancreatitis)
Saeed 2011 Not an RCT
Schuetz 2010 Not an RCT; before-after study design (post study survey)
Simmonds 2005 Meta-analysis of observational studies
Simon 2004 Meta-analysis of observational studies
Stocker 2010 Included a paediatric population only
Tang 2007 Meta-analysis of observational studies
Tang 2009 Meta-analysis of RCTs
Uzzan 2006 Meta-analysis of observational studies
RCT: randomised controlled trial
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Characteristics of ongoing studies [ordered by study ID]
NCT02130986
Trial name or title PCT Antibiotic Consensus Trial (ProACT)
Methods Randomised, single-blind, multicentre study
Participants Inclusion criteria:
1. ≥ 18 years old
2. a primary clinical diagnosis in the ED of acute LRTI (< 28 days duration)
3. clinician willing to consider PCT in antibiotic decision making
Exclusion criteria:
1. systemic antibiotics before ED presentation (all prophylactic antibiotic regimens, OR received > 1 dose
within 72 hours prior to ED presentation)
2. current vasopressor use
3. mechanical ventilation (via endotracheal tube)
4. known severe immunosuppression
5. accompanying non-respiratory infections
6. known lung abscess or empyema
7. chronic dialysis
8. metastatic cancer
9. surgery in the past 7 days (excluding minor surgery such as skin biopsy)
10. incarcerated or homeless
11. enrolled in ProACT in the past 30 days
Interventions Algorithm used in this study: Procalcitonin versus usual care group in patients with LRTI in the ED.
Procalcitonin cut-offs:
< 0.1 ng/L. Antibiotics strongly discouraged
0.1 to 0.25 ng/L. Antibiotics discouraged
> 0.25 to 0.5 ng/L. Antibiotics recommended
> 0.5 ng/L. Antibiotics strongly recommended
Outcomes • total antibiotic exposure days (time frame: 30 days). Total antibiotic exposure, defined as the total
number of antibiotic days by day 30
• combined endpoint of adverse outcomes that could be attributable to withholding antibiotics in LRTI
(time frame: 30 days)
• rate of antibiotic initiation by the initial ED clinician (time frame: during initial ED visit)
Starting date November 2014
Contact information Elizabeth A Gimbel, BS; gimbele@upmc.edu
Kourtney A Wofford, BA; woffordka@upmc.edu
Notes Collaborators: University of Pittsburgh National Institute of General Medical Sciences (NIGMS),
bioMérieux
Registration: NCT02130986
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NCT02261610
Trial name or title Pulmonary embolism and PCT. PE-PCT study
Methods Single-centre, prospective, randomised trial in France
Participants Inclusion criteria:
1. age over 18 years
2. CT diagnosis of pulmonary embolism with signs of pulmonary infarction
3. temperature > 37.8
4. prior agreement with the patient signing a consent
Exclusion criteria:
1. pregnant women
2. refusal of the patient
3. pulmonary neoplasia
4. antibiotic ongoing for more than 24 hours at the time of diagnosis of pulmonary embolism
5. cardiogenic shock (hypotension with mean arterial pressure less than 65 bpm)
6. suspicion of infection other than lung associated (urinary tract infection; prostatitis; ear, nose, and
throat infection; sinusitis, etc.)
7. patient under guardianship
8. patient unable to give consent
Interventions Algorithm used in this study: Procalcitonin algorithm to guide antibiotic therapy. In the control group, the
use of antibiotics will be guided by clinical criteria
Outcomes • percentage of participants treated with antibiotics in each group (time frame: at day 1)
• percentage of deaths (time frame: at day 1)
• percentage of antibiotics stop (time frame: at day 1)
• rate of new hospitalisations during the following month (time frame: at 1 month)
Starting date November 2014
Contact information Patrick Lacarin; placarin@chu-clermontferrand.fr
Notes Collaborators: Thermo Fisher Scientific
Registration: NCT02261610
NCT02332577
Trial name or title Study to compare the efficacy of pristinamycin (Pyostacine) versus amoxicillin in the treatment of acute
community acquired pneumonia
Methods A multicentre, non-inferiority, randomised, double-blind, phase IV study in France and Tunisia
Participants Inclusion criteria:
1. male or female older than 18 years with a presumed bacterial acute community-acquired pneumonia
presenting a PORT score of II or III (Fine II or III)
Exclusion criteria:
1. patients diagnosed with legionellosis
2. having received over 24 hours of systemic antibiotic therapy during the week preceding the start of
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study treatment
3. associated neoplasm (active cancer (of whatever type, solid or haematological) or diagnosed within the
year other than baso-cellular skin cancer)
4. severe or very severe COPD (GOLD3 and GOLD4)
5. history of bacterial pneumonia in the past 12 months
6. bronchopulmonary diseases likely to interfere with the assessment of the therapeutic response
7. known hypersensitivity to streptogramins, penicillin and other beta-lactam antibiotics or excipients of
the treatments studied
8. history of severe skin reaction after taking pristinamycin or amoxicillin
9. kidney disease (chronic kidney failure or creatinine clearance ≤ 30 mL/minute)
10. patients treated with allopurinol, colchicine, immunosuppressants (cyclosporin, tacrolimus,
mycophenolate mofetil, methotrexate, bio therapies), oral anticoagulants in the previous 6 months or
during the study
11. known HIV infection, whatever the stage
Interventions Algorithm used in this study: pristinamycin + placebo versus amoxicillin + placebo. To evaluate the clinical
efficacy of pristinamycin at a dose of 2 g x 2/day for 2 days then 1 g x 3/day for 5 to 7 days versus amoxicillin
1 g x 3/day for 7 to 9 days, 5 to 9 days after the end of treatment
Outcomes • percentage of cured participants established from the clinical course and pulmonary radiological course
(time frame: 5 to 9 days post-treatment)
• percentage of cured participants evaluated by bacteriological documentation and PCT levels (time
frame: 5 to 9 days post-treatment)
• percentage of cured participants evaluated by bacteriological documentation for pneumococcus (time
frame: 5 to 9 days post-treatment)
• percentage of participants with relapse (time frame: at day 30)
• mortality rate (time frame: at day 30)
• number of documented failures (time frame: 5 to 9 days post-treatment)
• proportion of participants with adverse events (time frame: up to day 30)
Starting date April 2015
Contact information Contact-Us@sanofi.com
Notes Collaborators: Clinical Sciences & Operations
Registration: NCT02332577
NCT02440828
Trial name or title Addition of tobramycin inhalation in the treatment of ventilator associated pneumonia (VAPORISE)
Methods Randomised trial, parallel assignment, double-blind (participant, investigator) in the Netherlands and Spain
Participants Inclusion criteria: 1) mechanical ventilation 48 hours or more; and 2) new or progressive radiologic pul-
monary infiltrate; together with at least 2 of the following 3 criteria (< 24 h):
• temperature > 38°C;
• leukocytosis > 12,000/mm3 or leukopenia < 4000/mm3 ;
• purulent respiratory secretions.
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Exclusion criteria:
1. patients with allergy to tobramycin
2. pregnancy
3. expected to die within 72 hours after enrolment
Interventions Algorithm used in this study:
Experimental arm: tobramycin inhalation twice daily; tobramycin inhalation (Bramitob) 300mg and standard
intravenous antibiotics treatment. Intervention: drug: tobramycin inhalation
Placebo comparator: placebo twice daily; placebo inhalation and standard intravenous antibiotics treatment.
Intervention: drug: placebo
Outcomes • response after 72 h of treatment (time frame: 72 hours)
• mortality rate (time frame: day 30) 30-day and 90-day mortality rate
• ICU survival (time frame: day 90)
• absence of hospital admittance at day 60 (time frame: day 60)
• discharge from the ICU (time frame: up to 60 days)
• adverse events
• day of normalisation of CRP
• eradication of pathogens
• Clinical Pulmonary Infectious Score
• APACHE II score
• Multiple Organ Dysfunction Score
• SOFA score
• Lung Injury Score
• day of normalisation of PCT
• day of normalisation of chest X-ray
Starting date March 2015
Contact information Rogier Hoek, MD; r.hoek@erasmusmc.nl
Menno Van der Eerden, MD, PhD; m.vandereerden@erasmusmc.nl
Notes Collaborators: Chiesi Farmaceutici S.p.A.
Registration: NCT02440828
NCT02787603
Trial name or title PCT in Early Antibiotic Interruption in PatientWith Bacterial Pulmonary infeCtion and Acute Heart Failure
(EPICAD)
Methods Randomised trial with parallel assignment, open label in Brazil
Participants Inclusion criteria:
1. Decompensated acute heart failure diagnosis and suspected pulmonary infection
2. BNP ≥ 500 pg/mL or NT-proBNP ≥ 450 pg/mL for patients ≤ 50 years old
3. BNP ≥ 500 pg/mL or NT-proBNP ≥ 900 pg/mL for patients 51 to 75 years old
4. BNP ≥ 500 pg/mL or NT-proBNP ≥ 1800 pg/mL for patients > 75 years old
Exclusion criteria:
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1. antibiotic use (oral or endovenous) in the last 15 days
2. acute coronary syndrome
3. creatinine > 3.0 mg/dL or haemodialysis
4. pregnancy
5. second suspected infection
6. suspected pulmonary thromboembolism
7. cancer
8. myocarditis
Interventions Algorithm used in this study:
Experimental: group A: interruption of antibiotic treatment based on PCT measurement
No intervention: group B: antibiotic therapy period determined by the physician without knowledge of PCT
levels
Outcomes • total period of antibiotic therapy (time frame: 30 days)
• hospitalisation (time frame: 30 days)
• mortality (time frame: 30 days)
• PCT levels during antibiotic therapy (time frame: 5 days)
Starting date January 2015
Contact information Mucio Tavares, PhD, MD; mucio@incor.usp.br
Aline Bossa, MSc; aline.bossa@incor.usp.br
Notes Collaborators: University of Sao Paulo General Hospital, bioMérieux
Registration: NCT02787603
NCT02862314
Trial name or title PCT Pneumonia/Pneumonitis Associated With ASPIration (PROPASPI)
Methods Randomised trial, parallel assignment, open label in France
Participants Inclusion criteria:
1. aged 18 or older
2. have undergone oro-tracheal intubation for a coma (Glasgow Coma Score ≤ 8)
3. with mechanical ventilation initiated in the first 48 hours following hospital admission
Exclusion criteria:
1. pregnancy
2. patients under legal custody
3. patients without health insurance
4. patients included in another interventional clinical study involving infections or antibiotics and having
the same primary parameter
5. moribund patients
6. situation in which the PCT concentration could be increased without correlation to an infectious
process (polytraumatised patients)
7. surgical interventions within the last 4 days
8. cardiorespiratory arrest
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9. administration of antithymocyte globulin
10. immunodepressed patients (bone marrow transplant patients, patients with severe neutropenia)
11. patients with an absolute indication for administration of antibiotics at the moment of ICU admission
(meningitis, pneumonia) or a chronic infection for which long-term antibiotic treatment is necessary
(endocarditis, osteoarticular infections, mediastinitis, deep abscesses, pneumocystis infection, toxoplasmosis,
tuberculosis)
12. patients with haemodynamic instability of septic origin or a respiratory insufficiency (defined by a ratio
PaO2/FiO2 ≤ 200 mmHg and pulmonary positive ≥ 5 cmH2O)
Interventions Algorithm used in this study:
Experimental: PCT group. The PCT concentration is measured at inclusion
No intervention: control group. Concentrations of PCT are not measured
Outcomes • duration of antibiotic treatment (time frame: during the first 15 days following admission to the ICU)
Starting date February 2015
Contact information Gilles Capellier, MDPH; gilles.capellier@univ-fcomte.fr
Sophie Depierre; sdepierre@chu-besancon.fr
Notes Collaborators: Centre Hospitalier Universitaire de Besancon
Registration: NCT02862314
NCT02931409
Trial name or title Intra-operative PEEP optimisation: effects on postoperative pulmonary complications and inflammatory
response
Methods Randomised trial, parallel assignment, single-blind in Hungary
Participants Inclusion criteria:
1. patients with bladder cancer undergoing radical cystectomy and urinary diversion (ileal conduit or
orthotopic bladder substitute)
Exclusion criteria:
1. age < 18 years
2. American society of Anesthesiology risk class IV
3. history of severe COPD (GOLD grade III or IV)
4. history of severe or uncontrolled bronchial asthma
5. history of severe restrictive pulmonary disease
6. pulmonary metastases
7. history of any thoracic surgery
8. need for thoracic drainage before surgery
9. renal replacement therapy prior to surgery
10. congestive heart failure (NYHA grade III or IV)
11. extreme obesity (BMI > 35 kg/m2)
12. lack of patient’s consent
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Interventions Algorithm used in this study:
Experimental: Optimal PEEP patients submitted to general anaesthesia and open radical cystectomy and
urinary diversion (20 participants) will be submitted an alveolar recruitment maneuver using the sustained
airway pressure by the CPAP method, applying 30 cmH2O PEEP for 30 seconds followed by a decremental
PEEP titration procedure directed by static pulmonary compliance (Cstat). During PEEP titration procedure,
PEEP will be decreased from 14 cmH2O by 2 cmH2O every 4 minutes, until a final PEEP of 6 cmH2O.
Optimal PEEP is considered to be a PEEP value resulting the highest possible Cstat measured by ventilator.
After PEEP titration procedure, a lung protective mechanical ventilation will be performed using optimal
PEEP and low tidal volumes
Active comparator: Standard PEEP. Patients submitted to general anaesthesia and open radical cystectomy and
urinary diversion (20 participants) will be submitted an alveolar recruitment manoeuvre using the sustained
airway pressure by the CPAP method, applying 30 cmH2O PEEP for 30 seconds followed by a standard lung
protective mechanical ventilation using a PEEP value of 6 cmH2O and low tidal volumes (6 mL/kg)
Outcomes • Postoperative Pulmonary Complications: new infiltrates or atelectasis on chest X-ray, abnormal
breathing sounds on auscultation, excessive bronchial secretions, unexplained fever, respiratory failure or
need for non-invasive or invasive ventilatory support.
• Procalcitonin Kinetics: serum procalcitonin levels during and after surgery
Starting date October 2016
Contact information Zoltán Ruszkai, MD; ruszkai.zoltan@peterfykh.hu
Notes Collaborator: Péterfy Sándor Hospital, Szeged University
Registration: NCT02931409
AB: antibiotic
ACCP: American College of Chest Physicians
APACHE II: Acute Physiology and Chronic Health Evaluation II
BMI: body mass index
BNP: B-type natriuretic peptide
COPD: chronic obstructive pulmonary disease







GOLD: Global Initiative for Chronic Obstructive Lung Disease
ICU: intensive care unit
LRTI: lower respiratory tract infection
NT-proBNP: N-terminal pro-B-type natriuretic peptide
NYHA: New York Heart Association
Pa: arterial
PaO2/FiO2: relationship between arterial oxygen tension (PaO2) and inspiratory oxygen fraction (FiO2)
PCT: procalcitonin
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PEEP: positive end-expiratory pressure
PORT: Pneumonia Patient Outcomes Research Team
RCT: randomised controlled trial
SIRS: systemic inflammatory response syndrome
SOFA: Sequential Organ Failure Assessment score
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D A T A A N D A N A L Y S E S
Comparison 1. Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting




participants Statistical method Effect size
1 Mortality at 30 days 32 10046 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.78, 1.01]
1.1 Primary care trials 2 1008 Odds Ratio (M-H, Random, 95% CI) 0.32 [0.01, 7.98]
1.2 Emergency department
trials
14 3805 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.70, 1.36]
1.3 Intensive care unit trials 16 5233 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.77, 1.00]
2 Treatment failure at 30 days 32 10046 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.81, 0.99]
2.1 Primary care trials 2 1008 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.72, 1.22]
2.2 Emergency department
trials
14 3805 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.69, 1.05]
2.3 Intensive care unit trials 16 5233 Odds Ratio (M-H, Random, 95% CI) 0.92 [0.81, 1.05]
Comparison 2. Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses




participants Statistical method Effect size
1 Mortality at 30 days stratified by
adherence
32 10046 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.78, 1.01]
1.1 Adherence to
procalcitonin algorithm > 70%
14 4422 Odds Ratio (M-H, Random, 95% CI) 1.05 [0.81, 1.37]
1.2 Adherence to
procalcitonin algorithm < 70%
or not available
18 5624 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.73, 0.97]
2 Treatment failure at 30 days
stratified by adherence
32 10046 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.81, 0.99]
2.1 Adherence to
procalcitonin algorithm > 70%
14 4422 Odds Ratio (M-H, Random, 95% CI) 0.87 [0.75, 1.02]
2.2 Adherence to
procalcitonin algorithm < 70%
or not available
18 5624 Odds Ratio (M-H, Random, 95% CI) 0.92 [0.81, 1.04]
3 Mortality at 30 days stratified by
allocation concealment
32 10046 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.78, 1.01]
3.1 Trials with concealed
allocation
22 7968 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.76, 1.01]
3.2 Trials without concealed
allocation
10 2078 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.70, 1.28]
4 Treatment failure at 30
days stratified by allocation
concealment
32 10046 Odds Ratio (M-H, Random, 95% CI) 0.90 [0.81, 0.99]
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4.1 Trials with concealed
allocation
22 7968 Odds Ratio (M-H, Random, 95% CI) 0.91 [0.82, 1.02]
4.2 Trials without concealed
allocation
10 2078 Odds Ratio (M-H, Random, 95% CI) 0.82 [0.64, 1.04]
5 Mortality at 30 days stratified by
blinded outcome assessment
32 10046 Odds Ratio (M-H, Fixed, 95% CI) 0.89 [0.78, 1.00]
5.1 Trials with blinded
outcome assessment
9 4664 Odds Ratio (M-H, Fixed, 95% CI) 1.05 [0.84, 1.32]
5.2 Trials without blinded
outcome assessment
23 5382 Odds Ratio (M-H, Fixed, 95% CI) 0.82 [0.70, 0.95]
6 Treatment failure at 30 days
stratified by blinded outcome
assessment
32 10046 Odds Ratio (M-H, Fixed, 95% CI) 0.90 [0.81, 0.99]
6.1 Trials with blinded
outcome assessment
9 4664 Odds Ratio (M-H, Fixed, 95% CI) 0.92 [0.79, 1.06]
6.2 Trials without blinded
outcome assessment
23 5382 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.77, 1.01]
7 Mortality at 30 days stratified by
follow up
32 10046 Odds Ratio (M-H, Fixed, 95% CI) 0.89 [0.78, 1.00]
7.1 Trials with 1 month follow
up for mortality
18 7337 Odds Ratio (M-H, Fixed, 95% CI) 0.85 [0.74, 0.98]
7.2 Trials with different follow
up for mortality
14 2709 Odds Ratio (M-H, Fixed, 95% CI) 1.01 [0.78, 1.30]
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Analysis 1.1. Comparison 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical
setting, Outcome 1 Mortality at 30 days.
Review: Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
Comparison: 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting
Outcome: 1 Mortality at 30 days








1 Primary care trials
Briel 2008 0/232 1/226 0.2 % 0.32 [ 0.01, 7.98 ]
Burkhardt 2010 0/275 0/275 Not estimable
Subtotal (95% CI) 507 501 0.2 % 0.32 [ 0.01, 7.98 ]
Total events: 0 (PCT-guided care), 1 (Controls)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 Emergency department trials
Christ-Crain 2004 4/124 3/119 0.7 % 1.29 [ 0.28, 5.88 ]
Christ-Crain 2006 18/151 20/151 3.4 % 0.89 [ 0.45, 1.75 ]
Stolz 2007 3/102 2/106 0.5 % 1.58 [ 0.26, 9.63 ]
Schuetz 2009 34/671 33/688 6.5 % 1.06 [ 0.65, 1.73 ]
Long 2009 0/63 0/64 Not estimable
Kristoffersen 2009 2/103 1/107 0.3 % 2.10 [ 0.19, 23.51 ]
Long 2011 0/77 0/79 Not estimable
Tang 2013 1/132 2/133 0.3 % 0.50 [ 0.04, 5.58 ]
Ogasawara 2014 5/48 10/48 1.2 % 0.44 [ 0.14, 1.41 ]
Long 2014 0/90 0/90 Not estimable
Verduri 2015 3/88 2/90 0.5 % 1.55 [ 0.25, 9.53 ]
Branche 2015 1/151 2/149 0.3 % 0.49 [ 0.04, 5.46 ]
Lima 2016 4/30 2/31 0.5 % 2.23 [ 0.38, 13.20 ]
Corti 2016 1/62 2/58 0.3 % 0.46 [ 0.04, 5.20 ]
Subtotal (95% CI) 1892 1913 14.3 % 0.97 [ 0.70, 1.36 ]
Total events: 76 (PCT-guided care), 79 (Controls)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.83, df = 10 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.88)
3 Intensive care unit trials
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Nobre 2008 8/39 8/40 1.3 % 1.03 [ 0.34, 3.09 ]
Stolz 2009 8/51 12/50 1.6 % 0.59 [ 0.22, 1.59 ]
Hochreiter 2009 15/57 14/53 2.2 % 0.99 [ 0.43, 2.32 ]
Schroeder 2009 3/14 3/13 0.5 % 0.91 [ 0.15, 5.58 ]
Bouadma 2010 65/307 64/314 10.4 % 1.05 [ 0.71, 1.55 ]
Maravi -Stojkovi 2011 3/102 3/103 0.6 % 1.01 [ 0.20, 5.13 ]
Layios 2012 56/258 53/251 8.7 % 1.04 [ 0.68, 1.58 ]
Ding 2013 21/33 20/35 1.6 % 1.31 [ 0.49, 3.48 ]
Oliveira 2013 16/49 15/45 2.1 % 0.97 [ 0.41, 2.29 ]
Annane 2013 7/30 10/28 1.2 % 0.55 [ 0.17, 1.72 ]
Deliberato 2013 2/42 4/39 0.5 % 0.44 [ 0.08, 2.54 ]
Shehabi 2014 30/196 26/198 4.9 % 1.20 [ 0.68, 2.11 ]
Najafi 2015 5/30 4/30 0.8 % 1.30 [ 0.31, 5.40 ]
Bloos 2016 140/552 149/537 21.6 % 0.88 [ 0.68, 1.16 ]
Wang 2016 2/96 5/95 0.6 % 0.38 [ 0.07, 2.02 ]
De Jong 2016 149/761 196/785 27.0 % 0.73 [ 0.57, 0.93 ]
Subtotal (95% CI) 2617 2616 85.6 % 0.88 [ 0.77, 1.00 ]
Total events: 530 (PCT-guided care), 586 (Controls)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.75, df = 15 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
Total (95% CI) 5016 5030 100.0 % 0.89 [ 0.78, 1.01 ]
Total events: 606 (PCT-guided care), 666 (Controls)
Heterogeneity: Tau2 = 0.0; Chi2 = 14.30, df = 27 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.063)
Test for subgroup differences: Chi2 = 0.72, df = 2 (P = 0.70), I2 =0.0%
0.005 0.1 1 10 200
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Analysis 1.2. Comparison 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical
setting, Outcome 2 Treatment failure at 30 days.
Review: Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
Comparison: 1 Procalcitonin algorithm versus no procalcitonin algorithm stratified by clinical setting
Outcome: 2 Treatment failure at 30 days








1 Primary care trials
Briel 2008 73/232 68/226 6.0 % 1.07 [ 0.72, 1.59 ]
Burkhardt 2010 86/275 96/275 7.5 % 0.85 [ 0.59, 1.21 ]
Subtotal (95% CI) 507 501 13.6 % 0.94 [ 0.72, 1.22 ]
Total events: 159 (PCT-guided care), 164 (Controls)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.64)
2 Emergency department trials
Christ-Crain 2004 10/124 8/119 1.0 % 1.22 [ 0.46, 3.20 ]
Christ-Crain 2006 36/151 56/151 3.8 % 0.53 [ 0.32, 0.87 ]
Stolz 2007 13/102 15/106 1.5 % 0.89 [ 0.40, 1.97 ]
Schuetz 2009 103/671 130/688 11.8 % 0.78 [ 0.59, 1.03 ]
Kristoffersen 2009 8/103 6/107 0.8 % 1.42 [ 0.47, 4.24 ]
Long 2009 4/63 6/64 0.6 % 0.66 [ 0.18, 2.44 ]
Long 2011 8/77 7/79 0.8 % 1.19 [ 0.41, 3.47 ]
Tang 2013 6/132 10/133 0.9 % 0.59 [ 0.21, 1.66 ]
Ogasawara 2014 12/48 18/48 1.2 % 0.56 [ 0.23, 1.33 ]
Long 2014 7/90 9/90 0.9 % 0.76 [ 0.27, 2.13 ]
Branche 2015 3/151 5/149 0.5 % 0.58 [ 0.14, 2.49 ]
Verduri 2015 19/88 12/90 1.5 % 1.79 [ 0.81, 3.95 ]
Corti 2016 22/62 15/58 1.5 % 1.58 [ 0.72, 3.46 ]
Lima 2016 6/30 4/31 0.5 % 1.69 [ 0.42, 6.70 ]
Subtotal (95% CI) 1892 1913 27.4 % 0.85 [ 0.69, 1.05 ]
Total events: 257 (PCT-guided care), 301 (Controls)
Heterogeneity: Tau2 = 0.01; Chi2 = 14.08, df = 13 (P = 0.37); I2 =8%
Test for overall effect: Z = 1.53 (P = 0.13)
3 Intensive care unit trials
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Nobre 2008 9/39 9/40 0.9 % 1.03 [ 0.36, 2.96 ]
Hochreiter 2009 15/57 14/53 1.3 % 0.99 [ 0.43, 2.32 ]
Stolz 2009 8/51 12/50 1.0 % 0.59 [ 0.22, 1.59 ]
Schroeder 2009 3/14 3/13 0.3 % 0.91 [ 0.15, 5.58 ]
Bouadma 2010 85/307 80/314 7.5 % 1.12 [ 0.78, 1.60 ]
Maravi -Stojkovi 2011 40/102 41/103 3.0 % 0.98 [ 0.56, 1.71 ]
Layios 2012 56/258 53/251 5.3 % 1.04 [ 0.68, 1.58 ]
Annane 2013 7/30 10/28 0.7 % 0.55 [ 0.17, 1.72 ]
Ding 2013 21/33 20/35 1.0 % 1.31 [ 0.49, 3.48 ]
Deliberato 2013 4/42 5/39 0.5 % 0.72 [ 0.18, 2.88 ]
Oliveira 2013 19/49 16/45 1.4 % 1.15 [ 0.50, 2.65 ]
Shehabi 2014 36/196 38/198 3.7 % 0.95 [ 0.57, 1.57 ]
Najafi 2015 5/30 4/30 0.5 % 1.30 [ 0.31, 5.40 ]
Wang 2016 2/96 5/95 0.3 % 0.38 [ 0.07, 2.02 ]
De Jong 2016 187/761 219/785 18.5 % 0.84 [ 0.67, 1.06 ]
Bloos 2016 140/552 149/537 13.2 % 0.88 [ 0.68, 1.16 ]
Subtotal (95% CI) 2617 2616 59.0 % 0.92 [ 0.81, 1.05 ]
Total events: 637 (PCT-guided care), 678 (Controls)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.02, df = 15 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
Total (95% CI) 5016 5030 100.0 % 0.90 [ 0.81, 0.99 ]
Total events: 1053 (PCT-guided care), 1143 (Controls)
Heterogeneity: Tau2 = 0.0; Chi2 = 21.69, df = 31 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Chi2 = 0.50, df = 2 (P = 0.78), I2 =0.0%
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Analysis 2.1. Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses,
Outcome 1 Mortality at 30 days stratified by adherence.
Review: Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
Comparison: 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses
Outcome: 1 Mortality at 30 days stratified by adherence








1 Adherence to procalcitonin algorithm > 70%
Christ-Crain 2004 4/124 3/119 0.7 % 1.29 [ 0.28, 5.88 ]
Christ-Crain 2006 18/151 20/151 3.4 % 0.89 [ 0.45, 1.75 ]
Briel 2008 0/232 1/226 0.2 % 0.32 [ 0.01, 7.98 ]
Nobre 2008 8/39 8/40 1.3 % 1.03 [ 0.34, 3.09 ]
Schuetz 2009 34/671 33/688 6.5 % 1.06 [ 0.65, 1.73 ]
Burkhardt 2010 0/275 0/275 Not estimable
Ding 2013 21/33 20/35 1.6 % 1.31 [ 0.49, 3.48 ]
Oliveira 2013 16/49 15/45 2.1 % 0.97 [ 0.41, 2.29 ]
Tang 2013 1/132 2/133 0.3 % 0.50 [ 0.04, 5.58 ]
Long 2014 0/90 0/90 Not estimable
Shehabi 2014 30/196 26/198 4.9 % 1.20 [ 0.68, 2.11 ]
Verduri 2015 3/88 2/90 0.5 % 1.55 [ 0.25, 9.53 ]
Lima 2016 4/30 2/31 0.5 % 2.23 [ 0.38, 13.20 ]
Wang 2016 2/96 5/95 0.6 % 0.38 [ 0.07, 2.02 ]
Subtotal (95% CI) 2206 2216 22.5 % 1.05 [ 0.81, 1.37 ]
Total events: 141 (PCT-guided care), 137 (Controls)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.91, df = 11 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.71)
2 Adherence to procalcitonin algorithm < 70% or not available
Stolz 2007 3/102 2/106 0.5 % 1.58 [ 0.26, 9.63 ]
Schroeder 2009 3/14 3/13 0.5 % 0.91 [ 0.15, 5.58 ]
Long 2009 0/63 0/64 Not estimable
Hochreiter 2009 15/57 14/53 2.2 % 0.99 [ 0.43, 2.32 ]
Kristoffersen 2009 2/103 1/107 0.3 % 2.10 [ 0.19, 23.51 ]
Stolz 2009 8/51 12/50 1.6 % 0.59 [ 0.22, 1.59 ]
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Bouadma 2010 65/307 64/314 10.4 % 1.05 [ 0.71, 1.55 ]
Maravi -Stojkovi 2011 3/102 3/103 0.6 % 1.01 [ 0.20, 5.13 ]
Long 2011 0/77 0/79 Not estimable
Layios 2012 56/258 53/251 8.7 % 1.04 [ 0.68, 1.58 ]
Deliberato 2013 2/42 4/39 0.5 % 0.44 [ 0.08, 2.54 ]
Annane 2013 7/30 10/28 1.2 % 0.55 [ 0.17, 1.72 ]
Ogasawara 2014 5/48 10/48 1.2 % 0.44 [ 0.14, 1.41 ]
Branche 2015 1/151 2/149 0.3 % 0.49 [ 0.04, 5.46 ]
Najafi 2015 5/30 4/30 0.8 % 1.30 [ 0.31, 5.40 ]
Corti 2016 1/62 2/58 0.3 % 0.46 [ 0.04, 5.20 ]
De Jong 2016 149/761 196/785 27.0 % 0.73 [ 0.57, 0.93 ]
Bloos 2016 140/552 149/537 21.6 % 0.88 [ 0.68, 1.16 ]
Subtotal (95% CI) 2810 2814 77.5 % 0.85 [ 0.73, 0.97 ]
Total events: 465 (PCT-guided care), 529 (Controls)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.35, df = 15 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.32 (P = 0.021)
Total (95% CI) 5016 5030 100.0 % 0.89 [ 0.78, 1.01 ]
Total events: 606 (PCT-guided care), 666 (Controls)
Heterogeneity: Tau2 = 0.0; Chi2 = 14.30, df = 27 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.063)
Test for subgroup differences: Chi2 = 2.04, df = 1 (P = 0.15), I2 =51%
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Analysis 2.2. Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses,
Outcome 2 Treatment failure at 30 days stratified by adherence.
Review: Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
Comparison: 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses
Outcome: 2 Treatment failure at 30 days stratified by adherence








1 Adherence to procalcitonin algorithm > 70%
Christ-Crain 2004 10/124 8/119 1.0 % 1.22 [ 0.46, 3.20 ]
Christ-Crain 2006 36/151 56/151 3.8 % 0.53 [ 0.32, 0.87 ]
Briel 2008 73/232 68/226 6.0 % 1.07 [ 0.72, 1.59 ]
Nobre 2008 9/39 9/40 0.9 % 1.03 [ 0.36, 2.96 ]
Schuetz 2009 103/671 130/688 11.8 % 0.78 [ 0.59, 1.03 ]
Burkhardt 2010 86/275 96/275 7.5 % 0.85 [ 0.59, 1.21 ]
Tang 2013 6/132 10/133 0.9 % 0.59 [ 0.21, 1.66 ]
Oliveira 2013 19/49 16/45 1.4 % 1.15 [ 0.50, 2.65 ]
Ding 2013 21/33 20/35 1.0 % 1.31 [ 0.49, 3.48 ]
Shehabi 2014 36/196 38/198 3.7 % 0.95 [ 0.57, 1.57 ]
Long 2014 7/90 9/90 0.9 % 0.76 [ 0.27, 2.13 ]
Verduri 2015 19/88 12/90 1.5 % 1.79 [ 0.81, 3.95 ]
Lima 2016 6/30 4/31 0.5 % 1.69 [ 0.42, 6.70 ]
Wang 2016 2/96 5/95 0.3 % 0.38 [ 0.07, 2.02 ]
Subtotal (95% CI) 2206 2216 41.3 % 0.87 [ 0.75, 1.02 ]
Total events: 433 (PCT-guided care), 481 (Controls)
Heterogeneity: Tau2 = 0.0; Chi2 = 12.79, df = 13 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.078)
2 Adherence to procalcitonin algorithm < 70% or not available
Stolz 2007 13/102 15/106 1.5 % 0.89 [ 0.40, 1.97 ]
Hochreiter 2009 15/57 14/53 1.3 % 0.99 [ 0.43, 2.32 ]
Long 2009 4/63 6/64 0.6 % 0.66 [ 0.18, 2.44 ]
Schroeder 2009 3/14 3/13 0.3 % 0.91 [ 0.15, 5.58 ]
Stolz 2009 8/51 12/50 1.0 % 0.59 [ 0.22, 1.59 ]
Kristoffersen 2009 8/103 6/107 0.8 % 1.42 [ 0.47, 4.24 ]
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Bouadma 2010 85/307 80/314 7.5 % 1.12 [ 0.78, 1.60 ]
Maravi -Stojkovi 2011 40/102 41/103 3.0 % 0.98 [ 0.56, 1.71 ]
Long 2011 8/77 7/79 0.8 % 1.19 [ 0.41, 3.47 ]
Layios 2012 56/258 53/251 5.3 % 1.04 [ 0.68, 1.58 ]
Deliberato 2013 4/42 5/39 0.5 % 0.72 [ 0.18, 2.88 ]
Annane 2013 7/30 10/28 0.7 % 0.55 [ 0.17, 1.72 ]
Ogasawara 2014 12/48 18/48 1.2 % 0.56 [ 0.23, 1.33 ]
Branche 2015 3/151 5/149 0.5 % 0.58 [ 0.14, 2.49 ]
Najafi 2015 5/30 4/30 0.5 % 1.30 [ 0.31, 5.40 ]
De Jong 2016 187/761 219/785 18.5 % 0.84 [ 0.67, 1.06 ]
Corti 2016 22/62 15/58 1.5 % 1.58 [ 0.72, 3.46 ]
Bloos 2016 140/552 149/537 13.2 % 0.88 [ 0.68, 1.16 ]
Subtotal (95% CI) 2810 2814 58.7 % 0.92 [ 0.81, 1.04 ]
Total events: 620 (PCT-guided care), 662 (Controls)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.66, df = 17 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
Total (95% CI) 5016 5030 100.0 % 0.90 [ 0.81, 0.99 ]
Total events: 1053 (PCT-guided care), 1143 (Controls)
Heterogeneity: Tau2 = 0.0; Chi2 = 21.69, df = 31 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Chi2 = 0.24, df = 1 (P = 0.62), I2 =0.0%
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Analysis 2.3. Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses,
Outcome 3 Mortality at 30 days stratified by allocation concealment.
Review: Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
Comparison: 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses
Outcome: 3 Mortality at 30 days stratified by allocation concealment








1 Trials with concealed allocation
Nobre 2008 8/39 8/40 1.3 % 1.03 [ 0.34, 3.09 ]
Briel 2008 0/232 1/226 0.2 % 0.32 [ 0.01, 7.98 ]
Schuetz 2009 34/671 33/688 6.5 % 1.06 [ 0.65, 1.73 ]
Stolz 2009 8/51 12/50 1.6 % 0.59 [ 0.22, 1.59 ]
Kristoffersen 2009 2/103 1/107 0.3 % 2.10 [ 0.19, 23.51 ]
Bouadma 2010 65/307 64/314 10.4 % 1.05 [ 0.71, 1.55 ]
Burkhardt 2010 0/275 0/275 Not estimable
Maravi -Stojkovi 2011 3/102 3/103 0.6 % 1.01 [ 0.20, 5.13 ]
Deliberato 2013 2/42 4/39 0.5 % 0.44 [ 0.08, 2.54 ]
Tang 2013 1/132 2/133 0.3 % 0.50 [ 0.04, 5.58 ]
Annane 2013 7/30 10/28 1.2 % 0.55 [ 0.17, 1.72 ]
Ding 2013 21/33 20/35 1.6 % 1.31 [ 0.49, 3.48 ]
Oliveira 2013 16/49 15/45 2.1 % 0.97 [ 0.41, 2.29 ]
Shehabi 2014 30/196 26/198 4.9 % 1.20 [ 0.68, 2.11 ]
Long 2014 0/90 0/90 Not estimable
Najafi 2015 5/30 4/30 0.8 % 1.30 [ 0.31, 5.40 ]
Verduri 2015 3/88 2/90 0.5 % 1.55 [ 0.25, 9.53 ]
Wang 2016 2/96 5/95 0.6 % 0.38 [ 0.07, 2.02 ]
De Jong 2016 149/761 196/785 27.0 % 0.73 [ 0.57, 0.93 ]
Corti 2016 1/62 2/58 0.3 % 0.46 [ 0.04, 5.20 ]
Bloos 2016 140/552 149/537 21.6 % 0.88 [ 0.68, 1.16 ]
Lima 2016 4/30 2/31 0.5 % 2.23 [ 0.38, 13.20 ]
Subtotal (95% CI) 3971 3997 82.6 % 0.88 [ 0.76, 1.01 ]
Total events: 501 (PCT-guided care), 559 (Controls)
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Heterogeneity: Tau2 = 0.0; Chi2 = 11.44, df = 19 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.059)
2 Trials without concealed allocation
Christ-Crain 2004 4/124 3/119 0.7 % 1.29 [ 0.28, 5.88 ]
Christ-Crain 2006 18/151 20/151 3.4 % 0.89 [ 0.45, 1.75 ]
Stolz 2007 3/102 2/106 0.5 % 1.58 [ 0.26, 9.63 ]
Schroeder 2009 3/14 3/13 0.5 % 0.91 [ 0.15, 5.58 ]
Hochreiter 2009 15/57 14/53 2.2 % 0.99 [ 0.43, 2.32 ]
Long 2009 0/63 0/64 Not estimable
Long 2011 0/77 0/79 Not estimable
Layios 2012 56/258 53/251 8.7 % 1.04 [ 0.68, 1.58 ]
Ogasawara 2014 5/48 10/48 1.2 % 0.44 [ 0.14, 1.41 ]
Branche 2015 1/151 2/149 0.3 % 0.49 [ 0.04, 5.46 ]
Subtotal (95% CI) 1045 1033 17.4 % 0.95 [ 0.70, 1.28 ]
Total events: 105 (PCT-guided care), 107 (Controls)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.63, df = 7 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
Total (95% CI) 5016 5030 100.0 % 0.89 [ 0.78, 1.01 ]
Total events: 606 (PCT-guided care), 666 (Controls)
Heterogeneity: Tau2 = 0.0; Chi2 = 14.30, df = 27 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.063)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
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Analysis 2.4. Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses,
Outcome 4 Treatment failure at 30 days stratified by allocation concealment.
Review: Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
Comparison: 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses
Outcome: 4 Treatment failure at 30 days stratified by allocation concealment








1 Trials with concealed allocation
Nobre 2008 9/39 9/40 0.9 % 1.03 [ 0.36, 2.96 ]
Briel 2008 73/232 68/226 6.0 % 1.07 [ 0.72, 1.59 ]
Kristoffersen 2009 8/103 6/107 0.8 % 1.42 [ 0.47, 4.24 ]
Stolz 2009 8/51 12/50 1.0 % 0.59 [ 0.22, 1.59 ]
Schuetz 2009 103/671 130/688 11.8 % 0.78 [ 0.59, 1.03 ]
Burkhardt 2010 86/275 96/275 7.5 % 0.85 [ 0.59, 1.21 ]
Bouadma 2010 85/307 80/314 7.5 % 1.12 [ 0.78, 1.60 ]
Maravi -Stojkovi 2011 40/102 41/103 3.0 % 0.98 [ 0.56, 1.71 ]
Ding 2013 21/33 20/35 1.0 % 1.31 [ 0.49, 3.48 ]
Oliveira 2013 19/49 16/45 1.4 % 1.15 [ 0.50, 2.65 ]
Deliberato 2013 4/42 5/39 0.5 % 0.72 [ 0.18, 2.88 ]
Tang 2013 6/132 10/133 0.9 % 0.59 [ 0.21, 1.66 ]
Annane 2013 7/30 10/28 0.7 % 0.55 [ 0.17, 1.72 ]
Long 2014 7/90 9/90 0.9 % 0.76 [ 0.27, 2.13 ]
Shehabi 2014 36/196 38/198 3.7 % 0.95 [ 0.57, 1.57 ]
Verduri 2015 19/88 12/90 1.5 % 1.79 [ 0.81, 3.95 ]
Najafi 2015 5/30 4/30 0.5 % 1.30 [ 0.31, 5.40 ]
Bloos 2016 140/552 149/537 13.2 % 0.88 [ 0.68, 1.16 ]
De Jong 2016 187/761 219/785 18.5 % 0.84 [ 0.67, 1.06 ]
Lima 2016 6/30 4/31 0.5 % 1.69 [ 0.42, 6.70 ]
Corti 2016 22/62 15/58 1.5 % 1.58 [ 0.72, 3.46 ]
Wang 2016 2/96 5/95 0.3 % 0.38 [ 0.07, 2.02 ]
Subtotal (95% CI) 3971 3997 83.7 % 0.91 [ 0.82, 1.02 ]
Total events: 893 (PCT-guided care), 958 (Controls)
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Heterogeneity: Tau2 = 0.0; Chi2 = 14.46, df = 21 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
2 Trials without concealed allocation
Christ-Crain 2004 10/124 8/119 1.0 % 1.22 [ 0.46, 3.20 ]
Christ-Crain 2006 36/151 56/151 3.8 % 0.53 [ 0.32, 0.87 ]
Stolz 2007 13/102 15/106 1.5 % 0.89 [ 0.40, 1.97 ]
Hochreiter 2009 15/57 14/53 1.3 % 0.99 [ 0.43, 2.32 ]
Long 2009 4/63 6/64 0.6 % 0.66 [ 0.18, 2.44 ]
Schroeder 2009 3/14 3/13 0.3 % 0.91 [ 0.15, 5.58 ]
Long 2011 8/77 7/79 0.8 % 1.19 [ 0.41, 3.47 ]
Layios 2012 56/258 53/251 5.3 % 1.04 [ 0.68, 1.58 ]
Ogasawara 2014 12/48 18/48 1.2 % 0.56 [ 0.23, 1.33 ]
Branche 2015 3/151 5/149 0.5 % 0.58 [ 0.14, 2.49 ]
Subtotal (95% CI) 1045 1033 16.3 % 0.82 [ 0.64, 1.04 ]
Total events: 160 (PCT-guided care), 185 (Controls)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.52, df = 9 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
Total (95% CI) 5016 5030 100.0 % 0.90 [ 0.81, 0.99 ]
Total events: 1053 (PCT-guided care), 1143 (Controls)
Heterogeneity: Tau2 = 0.0; Chi2 = 21.69, df = 31 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.16 (P = 0.031)
Test for subgroup differences: Chi2 = 0.71, df = 1 (P = 0.40), I2 =0.0%
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Analysis 2.5. Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses,
Outcome 5 Mortality at 30 days stratified by blinded outcome assessment.
Review: Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
Comparison: 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses
Outcome: 5 Mortality at 30 days stratified by blinded outcome assessment
Study or subgroup PCT-guided care Controls Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Trials with blinded outcome assessment
Stolz 2007 3/102 2/106 0.4 % 1.58 [ 0.26, 9.63 ]
Briel 2008 0/232 1/226 0.3 % 0.32 [ 0.01, 7.98 ]
Schuetz 2009 34/671 33/688 5.9 % 1.06 [ 0.65, 1.73 ]
Bouadma 2010 65/307 64/314 9.5 % 1.05 [ 0.71, 1.55 ]
Burkhardt 2010 0/275 0/275 Not estimable
Layios 2012 56/258 53/251 8.0 % 1.04 [ 0.68, 1.58 ]
Tang 2013 1/132 2/133 0.4 % 0.50 [ 0.04, 5.58 ]
Shehabi 2014 30/196 26/198 4.2 % 1.20 [ 0.68, 2.11 ]
Branche 2015 1/151 2/149 0.4 % 0.49 [ 0.04, 5.46 ]
Subtotal (95% CI) 2324 2340 28.9 % 1.05 [ 0.84, 1.32 ]
Total events: 190 (PCT-guided care), 183 (Controls)
Heterogeneity: Chi2 = 1.66, df = 7 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.65)
2 Trials without blinded outcome assessment
Christ-Crain 2004 4/124 3/119 0.6 % 1.29 [ 0.28, 5.88 ]
Christ-Crain 2006 18/151 20/151 3.3 % 0.89 [ 0.45, 1.75 ]
Nobre 2008 8/39 8/40 1.2 % 1.03 [ 0.34, 3.09 ]
Long 2009 0/63 0/64 Not estimable
Schroeder 2009 3/14 3/13 0.5 % 0.91 [ 0.15, 5.58 ]
Stolz 2009 8/51 12/50 1.9 % 0.59 [ 0.22, 1.59 ]
Hochreiter 2009 15/57 14/53 2.0 % 0.99 [ 0.43, 2.32 ]
Kristoffersen 2009 2/103 1/107 0.2 % 2.10 [ 0.19, 23.51 ]
Long 2011 0/77 0/79 Not estimable
Maravi -Stojkovi 2011 3/102 3/103 0.6 % 1.01 [ 0.20, 5.13 ]
Annane 2013 7/30 10/28 1.5 % 0.55 [ 0.17, 1.72 ]
Ding 2013 21/33 20/35 1.3 % 1.31 [ 0.49, 3.48 ]
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(. . . Continued)
Study or subgroup PCT-guided care Controls Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Oliveira 2013 16/49 15/45 2.0 % 0.97 [ 0.41, 2.29 ]
Deliberato 2013 2/42 4/39 0.8 % 0.44 [ 0.08, 2.54 ]
Ogasawara 2014 5/48 10/48 1.7 % 0.44 [ 0.14, 1.41 ]
Long 2014 0/90 0/90 Not estimable
Najafi 2015 5/30 4/30 0.6 % 1.30 [ 0.31, 5.40 ]
Verduri 2015 3/88 2/90 0.4 % 1.55 [ 0.25, 9.53 ]
Lima 2016 4/30 2/31 0.3 % 2.23 [ 0.38, 13.20 ]
Wang 2016 2/96 5/95 0.9 % 0.38 [ 0.07, 2.02 ]
Bloos 2016 140/552 149/537 21.4 % 0.88 [ 0.68, 1.16 ]
De Jong 2016 149/761 196/785 29.5 % 0.73 [ 0.57, 0.93 ]
Corti 2016 1/62 2/58 0.4 % 0.46 [ 0.04, 5.20 ]
Subtotal (95% CI) 2692 2690 71.1 % 0.82 [ 0.70, 0.95 ]
Total events: 416 (PCT-guided care), 483 (Controls)
Heterogeneity: Chi2 = 9.22, df = 19 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.60 (P = 0.0093)
Total (95% CI) 5016 5030 100.0 % 0.89 [ 0.78, 1.00 ]
Total events: 606 (PCT-guided care), 666 (Controls)
Heterogeneity: Chi2 = 14.30, df = 27 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.058)
Test for subgroup differences: Chi2 = 3.40, df = 1 (P = 0.07), I2 =71%
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Analysis 2.6. Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses,
Outcome 6 Treatment failure at 30 days stratified by blinded outcome assessment.
Review: Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
Comparison: 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses
Outcome: 6 Treatment failure at 30 days stratified by blinded outcome assessment
Study or subgroup PCT-guided care Controls Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Trials with blinded outcome assessment
Stolz 2007 13/102 15/106 1.5 % 0.89 [ 0.40, 1.97 ]
Briel 2008 73/232 68/226 5.5 % 1.07 [ 0.72, 1.59 ]
Schuetz 2009 103/671 130/688 12.6 % 0.78 [ 0.59, 1.03 ]
Burkhardt 2010 86/275 96/275 7.7 % 0.85 [ 0.59, 1.21 ]
Bouadma 2010 85/307 80/314 6.7 % 1.12 [ 0.78, 1.60 ]
Layios 2012 56/258 53/251 4.9 % 1.04 [ 0.68, 1.58 ]
Tang 2013 6/132 10/133 1.1 % 0.59 [ 0.21, 1.66 ]
Shehabi 2014 36/196 38/198 3.6 % 0.95 [ 0.57, 1.57 ]
Branche 2015 3/151 5/149 0.6 % 0.58 [ 0.14, 2.49 ]
Subtotal (95% CI) 2324 2340 44.1 % 0.92 [ 0.79, 1.06 ]
Total events: 461 (PCT-guided care), 495 (Controls)
Heterogeneity: Chi2 = 4.66, df = 8 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
2 Trials without blinded outcome assessment
Christ-Crain 2004 10/124 8/119 0.9 % 1.22 [ 0.46, 3.20 ]
Christ-Crain 2006 36/151 56/151 5.0 % 0.53 [ 0.32, 0.87 ]
Nobre 2008 9/39 9/40 0.8 % 1.03 [ 0.36, 2.96 ]
Hochreiter 2009 15/57 14/53 1.2 % 0.99 [ 0.43, 2.32 ]
Schroeder 2009 3/14 3/13 0.3 % 0.91 [ 0.15, 5.58 ]
Stolz 2009 8/51 12/50 1.2 % 0.59 [ 0.22, 1.59 ]
Kristoffersen 2009 8/103 6/107 0.6 % 1.42 [ 0.47, 4.24 ]
Long 2009 4/63 6/64 0.6 % 0.66 [ 0.18, 2.44 ]
Maravi -Stojkovi 2011 40/102 41/103 2.9 % 0.98 [ 0.56, 1.71 ]
Long 2011 8/77 7/79 0.7 % 1.19 [ 0.41, 3.47 ]
Annane 2013 7/30 10/28 0.9 % 0.55 [ 0.17, 1.72 ]
Oliveira 2013 19/49 16/45 1.2 % 1.15 [ 0.50, 2.65 ]
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(. . . Continued)
Study or subgroup PCT-guided care Controls Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ding 2013 21/33 20/35 0.8 % 1.31 [ 0.49, 3.48 ]
Deliberato 2013 4/42 5/39 0.5 % 0.72 [ 0.18, 2.88 ]
Ogasawara 2014 12/48 18/48 1.6 % 0.56 [ 0.23, 1.33 ]
Long 2014 7/90 9/90 1.0 % 0.76 [ 0.27, 2.13 ]
Verduri 2015 19/88 12/90 1.1 % 1.79 [ 0.81, 3.95 ]
Najafi 2015 5/30 4/30 0.4 % 1.30 [ 0.31, 5.40 ]
Bloos 2016 140/552 149/537 13.1 % 0.88 [ 0.68, 1.16 ]
De Jong 2016 187/761 219/785 18.9 % 0.84 [ 0.67, 1.06 ]
Wang 2016 2/96 5/95 0.6 % 0.38 [ 0.07, 2.02 ]
Lima 2016 6/30 4/31 0.4 % 1.69 [ 0.42, 6.70 ]
Corti 2016 22/62 15/58 1.2 % 1.58 [ 0.72, 3.46 ]
Subtotal (95% CI) 2692 2690 55.9 % 0.88 [ 0.77, 1.01 ]
Total events: 592 (PCT-guided care), 648 (Controls)
Heterogeneity: Chi2 = 16.89, df = 22 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.061)
Total (95% CI) 5016 5030 100.0 % 0.90 [ 0.81, 0.99 ]
Total events: 1053 (PCT-guided care), 1143 (Controls)
Heterogeneity: Chi2 = 21.69, df = 31 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.18 (P = 0.029)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 2.7. Comparison 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses,
Outcome 7 Mortality at 30 days stratified by follow up.
Review: Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
Comparison: 2 Procalcitonin algorithm versus no procalcitonin algorithm, sensitivity analyses
Outcome: 7 Mortality at 30 days stratified by follow up
Study or subgroup PCT-guided care Controls Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Trials with 1 month follow up for mortality
Christ-Crain 2004 4/124 3/119 0.6 % 1.29 [ 0.28, 5.88 ]
Briel 2008 0/232 1/226 0.3 % 0.32 [ 0.01, 7.98 ]
Nobre 2008 8/39 8/40 1.2 % 1.03 [ 0.34, 3.09 ]
Schuetz 2009 34/671 33/688 5.9 % 1.06 [ 0.65, 1.73 ]
Stolz 2009 8/51 12/50 1.9 % 0.59 [ 0.22, 1.59 ]
Bouadma 2010 65/307 64/314 9.5 % 1.05 [ 0.71, 1.55 ]
Burkhardt 2010 0/275 0/275 Not estimable
Maravi -Stojkovi 2011 3/102 3/103 0.6 % 1.01 [ 0.20, 5.13 ]
Long 2011 0/77 0/79 Not estimable
Oliveira 2013 16/49 15/45 2.0 % 0.97 [ 0.41, 2.29 ]
Ding 2013 21/33 20/35 1.3 % 1.31 [ 0.49, 3.48 ]
Ogasawara 2014 5/48 10/48 1.7 % 0.44 [ 0.14, 1.41 ]
Branche 2015 1/151 2/149 0.4 % 0.49 [ 0.04, 5.46 ]
De Jong 2016 149/761 196/785 29.5 % 0.73 [ 0.57, 0.93 ]
Bloos 2016 140/552 149/537 21.4 % 0.88 [ 0.68, 1.16 ]
Wang 2016 2/96 5/95 0.9 % 0.38 [ 0.07, 2.02 ]
Corti 2016 1/62 2/58 0.4 % 0.46 [ 0.04, 5.20 ]
Lima 2016 4/30 2/31 0.3 % 2.23 [ 0.38, 13.20 ]
Subtotal (95% CI) 3660 3677 77.8 % 0.85 [ 0.74, 0.98 ]
Total events: 461 (PCT-guided care), 525 (Controls)
Heterogeneity: Chi2 = 9.33, df = 15 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 2.20 (P = 0.028)
2 Trials with different follow up for mortality
Christ-Crain 2006 18/151 20/151 3.3 % 0.89 [ 0.45, 1.75 ]
Stolz 2007 3/102 2/106 0.4 % 1.58 [ 0.26, 9.63 ]
Kristoffersen 2009 2/103 1/107 0.2 % 2.10 [ 0.19, 23.51 ]
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(. . . Continued)
Study or subgroup PCT-guided care Controls Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hochreiter 2009 15/57 14/53 2.0 % 0.99 [ 0.43, 2.32 ]
Long 2009 0/63 0/64 Not estimable
Schroeder 2009 3/14 3/13 0.5 % 0.91 [ 0.15, 5.58 ]
Layios 2012 56/258 53/251 8.0 % 1.04 [ 0.68, 1.58 ]
Tang 2013 1/132 2/133 0.4 % 0.50 [ 0.04, 5.58 ]
Annane 2013 7/30 10/28 1.5 % 0.55 [ 0.17, 1.72 ]
Deliberato 2013 2/42 4/39 0.8 % 0.44 [ 0.08, 2.54 ]
Long 2014 0/90 0/90 Not estimable
Shehabi 2014 30/196 26/198 4.2 % 1.20 [ 0.68, 2.11 ]
Najafi 2015 5/30 4/30 0.6 % 1.30 [ 0.31, 5.40 ]
Verduri 2015 3/88 2/90 0.4 % 1.55 [ 0.25, 9.53 ]
Subtotal (95% CI) 1356 1353 22.2 % 1.01 [ 0.78, 1.30 ]
Total events: 145 (PCT-guided care), 141 (Controls)
Heterogeneity: Chi2 = 3.72, df = 11 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.06 (P = 0.95)
Total (95% CI) 5016 5030 100.0 % 0.89 [ 0.78, 1.00 ]
Total events: 606 (PCT-guided care), 666 (Controls)
Heterogeneity: Chi2 = 14.30, df = 27 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.058)
Test for subgroup differences: Chi2 = 1.26, df = 1 (P = 0.26), I2 =21%
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Table 1. Characteristics of included trials
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Table 1. Characteristics of included trials (Continued)
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AECOPD: acute exacerbation of chronic obstructive pulmonary disease
ARI: acute respiratory infection
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CAP: community-acquired pneumonia





ICU: intensive care unit
PCT: procalcitonin
R: recommendation for or against antibiotics
SIRS: systemic inflammatory response syndrome
VAP: ventilator-associated pneumonia
Table 2. Baseline characteristics of included participants
Parameter Control (n = 3372) PCT group (n = 3336)
Demographics
Age (year), mean (SD) 61.2 ± 18.4 60.7 ± 18.8
Male gender, n (%) 1910 (56.6%) 1898 (56.9%)
Clinical setting, no (%)
Primary care 501 (14.9%) 507 (15.2%)
Emergency department 1638 (48.6%) 1615 (48.4%)
Intensive care unit 1233 (36.6%) 1214 (36.4%)
Primary diagnosis
Total upper ARI, n (%) 280 (8.3%) 292 (8.8%)
Common cold 156 (4.6%) 149 (4.5%)
Rhino-sinusitis, otitis 67 (2.0%) 73 (2.2%)
Pharyngitis, tonsillitis 46 (1.4%) 61 (1.8%)
Total lower ARI, n (%) 3092 (91.7%) 3044 (91.2%)
Community-acquired pneumonia 1468 (43.5%) 1442 (43.2%)
Hospital-acquired pneumonia 262 (7.8%) 243 (7.3%)
Ventilator-associated pneumonia 186 (5.5%) 194 (5.8%)
Acute bronchitis 287 (8.5%) 257 (7.7%)
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Table 2. Baseline characteristics of included participants (Continued)
Exacerbation of COPD 631 (18.7%) 621 (18.6%)
Exacerbation of asthma 127 (3.8%) 143 (4.3%)
Other lower ARI 131 (3.9%) 144 (4.3%)
Procalcitonin upon enrolment
PCT< 0.1 ug/L 921 (35.6%) 981 (30.9%)
PCT 0.1 to 0.25 ug/L 521 (20.1%) 608 (19.2%)
PCT > 0.25 to 0.5 ug/L 308 (11.9%) 383 (12.1%)
PCT > 0.5 to 2.0 ug/L 358 (13.8%) 520 (16.4%)
PCT > 2.0 ug/L 482 (18.6%) 679 (21.4%)
ARI: acute respiratory infection
COPD: chronic obstructive pulmonary disease
PCT: procalcitonin
SD: standard deviation













Annane 2013 Yes (central
randomisation)
No 58/58 (100%) 63% adherence LOS
Bloos 2016 Yes (central
randomisation)
No 1045/1089 (96%) 49.6% adherence 28 days and 90 days
Bouadma 2010 Yes (central
randomisation)
Yes 393/394 (100%) 47% adherence 28 days and 60 days
Branche 2015 Yes
(central randomisa-
tion using blocks of
4)
No 250/300 (83.3%) 64% adherence 1 month and 3
months
Briel 2008 Yes (central
randomisation)
Yes 454/458 (99%) 85% adherence 28 days
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Table 3. Quality assessment of trials (Continued)
Burkhardt 2010 Yes (central
randomisation)
Yes 546/550 (99%) 87% adherence 28 days
Christ-Crain 2004 No (alternating
weeks)
No 230/243 (95%) 83% adherence 10 to 14 days
Christ-Crain 2006 Yes (sequentially
numbered, opaque,
sealed envelopes)
No 300/302 (99%) 87% adherence 56 days





No 120/120 (100%) 61.1% adherence 28 days
De Jong 2016 Yes (central
randomisation)
No 1546/1546 (100%) 44% adherence 28 days and 1 year
Deliberato 2013 Yes (opaque, sealed
envelopes)
No 81/81 (100%) 52% adherence LOS
Ding 2013 Yes (central
randomisation)
No 68/78 (87.2%) Not reported 30 days
Hochreiter 2009 No (unconcealed
drawing of lots)
No 43/43 (100% until
discharge)
Not reported LOS
Kristoffersen 2009 Yes (central
randomisation)
No 210/210 (100% un-
til discharge)
59% adherence LOS
Layios 2012 Not reported No 509/509 (100%) Not reported Intensive care unit
LOS
Lima 2016 Yes (sequentially
numbered, opaque,
sealed envelopes)
No 61/62 (98.4%) 73.3% adherence 28 days and 90 days
Long 2009 No (odd and even
patient ID num-
bers)
No 127/127 (100%) Not reported Not reported
Long 2011 No (odd and even
patient ID num-
bers)
No 156/156 (100%) Not reported 28 days
Long 2014 Yes (central
randomisation)
No 169/180 (93.9%) 96.6% adherence LOS and 1 year
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No 205/205 (100%) Not reported 30 days and LOS
Najafi 2015 Yes (central
randomisation)
No 30/30 (100%) Not reported LOS
Nobre 2008 Yes (sequentially
numbered, opaque,
sealed envelopes)
No 52/52 (100%) 81% adherence 28 days and LOS
Ogasawara 2014 Not reported No 96/96 (100%) Not reported 30 days
Oliveira 2013 Yes (central
randomisation)
No 94/94 (100%) 86.2% adherence 28 days
Schroeder 2009 No (unconcealed
drawing of lots)
No 8/8 (100%until dis-
charge)
Not reported LOS
Schuetz 2009 Yes (central
randomisation)
Yes 1358/1359 (100%) 91% adherence 28 days
Shehabi 2014 Yes (central
randomisation)
Yes 394/394 (100%) Not reported LOS and 90 days
Stolz 2007 Yes (sequentially
numbered, opaque,
sealed envelopes)
Yes 208/208 (100%) Not reported 6 months
Stolz 2009 Yes (sequentially
numbered, opaque,
sealed envelopes)
No 101/101 (100%) Not reported 28 days
Tang 2013 Yes (sequentially
numbered, opaque,
sealed envelopes)
Yes 258/265 (97.4%) Not reported 6 weeks
Verduri 2015 Yes (central
randomisation)
No 178/178 (100%) Not reported 6 months
Wang 2016 Yes (those
responsible for allo-
cation concealment
were not involved in
the measurement of
results)
No 191/191 (100%) 82.3% ad-
herence (17 partici-
pants in the control
group received AB)
30 days
LOS: length of stay
PCT: procalcitonin
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Table 4. Clinical endpoints overall and stratified by setting and ARI diagnosis
Control group PCT group Measures of effect: adjusted OR
or difference (95% CI), P value
P for interaction
Overall 3372 3336
30 days mortality, n (%) 336 (10.0%) 286 (8.6%) 0.83 (0.70 to 0.99), P = 0.037 NA
Treatment failure, n (%) 841 (24.9%) 768 (23.0%) 0.90 (0.80 to 1.01), P = 0.068 NA
Length of ICU stay,
mean (±SD)
13.3 ± 16.0 13.7 ± 17.2 0.39 (-0.81 to 1.58), P = 0.524 NA
Length of hospital stay,
mean (±SD)
13.7 ± 20.6 13.4 ± 18.4 -0.19 (-0.96 to 0.58), P = 0.626 NA
Antibiotic-related side
effects, n (%)
336 (22.1%) 247 (16.3%) 0.68 (0.57 to 0.82), P < 0.001 NA
According to setting
Primary care 501 507
30 days mortality, n (%) 1 (0.2%) 0 (0.0%) NA NA
Treatment failure, n (%) 164 (32.7%) 159 (31.4%) 0.96 (0.73 to 1.25), P = 0.751 0.715
Days with restricted ac-
tivities, mean (±SD)
8.9 ± 4.2 8.9 ± 4.1 0.07 (-0.44 to 0.59), P = 0.777 NA
Antibiotic-related side
effects, n (%)
128 (25.7%) 102 (20.2%) 0.65 (0.46 to 0.91), P = 0.012 0.596
Emergency department 1638 1615
30 days mortality, n (%) 62 (3.8%) 57 (3.5%) 0.91 (0.63 to 1.33), P = 0.635 0.546
Treatment failure, n (%) 292 (17.8%) 259 (16.0%) 0.87 (0.72 to 1.05), P = 0.141 0.807
Length of hospital stay,
mean (±SD)
8.2 ± 10.5 8.1 ± 7.5 -0.14 (-0.73 to 0.44), P = 0.631 0.684
Antibiotic-related side
effects, n (%)
208 (20.3%) 145 (14.4%) 0.66 (0.52 to 0.83), P = 0.001 0.596
Intensive care unit 1233 1214
30 days mortality, n (%) 273 (22.3%) 229 (19.0%) 0.84 (0.69 to 1.02), P = 0.081 0.619
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Table 4. Clinical endpoints overall and stratified by setting and ARI diagnosis (Continued)
Length of ICU stay,
mean (±SD)
14.8 ± 16.2 15.3 ± 17.5 0.56 (-0.82 to 1.93), P = 0.427 0.849
Length of hospital stay,
mean (±SD)





30 days mortality, n (%) 206 (14.1%) 175 (12.2%) 0.82 (0.66 to 1.03), P = 0.083 0.958
Treatment failure, n (%) 385 (26.2%) 317 (22.0%) 0.78 (0.66 to 0.93), P = 0.005 0.052
Length of ICU stay,
mean (±SD)
10.5 ± 10.3 11.9 ± 13.3 1.45 (0.15 to 2.75), P = 0.029 0.119
Length of hospital stay,
mean (±SD)
13.3 ± 15.7 13.9 ± 16.1 0.74 (-0.25 to 1.73), P = 0.143 0.094
Antibiotic-related side
effects, n (%)
186 (27.7%) 127 (19.1%) 0.62 (0.48 to 0.80), P < 0.001 0.227
Exacerbation of COPD 631 621
30 days mortality, n (%) 24 (3.8%) 19 (3.1%) 0.8 (0.43 to 1.48), P = 0.472 0.847
Treatment failure, n (%) 110 (17.4%) 104 (16.7%) 0.94 (0.70 to 1.27), P = 0.704 0.676
Length of hospital stay,
mean (±SD)
9.3 ± 13.9 8.4 ± 7.2 -0.60 (-1.84 to 0.64), P = 0.342 0.658
Antibiotic-related side
effects, n (%)
30 (10.9%) 29 (10.5%) 0.93 (0.53 to 1.63), P = 0.805 0.198
Acute bronchitis 287 257
30 days mortality, n (%) 0 (0.0%) 2 (0.8%) NA NA
Treatment failure, n (%) 55 (19.2%) 52 (20.2%) 1.11 (0.72 to 1.70), P = 0.643 0.4
Length of hospital stay,
mean (±SD)
2.6 ± 5.7 2.2 ± 4.7 -0.21 (-0.90 to 0.48), P = 0.556 0.97
Antibiotic-related side
effects, n (%)
54 (21.6%) 39 (17.3%) 0.77 (0.49 to 1.22), P = 0.263 0.657
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30 days mortality, n (%) 29 (15.6%) 23 (12.0%) 0.75 (0.41 to 1.39), P = 0.366 0.644
Treatment failure, n (%) 51 (27.4%) 44 (22.7%) 0.78 (0.48 to 1.28), P = 0.332 0.522
Length of ICU stay,
mean (±SD)
23.5 ± 20.5 21.8 ± 19.1 -1.74 (-5.64 to 2.17), P = 0.383 0.441
Length of hospital stay,
mean (±SD)
33.8 ± 27.6 32.0 ± 23.1 -2.14 (-7.04 to 2.75), P = 0.391 0.448
Measures of effect: dichotomous outcomes are reported as adjusted OR (95% CI) and continuous outcomes are adjusted mean
differences and confidence intervals
ARI: acute respiratory infection
CI: confidence interval
COPD: chronic obstructive pulmonary disease





Table 5. Sensitivity analysis
Mortality
Main analysis Control group PCT group Adjusted OR (95% CI), P value P for interaction
All participants 336 (10.0%) 286 (8.6%) 0.83 (0.70 to 0.99), P = 0.037 NA
Adherence
High adherence 82 (4.5%) 75 (4.1%) 0.88 (0.63 to 1.22), P = 0.434 0.617
Low adherence (< 70%
or not reporting)
254 (16.4%) 211 (14.0%) 0.83 (0.67 to 1.02), P = 0.073
Allocation
Low risk for allocation
concealment bias
305 (10.6%) 250 (8.8%) 0.80 (0.67 to 0.97), P = 0.021 0.229
High risk for allocation
concealment bias (or not
reporting)
31 (6.5%) 36 (7.3%) 1.12 (0.66 to 1.91), P = 0.672
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113 (6.5%) 102 (5.9%) 0.85 (0.64 to 1.13), P = 0.259 0.537
No blinded outcome as-
sessment
223 (13.8%) 184 (11.5%) 0.81 (0.65 to 1.01), P = 0.062
Follow-up
Follow up for mortality
at 1 month
275 (10.7%) 224 (8.9%) 0.81 (0.67 to 0.99), P = 0.039 0.325
Follow up for mortality
< 1 month
61 (7.6%) 62 (7.6%) 0.94 (0.64 to 1.38), P = 0.756
Treatment failure Control group PCT group Adjusted OR (95% CI), P value P for interaction
All participants 841 (24.9%) 768 (23.0%) 0.90 (0.80 to 1.01), P = 0.068 NA
Adherence
High adherence 419 (23.1%) 381 (21.0%) 0.89 (0.76 to 1.04), P = 0.148 0.752
Low adherence (< 70%
or not reporting)
422 (27.1%) 387 (25.5%) 0.92 (0.77 to 1.08), P = 0.301
Allocation
Low risk for allocation
concealment bias
776 (26.8%) 699 (24.6%) 0.89 (0.79 to 1.01), P = 0.069 0.486
High risk for allocation
concealment bias (or not
reporting)




412 (23.5%) 367 (21.1%) 0.88 (0.75 to 1.03), P = 0.117 0.574
No blinded outcome as-
sessment
429 (26.5%) 401 (25.1%) 0.94 (0.79 to 1.11), P = 0.438
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Table 6. Antibiotic treatment overall and stratified by setting and ARI diagnosis
Parameter Control group PCT group Measures of effect: adjusted OR





2894 (86.3%) 2351 (71.5%) 0.27 (0.24 to 0.32), P < 0.001
Duration of antibiotics
(days), mean (±SD)
9.4 ± 6.2 8.0 ± 6.5 -1.83 (-2.15 to -1.50), P < 0.001
Total exposure of antibi-
otics (days), mean (±SD)
8.1 ± 6.6 5.7 ± 6.6 -2.43 (-2.71 to -2.15), P < 0.001
Setting-specific outcomes
Primary care 501 507
Initiation of antibiotics,
n (%)
316 (63.1%) 116 (22.9%) 0.13 (0.09 to 0.18), P < 0.001 < 0.001
Duration of antibiotics
(days), mean (±SD)
7.3 ± 2.5 7.0 ± 2.8 -0.52 (-1.07 to 0.04), P = 0.068 0.064
Total exposure of antibi-
otics (days), mean (±SD)
4.6 ± 4.1 1.6 ± 3.2 -3.02 (-3.45 to -2.58), P < 0.001 0.101
Emergency department 1638 1615
Initiation of antibiotics,
n (%)
1354 (83.2%) 1119 (71.3%) 0.49 (0.41 to 0.58), P < 0.001 < 0.001
Duration of antibiotics
(days), mean (±SD)
9.8 ± 5.4 7.3 ± 5.1 -2.45 (-2.86 to -2.05), P < 0.001 < 0.001
Total exposure of antibi-
otics (days), mean (±SD)
8.2 ± 6.2 5.2 ± 5.4 -3.02 (-3.41 to -2.62), P < 0.001 < 0.001
Intensive care unit 1233 1214
Initiation of antibiotics,
n (%)
1224 (99.8%) 1116 (91.9%) 0.02 (0.01 to 0.05), P < 0.001 < 0.001
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Table 6. Antibiotic treatment overall and stratified by setting and ARI diagnosis (Continued)
Duration of antibiotics
(days), mean (±SD)
9.5 ± 7.4 8.8 ± 7.8 -1.23 (-1.82 to -0.65), P < 0.001 < 0.001
Total exposure of antibi-
otics (days), mean (±SD)







1455 (99.4%) 1340 (92.9%) 0.08 (0.04 to 0.15), P < 0.001 < 0.001
Duration of antibiotics
(days), mean (±SD)
10.5 ± 6.2 8.0 ± 5.7 -2.45 (-2.87 to -2.02), P < 0.001 < 0.001
Total exposure of antibi-
otics (days), mean (±SD)
10.4 ± 6.2 7.5 ± 5.9 -2.94 (-3.38 to -2.50), P < 0.001 0.004
Exacerbation of COPD 631 621
Initiation of antibiotics,
n (%)
453 (71.8%) 266 (42.8%) 0.29 (0.23 to 0.36), P < 0.001 0.017
Duration of antibiotics
(days), mean (±SD)
7.4 ± 5.3 7.2 ± 6.7 -1.15 (-2.00 to -0.31), P = 0.007 0.003
Total exposure of antibi-
otics (days), mean (±SD)
5.3 ± 5.6 3.1 ± 5.6 -2.22 (-2.83 to -1.60), P < 0.001 0.506
Acute bronchitis 287 257
Initiation of antibiotics,
n (%)
189 (65.9%) 68 (26.5%) 0.18 (0.12 to 0.26), P < 0.001 < 0.001
Duration of antibiotics
(days), mean (±SD)
7.1 ± 3.0 6.4 ± 3.5 -0.35 (-1.15 to 0.45), P = 0.393 0.359
Total exposure of antibi-
otics (days), mean (±SD)






186 (100.0%) 193 (99.5%) NA NA
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Table 6. Antibiotic treatment overall and stratified by setting and ARI diagnosis (Continued)
Duration of antibiotics
(days), mean (±SD)
13.1 ± 7.9 10.8 ± 8.7 -2.22 (-3.80 to -0.65), P = 0.006 0.253
Total exposure of antibi-
otics (days), mean (±SD)
13.1 ± 7.9 10.8 ± 8.7 -2.45 (-4.09 to -0.82), P = 0.003 0.786
Note: Duration refers to the total days of antibiotic therapy in participants in whom antibiotics were initiated. Total exposure refers to
the total days of antibiotic therapy in all randomised participants.
Measures of effect: dichotomous outcomes are reported as adjusted OR (95% CI) and continuous outcomes are adjusted mean
differences and confidence intervals
ARI: acute respiratory infection
CI: confidence interval





A P P E N D I C E S
Appendix 1. CENTRAL (Cochrane Library via Wiley) search strategy
[mh Calcitonin] OR Procalcitonin:ti,ab OR ProCT:ti,ab OR (calcitonin:ti,ab AND (precursor:ti,ab OR precursors:ti,ab))
AND
[mh “Anti-Bacterial Agents”] OR (antibiotic OR Antibiotics OR antibacterial OR anti-bacterial OR amoxicillin OR amoxycillin OR
penicillin OR ampicillin OR cotrimoxazole OR chloramphenicol OR trimethoprim OR sulphamethoxazole OR “tmp smx” OR tmp-
smx):ti,ab
AND
[mh Biomarkers] OR (Biomarker OR Biomarkers OR Marker OR Level OR Levels OR Guide OR Guidance):ti,ab
Appendix 2. MEDLINE (Ovid) search strategy
exp Calcitonin/ OR Procalcitonin.tw. OR ProCT.tw. OR (calcitonin.tw. AND (precursor.tw. OR precursors.tw.))
AND
exp Anti-Bacterial Agents/ OR (antibiotic OR Antibiotics OR antibacterial OR anti-bacterial OR amoxicillin or amoxycillin OR
penicillin OR ampicillin OR cotrimoxazole OR chloramphenicol OR trimethoprim OR sulphamethoxazole OR tmp smx OR tmp-
smx).tw,nm.
AND
exp Biomarkers/ OR (Biomarker OR Biomarkers OR Marker OR Level OR Levels OR Guide OR Guidance).tw.
AND
((randomised controlled trial or controlled clinical trial).pt. or randomized.ab. or randomised.ab. or placebo.ab. or drug therapy.fs. or
randomly.ab. or trial.ab. or groups.ab.) NOT (exp animals/ not humans.sh.)
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Appendix 3. Embase.com (Elsevier) search strategy
’Calcitonin’/exp OR Procalcitonin:ti,ab OR ProCT:ti,ab OR (calcitonin:ti,ab AND (precursor:ti,ab OR precursors:ti,ab))
AND
’antiinfective agent’/exp OR (antibiotic OR Antibiotics OR antibacterial OR anti-bacterial OR amoxicillin OR amoxycillin OR
penicillin OR ampicillin OR cotrimoxazole OR chloramphenicol OR trimethoprim OR sulphamethoxazole OR “tmp smx” OR tmp-
smx):ti,ab
AND
’biological marker’/exp OR (Biomarker OR Biomarkers OR Marker OR Level OR Levels OR Guide OR Guidance):ti,ab
AND
random*OR factorial OR crossoverOR placeboORblindORblindedOR assign OR assigned OR allocate OR allocatedOR ’crossover
procedure’/expOR ’double-blind procedure’/expOR ’randomised controlled trial’/expOR ’single-blind procedure’/expNOT (’animal’/
exp NOT (’animal’/exp AND ’human’/exp))
Appendix 4. Previous MEDLINE (Ovid) search strategy
Search used for previous versions of this Cochrane Review
1 procalcitonin.tw.
2 calcitonin precursor*.tw.
3 exp Anti-Bacterial Agents/
4 antibiotic.tw.
5 1 or 2
6 3 or 4
7 5 and 6
F E E D B A C K
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections, 22 October
2017
Summary
In the 2012 update of this review (Schuetz, 2012), (Maravic-Stojkovic, 2011) was excluded due to “[no] evidence of respiratory
infection”. In this 2017 update, (Maravic-Stojkovic, 2011) has now been included. The reasons for this change do not seem to be
explicitly provided in the review. The “What’s new” section does say “new trials” were included but (Maravic-Stojkovic, 2011) had
already been published, identified and excluded in the previous review.
Schuetz, P.,Müller, B., Christ-Crain,M., Stolz,D., Tamm,M., Bouadma, L.,…Briel,M. (2012). Procalcitonin to initiate or discontinue
antibiotics in acute respiratory tract infections. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd007498.pub2
Maravic-Stojkovic, V., Lausevic-Vuk, L., Jovic, M., Rankovic, A., Borzanovic, M., & Marinkovic, J. (2011). Procalcitonin-based
therapeutic strategy to reduce antibiotic use in patients after cardiac surgery: A randomized controlled trial. Srpski Arhiv Za Celokupno




I do not have any affiliation with or involvement in any organisation with a financial interest in the subject matter of my comment.
Reply
Based on the 2012 review of abstracts we did not believe that the Maravic dataset would have “patients with acute respiratory tract
infection included” (our main inclusion criterion) based on the description in the abstract “The prospective study included 205 patients
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who underwent open heart surgery. The patients were randomly assigned for procalcitonin-guided antibiotic treatment (PCT-group; n=
102) or standard care (standard group; n=103). On the basis of serum procalcitonin concentrations, usage of antibiotics was encouraged
(PCT≥0.5 ng/mL) or discouraged.”
For the 2017 update we decided to check again all trials with investigators and indeed found that 5 out of the 205 patients had hospital-
acquired pneumonia (HAP) - these 5 patients were then included in the final analysis.
Thus - the 5 patients from the Maravic study should have been included in the 2012 review already but slipped our attention due to
the focus of the study on cardiac surgery patients.
Contributors
Philipp Scheutz
WH A T ’ S N E W
Date Event Description
26 October 2017 Amended Correction to Sumary of findings table GRADE icon.
26 October 2017 Feedback has been incorporated Feedback comment and reply added to the review.
H I S T O R Y
Date Event Description
10 February 2017 New citation required and conclusions have changed Procalcitonin-guided antibiotic treatment improves
clinical outcomes and reduces antibiotic consumption
10 February 2017 New search has been performed We updated our searches and analyses. We included 12
new trials in individual participant analysis (Bloos 2016;
Branche 2015; Corti 2016; De Jong 2016; Deliberato
2013; Layios 2012; Long 2014; Maravi -Stojkovi
2011; Oliveira 2013; Shehabi 2014; Verduri 2015;
Wang 2016). We identified six new trials that were
excluded from individual participant analysis (Annane
2013; Ding 2013; Lima 2016; Najafi 2015; Ogasawara
2014; Tang 2013).We identified seven new ongoing tri-
als (NCT02130986; NCT02261610; NCT02332577;
NCT02440828; NCT02787603; NCT02862314;
NCT02931409). Our new results show that mortality
is significantly lower in the procalcitonin group
125Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
Philipp Schuetz, Beat Mueller, Heiner Bucher, and Matthias Briel conceived the study and wrote the initial protocol.
Philipp Schuetz and Matthias Briel performed the analysis of the initial review, and Philipp Schuetz, Yannick Wirz, and Ramon Sager
performed the analysis of the 2017 update including the writing of the manuscript. Philipp Schuetz, Mirjam Christ-Crain, Daiana
Stolz, Michael Tamm, Lila Bouadma, Charles E Luyt, Michel Wolff, Jean Chastre, Florence Tubach, Kristina B Kristoffersen, Olaf
Burkhardt, Tobias Welte, Stefan Schroeder, Vandack Nobre, Long Wei, Heiner C Bucher, Djillali Annane, Konrad Reinhart, Angela
Branche, Pierre Damas, Maarten Nijsten, DylanW de Lange, Rodrigo ODeliberato, Stella SS Lima, VeraMaravi -Stojkovi , Alessia
Verduri, Bin Cao, Yahya Shehabi,, Albertus Beishuizen, Jens-Ulrik S Jensen, Caspar Corti, Matthias Briel, Beat Mueller, Jos A Van
Oers, Ann R Falsey, and Evelien de Jong are investigators of included trials, provided data from their respective trials, and resolved
queries about their trial data.
All authors amended and commented on the manuscript and approved the final version. Philipp Schuetz, Beat Mueller, and Matthias
Briel oversaw the study and act as guarantors.
D E C L A R A T I O N S O F I N T E R E S T
Philipp Schuetz received support (paid to his employer) from Thermo Fisher, Roche Diagnostics, Abbott and bioMerieux to attend
meetings and fulfil speaking engagements. These conflicts breach Cochrane’s Commercial Sponsorship Policy (Clause 3), therefore
Philipp Schuetz will step down as lead author at the next update of the review. Dr Schuetz’s declared conflicts were referred to the
Funding Arbiter Panel and Cochrane’s Deputy Editor-in-Chief who have agreed this course of action but as an exception which does
not set a precedent for similar situations in the future.
Beat Mueller reports that within the last 3 years he was part of the speaker bureau of B·R·A·H·M·S and bioMérieux to give educational
talks. His institution received compensation for flight and travel expenses, and to cover his absence from work.
Yannick Wirz: None known.
Ramon Sager: None known.
Mirjam Christ-Crain received support from B·R·A·H·M·S and bioMérieux to attend meetings and fulfilled speaking engagements.
Daiana Stolz received fees for lectures or occasional advisory committees from Boehringer Ingelheim, Almirall, Novartis, Glaxo,
AstraZeneca, and Roche. Dr Stolz’s institution received unrestricted research grants fromResMed, Weinmann AG, AstraZeneca, Boston
Scientific, and Curetis AG.
Michael Tamm: None known.
Lila Bouadma: None known.
Charles E Luyt received lecture fees from B·R·A·H·M·S and Merck Sharp & Dohme-Chibret.
Michel Wolff received consulting and lectures fees from Merck Sharp & Dohme-Chibret, Janssen-Cilag, Gilead, and Astellas Pharma.
Jean Chastre received consulting and lecture fees from Pfizer, B·R·A·H·M·S, Wyeth, Johnson & Johnson, Nektar-Bayer, and Arpida.
Florence Tubach: My institution received some funds from B·R·A·H·M·S for implementing the PRORATA trial, whose data are
involved in the review.
Kristina B Kristoffersen: None known.
Olaf Burkhardt received research support from B·R·A·H·M·S.
Tobias Welte received lecture fees and research support from B·R·A·H·M·S.
Stefan Schroeder received lecture fees and research support from B·R·A·H·M·S.
Vandack Nobre: None known.
Long Wei: None known.
126Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Heiner C Bucher: None known.
Neera Bhatnagar: None known.
Djillali Annane: None known.
Konrad Reinhart received fees for consultancy from Adrenomed, Henningsdorf Berlin, Germany; holds equity in InflaRx, Jena,
Germany; and is unpaid chair of the Global Sepsis Alliance, which receives funds from several companies with interest in sepsis
diagnostics.
Angela Branche: This work was partially supported by the National Institutes of Health, National Institute of Allergy and Infectious
Diseases (contract HHSN27220120005C). This author has nothing else to declare.
Pierre Damas: None known.
Maarten Nijsten: None known.
Dylan W de Lange: The department where Dylan de Lange worked received financial compensation for a randomisation tool during
the SAPS trial.
Rodrigo O Deliberato: None known.
Stella SS Lima: None known.
Vera Maravi -Stojkovi : None known.
Alessia Verduri: None known.
Bin Cao: None known.
Yahya Shehabi received unrestricted research and educational grants from Thermo Fisher, bioMérieux, Pfizer, and Orion Pharma.
Albertus Beishuizen: None known.
Jens-Ulrik S Jensen declares that he was invited to the EuropeanRespiratory Societymeeting 2016 byRoche Pharmaceuticals. Otherwise,
he has no disclosures.
Caspar Corti received an unrestricted grant of USD 2000 from Thermo Fisher Scientific, MA, USA; bioMérieux Denmark ApS
supported the study non-financially.
Jos A Van Oers: None known.
Ann R Falsey: The relationships with noted industry partners had no role or influence in the study.
Evelien de Jong received lecturing fees from Thermo Fisher.
Carolina F Oliveira: None known.
Bianca Beghe: None known.
Matthias Briel: Unrestricted grant from B·R·A·H·M·S AG (now Thermo Fisher) that partially covered working hours to a previous
version of this Cochrane Review. B·R·A·H·M·S had no role in the design, conduct, analysis, or writing of our manuscript.
Funding:The initial reviewwas partly fundedby unrestricted research grants fromB·R·A·H·M·S/ThermoFisher Scientific, theGottfried
and Julia Bangerter-Rhyner-Foundation, the Swiss Foundation for Grants in Biology and Medicine (SSMBS, PASMP3-127684/1),
and santésuisse to cover salary time related to this review. The sponsors had no role in the study design, data collection, data analysis
or data interpretation, or writing of the report. No funding was received for this update.
No commercial sponsor had any involvement in the design and conduct of this review, namely collection, management, analysis, and
interpretation of the data; and preparation, decision to submit, review, or approval of the manuscript.
127Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• Gottfried and Julia Bangerter-Rhyner-Foundation, the Swiss Foundation for Grants in Biology and Medicine and santésuisse,
Switzerland.
Unrestricted research grant to cover salary time related to this review
• National Institute for Health Research, UK.
This update was supported by the National Institute for Health Research, via Cochrane Infrastructure and Cochrane Programme
Grant funding (NIHR Cochrane Programme Grant 16-72-15) to the Acute Respiratory Infections Group. The views and opinions
expressed herein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National
Health Service or the Department of Health.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We changed the co-primary endpoint of combined disease-specific failure at 30 days (mentioned in the protocol) to setting-specific
treatment failure at 30 days as defined above for reasons of standardisation across trials. We limited the analysis of the secondary
outcome number of ’sick days’ (days with restricted activities from the ARI within 14 days following randomisation) to the primary
care trials because other trials did not assess this outcome.
In addition, based on referee comments during the initial editorial process of the initial review (Schuetz 2012), we added further
sensitivity analyses to investigate the robustness of our results. Specifically, we performed sensitivity analyses excluding trials with low
adherence to PCT algorithms (< 70%) or not reporting adherence.We also performed sensitivity analyses with respect tomethodological
quality criteria (allocation concealment and blinded outcome assessment). We further performed a sensitivity analysis excluding trials
with a follow-up time for mortality different than one month. We conducted meta-analyses with aggregated data of included trials
to further investigate heterogeneity (inconsistency measure I2 statistic and Cochran Q test) of intervention effects and trial subgroups
based on adherence to PCT algorithms.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Disease; Anti-Bacterial Agents [∗therapeutic use]; Bacterial Infections [blood; ∗drug therapy; mortality]; Biomarkers [blood];
Calcitonin [∗blood]; Calcitonin Gene-Related Peptide; Cause of Death; Protein Precursors [∗blood]; Randomized Controlled Trials as
Topic; Respiratory Tract Infections [blood; ∗drug therapy; mortality]; Treatment Failure
MeSH check words
Humans
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